

1

Literaturverzeichnis

1. Meisinger C, Ittermann T, Wallaschofski H, Heier M, Below H, Kramer A, et al. Geographic variations in the frequency of thyroid disorders and thyroid peroxidase antibodies in persons without former thyroid disease within Germany. *Eur J Endocrinol*. 2012;167(3):363-71. URL: <https://pubmed.ncbi.nlm.nih.gov/22700599/>
2. Reiners C, Wegscheider K, Schicha H, Theissen P, Vaupel R, Wrbitzky R, et al. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. *Thyroid*. 2004;14(11):926-32. URL: <https://pubmed.ncbi.nlm.nih.gov/15671771/>
3. Krebs in Deutschland. Schilddrüse. 2021;126. URL: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2021/kid_2021_c73_schilddruese.pdf?__blob=publicationFile
4. Brenner D, Ruan Y, Shaw E, O'Sullivan D, Poirier A, Heer E, et al. Age-standardized cancer-incidence trends in Canada, 1971-2015. *CMAJ*. 2019;191(46):E1262-E1273. URL: <https://pubmed.ncbi.nlm.nih.gov/31740536/>
5. Lim H, Devesa S, Sosa J, Check D, Kitahara C. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. *JAMA*. 2017;317(13):1338-1348. URL: <https://pubmed.ncbi.nlm.nih.gov/28362912/>
6. Dal Maso L, Panato C, Franceschi S, Serraino D, Buzzoni C, Busco S, et al. The impact of overdiagnosis on thyroid cancer epidemic in Italy, 1998-2012. *Eur J Cancer*. 2018;94:6-15. URL: <https://pubmed.ncbi.nlm.nih.gov/29502036/>
7. Seib C, Sosa J. Evolving Understanding of the Epidemiology of Thyroid Cancer. *Endocrinol Metab Clin North Am*. 2019;48(1):23-35. URL: <https://pubmed.ncbi.nlm.nih.gov/30717905/>
8. Powers A, Marcadis A, Lee M, Morris L, Marti J. Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016. *JAMA*. 2019;322(24):2440-2441. URL: <https://pubmed.ncbi.nlm.nih.gov/31860035/>
9. Wiltshire J, Drake T, Uttley L, Balasubramanian S. Systematic Review of Trends in the Incidence Rates of Thyroid Cancer. *Thyroid*. 2016;26(11):1541-1552. URL: <https://pubmed.ncbi.nlm.nih.gov/27571228/>
10. Farahati J, Mäder U, Gilman E, Görges R, Maric I, Binse I, et al. Changing trends of incidence and prognosis of thyroid carcinoma. *Nuklearmedizin*. 2019;58(2):86-92. URL: <https://pubmed.ncbi.nlm.nih.gov/30917397/>
11. Krebs in Deutschland. Schilddrüse. 2019;118. URL: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/kid_2019_c73_schilddruese.pdf?__blob=publicationFile
12. Mirian C, Grønhøj C, Jensen D, Jakobsen K, Karnov K, Jensen J, et al. Trends in thyroid cancer: Retrospective analysis of incidence and survival in Denmark 1980-2014. *Cancer Epidemiol*. 2018;55:81-87. URL: <https://pubmed.ncbi.nlm.nih.gov/29852396/>
13. Ren Y, Liu Q, Ge M, Li H, Liu B, Zhang Y, et al. [Incidence and mortality of thyroid cancer in cancer registries of Zhejiang Province, 2010-2014]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2019;53(10):1062-1065. URL: <https://pubmed.ncbi.nlm.nih.gov/31607057/>
14. Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh I, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. *Am J Transl Res*. 2019;11(9):5888-5896. URL: <https://pubmed.ncbi.nlm.nih.gov/31632557/>

15. Borges A, Miranda-Filho A, Koifman S, Koifman R. Thyroid Cancer Incidences From Selected South America Population-Based Cancer Registries: An Age-Period-Cohort Study. *J Glob Oncol*. 2018;4:1-11. URL: <https://pubmed.ncbi.nlm.nih.gov/30241178/>
16. Safavi A, Azizi F, Jafari R, Chaibakhsh S, Safavi A. Thyroid Cancer Epidemiology in Iran: a Time Trend Study. *Asian Pac J Cancer Prev*. 2016;17(1):407-12. URL: <https://pubmed.ncbi.nlm.nih.gov/26838247/>
17. Ahn H, Kim H, Kim K, Lee Y, Han S, Kim Y, et al. Thyroid Cancer Screening in South Korea Increases Detection of Papillary Cancers with No Impact on Other Subtypes or Thyroid Cancer Mortality. *Thyroid*. 2016;26(11):1535-1540. URL: <https://pubmed.ncbi.nlm.nih.gov/27627550/>
18. Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. *Lancet Diabetes Endocrinol*. 2021;9(4):225-234. URL: <https://pubmed.ncbi.nlm.nih.gov/33662333/>
19. Eng C, Mulligan L, Healey C, Houghton C, Frilling A, Raue F, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. *Cancer Res*. 1996;56(9):2167-70. URL: <https://pubmed.ncbi.nlm.nih.gov/8616867/>
20. Marsh D, Andrew S, Eng C, Learoyd D, Capes A, Pojer R, et al. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. *Cancer Res*. 1996;56(6):1241-3. URL: <https://pubmed.ncbi.nlm.nih.gov/8640806/>
21. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 International RET mutation consortium analysis. *JAMA*. 1996;276(19):1575-9. URL: <https://pubmed.ncbi.nlm.nih.gov/8918855/>
22. Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016;26(1):1-133. URL: <https://pubmed.ncbi.nlm.nih.gov/26462967/>
23. Cirello V. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors. *Minerva Endocrinol (Torino)*. 2021;46(1):5-20. URL: <https://pubmed.ncbi.nlm.nih.gov/33045820/>
24. Cetta F. FAP Associated Papillary Thyroid Carcinoma: A Peculiar Subtype of Familial Nonmedullary Thyroid Cancer. *Patholog Res Int*. 2015;2015:309348. URL: <https://pubmed.ncbi.nlm.nih.gov/26697262/>
25. Tan M, Mester J, Ngeow J, Rybicki L, Orloff M, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res*. 2012;18(2):400-7. URL: <https://pubmed.ncbi.nlm.nih.gov/22252256/>
26. Kamilaris C, Faucz F, Voutetakis A, Stratakis C. Carney Complex. *Exp Clin Endocrinol Diabetes*. 2019;127(2-03):156-164. URL: <https://pubmed.ncbi.nlm.nih.gov/30428497/>
27. Lauper J, Krause A, Vaughan T, Monnat R. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. *PLoS One*. 2013;8(4):e59709. URL: <https://pubmed.ncbi.nlm.nih.gov/23573208/>
28. Hińcza K, Kowalik A, Kowalska A. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer. *Genes (Basel)*. 2019;10(7): URL: <https://pubmed.ncbi.nlm.nih.gov/31247975/>
29. Nosé V. Familial follicular cell tumors: classification and morphological characteristics. *Endocr Pathol*. 2010;21(4):219-26. URL: <https://pubmed.ncbi.nlm.nih.gov/20878367/>

30. Sturgeon C, Clark O. Familial nonmedullary thyroid cancer. *Thyroid*. 2005;15(6):588-93. URL: <https://pubmed.ncbi.nlm.nih.gov/16029126/>
31. Malchoff C, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V, et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. *J Clin Endocrinol Metab*. 2000;85(5):1758-64. URL: <https://pubmed.ncbi.nlm.nih.gov/10843148/>
32. Liao S, Song W, Liu Y, Deng S, Liang Y, Tang Z, et al. Familial multinodular goiter syndrome with papillary thyroid carcinomas: mutational analysis of the associated genes in 5 cases from 1 Chinese family. 2013;13:48. URL: <https://doi.org/10.1186/1472-6823-13-48>
33. Malchoff C, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Malchoff D. Familial papillary thyroid carcinoma is genetically distinct from familial adenomatous polyposis coli. *Thyroid*. 1999;9(3):247-52. URL: <https://pubmed.ncbi.nlm.nih.gov/10211600/>
34. Guilmette J, Nosé V. Hereditary and familial thyroid tumours. *Histopathology*. 2018;72(1):70-81. URL: <https://pubmed.ncbi.nlm.nih.gov/29239041/>
35. Iglesias M, Schmidt A, Ghuzlan A, Lacroix L, Vathaire F, Chevillard S, et al. Radiation exposure and thyroid cancer: a review. *Arch Endocrinol Metab*. 2017;61(2):180-187. URL: <https://pubmed.ncbi.nlm.nih.gov/28225863/>
36. Kitahara C, Berrington de Gonzalez A, Bouville A, Brill A, Doody M, Melo D, et al. Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism. *JAMA Intern Med*. 2019;179(8):1034-1042. URL: <https://pubmed.ncbi.nlm.nih.gov/31260066/>
37. Listewnik M, Birkenfeld B, Chosia M, Elbl B, Niedziałowska K, Sawrymowicz M. The occurrence of malignant thyroid lesions in patients after radioiodine treatment due to benign thyroid diseases. *Endokrynol Pol*. 2010;61(5):454-7. URL: <https://pubmed.ncbi.nlm.nih.gov/21049457/>
38. Hu M, Zhang C, Liang L, Wang S, Zheng X, Zhang Q, et al. Fasting serum glucose, thyroid-stimulating hormone, and thyroid hormones and risk of papillary thyroid cancer: A case-control study. *Head Neck*. 2019;41(7):2277-2284. URL: <https://pubmed.ncbi.nlm.nih.gov/30759328/>
39. Cao Y, Wang Z, Gu J, Hu F, Qi Y, Yin Q, et al. Reproductive Factors but Not Hormonal Factors Associated with Thyroid Cancer Risk: A Systematic Review and Meta-Analysis. *Biomed Res Int*. 2015;2015:103515. URL: <https://pubmed.ncbi.nlm.nih.gov/26339585/>
40. Braganza M, Berrington de González A, Schonfeld S, Wentzensen N, Brenner A, Kitahara C. Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer. *Cancer Prev Res (Phila)*. 2014;7(4):418-25. URL: <https://pubmed.ncbi.nlm.nih.gov/24449056/>
41. Paparodis R, Imam S, Todorova-Koteva K, Staii A, Jaume J. Hashimoto's thyroiditis pathology and risk for thyroid cancer. *Thyroid*. 2014;24(7):1107-14. URL: <https://pubmed.ncbi.nlm.nih.gov/24708347/>
42. Silva de Morais N, Stuart J, Guan H, Wang Z, Cibas E, Frates M, et al. The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer. *J Endocr Soc*. 2019;3(4):791-800. URL: <https://pubmed.ncbi.nlm.nih.gov/30963137/>
43. Kitahara C, Yanik E, Ladenson P, Hernandez B, Lynch C, Pawlish K, et al. Risk of Thyroid Cancer Among Solid Organ Transplant Recipients. *Am J Transplant*. 2017;17(11):2911-2921. URL: <https://pubmed.ncbi.nlm.nih.gov/28397388/>
44. Lengwiler E, Stampf S, Zippelius A, Salati E, Zaman K, Schäfer N, et al. Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study. *Swiss Med Wkly*. 2019;149:w20078. URL: <https://pubmed.ncbi.nlm.nih.gov/31104307/>

45. Lee J, Hwang Y, Song R, Yi J, Yu H, Kim S, et al. Relationship between iodine levels and papillary thyroid carcinoma: A systematic review and meta-analysis. *Head Neck*. 2017;39(8):1711-1718. URL: <https://pubmed.ncbi.nlm.nih.gov/28513893/>
46. Woliński K, Szkudlarek M, Szczepanek-Parulska E, Ruchała M. Usefulness of different ultrasound features of malignancy in predicting the type of thyroid lesions: a meta-analysis of prospective studies. *Pol Arch Med Wewn*. 2014;124(3):97-104. URL: <https://pubmed.ncbi.nlm.nih.gov/24473342/>
47. Remonti L, Kramer C, Leitão C, Pinto L, Gross J. Thyroid ultrasound features and risk of carcinoma: a systematic review and meta-analysis of observational studies. *Thyroid*. 2015;25(5):538-50. URL: <https://pubmed.ncbi.nlm.nih.gov/25747526/>
48. Vaccarella S, Franceschi S, Bray F, Wild C, Plummer M, Dal Maso L. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. *N Engl J Med*. 2016;375(7):614-7. URL: <https://pubmed.ncbi.nlm.nih.gov/27532827/>
49. Brito J, Gionfriddo M, Al Nofal A, Boehmer K, Leppin A, Reading C, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2014;99(4):1253-63. URL: <https://pubmed.ncbi.nlm.nih.gov/24276450/>
50. Al Nofal A, Gionfriddo M, Javed A, Haydour Q, Brito J, Prokop L, et al. Accuracy of thyroid nodule sonography for the detection of thyroid cancer in children: systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. 2016;84(3):423-30. URL: <https://pubmed.ncbi.nlm.nih.gov/25845503/>
51. Kwak J, Han K, Yoon J, Moon H, Son E, Park S, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. *Radiology*. 2011;260(3):892-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21771959/>
52. Horvath E, Silva C, Majlis S, Rodriguez I, Skoknic V, Castro A, et al. Prospective validation of the ultrasound based TIRADS (Thyroid Imaging Reporting And Data System) classification: results in surgically resected thyroid nodules. *Eur Radiol*. 2017;27(6):2619-2628. URL: <https://pubmed.ncbi.nlm.nih.gov/27718080/>
53. Tessler F, Middleton W, Grant E, Hoang J, Berland L, Teefey S, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. *J Am Coll Radiol*. 2017;14(5):587-595. URL: <https://pubmed.ncbi.nlm.nih.gov/28372962/>
54. Russ G, Bonnema S, Erdogan M, Durante C, Ngu R, Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. *Eur Thyroid J*. 2017;6(5):225-237. URL: <https://pubmed.ncbi.nlm.nih.gov/29167761/>
55. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, et al. Guidelines for the management of thyroid cancer. *Clin Endocrinol (Oxf)*. 2014;81 Suppl 1:1-122
56. Shin J, Baek J, Chung J, Ha E, Kim J, Lee Y, et al. Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. *Korean J Radiol*. 2016;17(3):370-95. URL: <https://pubmed.ncbi.nlm.nih.gov/27134526/>
57. Migda B, Migda M, Migda M, Slapa R. Use of the Kwak Thyroid Image Reporting and Data System (K-TIRADS) in differential diagnosis of thyroid nodules: systematic review and meta-analysis. *Eur Radiol*. 2018;28(6):2380-2388. URL: <https://pubmed.ncbi.nlm.nih.gov/29294156/>
58. Wei X, Li Y, Zhang S, Gao M. Meta-analysis of thyroid imaging reporting and data system in the ultrasonographic diagnosis of 10,437 thyroid nodules. *Head Neck*. 2016;38(2):309-15. URL: <https://pubmed.ncbi.nlm.nih.gov/25244250/>

59. Castellana M, Castellana C, Treglia G, Giorgino F, Giovannella L, Russ G, et al. Performance of Five Ultrasound Risk Stratification Systems in Selecting Thyroid Nodules for FNA. *J Clin Endocrinol Metab.* 2020;105(5): URL: <https://pubmed.ncbi.nlm.nih.gov/31690937/>
60. Wu X, Du J, Wang H, Jin C, Sui G, Yang D, et al. Comparison and preliminary discussion of the reasons for the differences in diagnostic performance and unnecessary FNA biopsies between the ACR TIRADS and 2015 ATA guidelines. *Endocrine.* 2019;65(1):121-131. URL: <https://pubmed.ncbi.nlm.nih.gov/30830584/>
61. Middleton W, Teefey S, Reading C, Langer J, Beland M, Szabunio M, et al. Comparison of Performance Characteristics of American College of Radiology TI-RADS, Korean Society of Thyroid Radiology TIRADS, and American Thyroid Association Guidelines. *AJR Am J Roentgenol.* 2018;210(5):1148-1154. URL: <https://pubmed.ncbi.nlm.nih.gov/29629797/>
62. Xu T, Wu Y, Wu R, Zhang Y, Gu J, Ye X, et al. Validation and comparison of three newly-released Thyroid Imaging Reporting and Data Systems for cancer risk determination. *Endocrine.* 2019;64(2):299-307. URL: <https://pubmed.ncbi.nlm.nih.gov/30474824/>
63. Ha E, Na D, Moon W, Lee Y, Choi N. Diagnostic Performance of Ultrasound-Based Risk-Stratification Systems for Thyroid Nodules: Comparison of the 2015 American Thyroid Association Guidelines with the 2016 Korean Thyroid Association/Korean Society of Thyroid Radiology and 2017 American College of Radiology Guidelines. *Thyroid.* 2018;28(11):1532-1537. URL: <https://pubmed.ncbi.nlm.nih.gov/30311862/>
64. Seifert P, Schenke S, Zimny M, Stahl A, Grunert M, Klemen B, et al. Diagnostic Performance of Kwak, EU, ACR, and Korean TIRADS as Well as ATA Guidelines for the Ultrasound Risk Stratification of Non-Autonomously Functioning Thyroid Nodules in a Region with Long History of Iodine Deficiency: A German Multicenter Trial. *Cancers (Basel).* 2021;13(17): URL: <https://pubmed.ncbi.nlm.nih.gov/34503277/>
65. Yoon J, Lee H, Kim E, Moon H, Kwak J. Malignancy Risk Stratification of Thyroid Nodules: Comparison between the Thyroid Imaging Reporting and Data System and the 2014 American Thyroid Association Management Guidelines. *Radiology.* 2016;278(3):917-24. URL: <https://pubmed.ncbi.nlm.nih.gov/26348102/>
66. Castellana M, Trimboli P, Piccardo A, Giovannella L, Treglia G. Performance of. *J Clin Med.* 2019;8(9): URL: <https://pubmed.ncbi.nlm.nih.gov/31466411/>
67. Seifert P, Görges R, Zimny M, Kreissl M, Schenke S. Interobserver agreement and efficacy of consensus reading in Kwak-, EU-, and ACR-thyroid imaging recording and data systems and ATA guidelines for the ultrasound risk stratification of thyroid nodules. *Endocrine.* 2020;67(1):143-154. URL: <https://pubmed.ncbi.nlm.nih.gov/31741167/>
68. Tessler F, Middleton W, Grant E. Thyroid Imaging Reporting and Data System (TI-RADS): A User's Guide. *Radiology.* 2018;287(1):29-36. URL: <https://pubmed.ncbi.nlm.nih.gov/29558300/>
69. Lin P, Chen M, Liu B, Wang S, Li X. Diagnostic performance of shear wave elastography in the identification of malignant thyroid nodules: a meta-analysis. *Eur Radiol.* 2014;24(11):2729-38. URL: <https://pubmed.ncbi.nlm.nih.gov/25113648/>
70. Trimboli P, Treglia G, Sadeghi R, Romanelli F, Giovannella L. Reliability of real-time elastography to diagnose thyroid nodules previously read at FNAC as indeterminate: a meta-analysis. *Endocrine.* 2015;50(2):335-43. URL: <https://pubmed.ncbi.nlm.nih.gov/25534701/>
71. Veer V, Puttagunta S. The role of elastography in evaluating thyroid nodules: a literature review and meta-analysis. *Eur Arch Otorhinolaryngol.* 2015;272(8):1845-55. URL: <https://pubmed.ncbi.nlm.nih.gov/24997982/>
72. Tian W, Hao S, Gao B, Jiang Y, Zhang S, Guo L, et al. Comparison of Diagnostic Accuracy of Real-Time Elastography and Shear Wave Elastography in Differentiation Malignant From

- Benign Thyroid Nodules. *Medicine (Baltimore)*. 2015;94(52):e2312. URL: <https://pubmed.ncbi.nlm.nih.gov/26717367/>
73. Zhao C, Xu H. Ultrasound elastography of the thyroid: principles and current status. *Ultrasonography*. 2019;38(2):106-124. URL: <https://pubmed.ncbi.nlm.nih.gov/30690960/>
 74. Bamber J, Cosgrove D, Dietrich C, Fromageau J, Bojunga J, Calliada F, et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography Part 1: Basic principles and technology. *Ultraschall Med*. 2013;34(2):169-84. URL: <https://pubmed.ncbi.nlm.nih.gov/23558397/>
 75. Chammas M, Moon H, Kim E. Why do we have so many controversies in thyroid nodule Doppler US?. *Radiology*. 2011;259(1):304. URL: <https://pubmed.ncbi.nlm.nih.gov/21436101/>
 76. Razavi S, Hadduck T, Sadigh G, Dwamena B. Comparative effectiveness of elastographic and B-mode ultrasound criteria for diagnostic discrimination of thyroid nodules: a meta-analysis. *AJR Am J Roentgenol*. 2013;200(6):1317-26. URL: <https://pubmed.ncbi.nlm.nih.gov/23701071/>
 77. Moon H, Kwak J, Kim M, Son E, Kim E. Can vascularity at power Doppler US help predict thyroid malignancy?. *Radiology*. 2010;255(1):260-9. URL: <https://pubmed.ncbi.nlm.nih.gov/20308462/>
 78. Mohebbi M, Dehaki M, Mozaffari M. Comparison between ultrasonographic findings and fine needle aspiration cytology in differentiating malignant and benign thyroid nodules. *Eur J Transl Myol*. 2019;29(3):8354. URL: <https://pubmed.ncbi.nlm.nih.gov/31579481/>
 79. Debnam J, Vu T, Sun J, Wei W, Krishnamurthy S, Zafereo M, et al. Vascular flow on doppler sonography may not be a valid characteristic to distinguish colloid nodules from papillary thyroid carcinoma even when accounting for nodular size. *Gland Surg*. 2019;8(5):461-468. URL: <https://pubmed.ncbi.nlm.nih.gov/31741876/>
 80. Lacout A, Chevenet C, Salas J, Marcy P. Thyroid Doppler US: Tips and tricks. *J Med Imaging Radiat Oncol*. 2016;60(2):210-5. URL: <https://pubmed.ncbi.nlm.nih.gov/26663777/>
 81. Yang G, Fried K. Most Thyroid Cancers Detected by Sonography Lack Intranodular Vascularity on Color Doppler Imaging: Review of the Literature and Sonographic-Pathologic Correlations for 698 Thyroid Neoplasms. *J Ultrasound Med*. 2017;36(1):89-94. URL: <https://pubmed.ncbi.nlm.nih.gov/27943373/>
 82. Chammas M, Gerhard R, de Oliveira I, Widman A, de Barros N, Durazzo M, et al. Thyroid nodules: evaluation with power Doppler and duplex Doppler ultrasound. *Otolaryngol Head Neck Surg*. 2005;132(6):874-82. URL: <https://pubmed.ncbi.nlm.nih.gov/15944558/>
 83. Ma X, Zhang B, Ling W, Liu R, Jia H, Zhu F, et al. Contrast-enhanced sonography for the identification of benign and malignant thyroid nodules: Systematic review and meta-analysis. *J Clin Ultrasound*. 2016;44(4):199-209. URL: <https://pubmed.ncbi.nlm.nih.gov/26402325/>
 84. Liu Q, Cheng J, Li J, Gao X, Li H. The diagnostic accuracy of contrast-enhanced ultrasound for the differentiation of benign and malignant thyroid nodules: A PRISMA compliant meta-analysis. *Medicine (Baltimore)*. 2018;97(49):e13325. URL: <https://pubmed.ncbi.nlm.nih.gov/30544392/>
 85. Xu Y, Qi X, Zhao X, Ren W, Ding W. Clinical diagnostic value of contrast-enhanced ultrasound and TI-RADS classification for benign and malignant thyroid tumors: One comparative cohort study. *Medicine (Baltimore)*. 2019;98(4):e14051. URL: <https://pubmed.ncbi.nlm.nih.gov/30681562/>
 86. Zhao H, Liu X, Lei B, Cheng P, Li J, Wu Y, et al. Impact of thyroid nodule sizes on the diagnostic performance of Korean thyroid imaging reporting and data system and contrast-enhanced ultrasound. *Clin Hemorheol Microcirc*. 2019;72(3):317-326. URL: <https://pubmed.ncbi.nlm.nih.gov/30856106/>

87. Li F, Wang Y, Bai B, Wang S, Liu S. Advantages of Routine Ultrasound Combined With Contrast-Enhanced Ultrasound in Diagnosing Papillary Thyroid Carcinoma. *Ultrasound Q*. 2017;33(3):213-218. URL: <https://pubmed.ncbi.nlm.nih.gov/28832401/>
88. Ma H, Yang J, Leng Z, Chang Y, Kang H, Teng L. Preoperative prediction of papillary thyroid microcarcinoma via multiparameter ultrasound. *Acta Radiol*. 2017;58(11):1303-1311. URL: <https://pubmed.ncbi.nlm.nih.gov/28194993/>
89. Zhang Y, Xu T, Gong H, Li C, Ye X, Lin H, et al. Application of high-resolution ultrasound, real-time elastography, and contrast-enhanced ultrasound in differentiating solid thyroid nodules. *Medicine (Baltimore)*. 2016;95(45):e5329. URL: <https://pubmed.ncbi.nlm.nih.gov/27828854/>
90. Liu Y, Wu H, Zhou Q, Gou J, Xu J, Liu Y, et al. Diagnostic Value of Conventional Ultrasonography Combined with Contrast-Enhanced Ultrasonography in Thyroid Imaging Reporting and Data System (TI-RADS) 3 and 4 Thyroid Micronodules. *Med Sci Monit*. 2016;22:3086-94. URL: <https://pubmed.ncbi.nlm.nih.gov/27580248/>
91. Zhang Y, Zhou P, Tian S, Zhao Y, Li J, Li L. Usefulness of combined use of contrast-enhanced ultrasound and TI-RADS classification for the differentiation of benign from malignant lesions of thyroid nodules. *Eur Radiol*. 2017;27(4):1527-1536. URL: <https://pubmed.ncbi.nlm.nih.gov/27525973/>
92. Deng J, Zhou P, Tian S, Zhang L, Li J, Qian Y. Comparison of diagnostic efficacy of contrast-enhanced ultrasound, acoustic radiation force impulse imaging, and their combined use in differentiating focal solid thyroid nodules. *PLoS One*. 2014;9(3):e90674. URL: <https://pubmed.ncbi.nlm.nih.gov/24594879/>
93. Agha A, Jung E, Janke M, Hornung M, Georgieva M, Schlitt H, et al. Preoperative diagnosis of thyroid adenomas using high resolution contrast-enhanced ultrasound (CEUS). *Clin Hemorheol Microcirc*. 2013;55(4):403-9. URL: <https://pubmed.ncbi.nlm.nih.gov/24113497/>
94. Leenhardt L, Erdogan M, Hegedus L, Mandel S, Paschke R, Rago T, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. *Eur Thyroid J*. 2013;2(3):147-59. URL: <https://pubmed.ncbi.nlm.nih.gov/24847448/>
95. Hwang H, Orloff L. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. *Laryngoscope*. 2011;121(3):487-91. URL: <https://pubmed.ncbi.nlm.nih.gov/21344423/>
96. O'Connell K, Yen T, Quiroz F, Evans D, Wang T. The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer. *Surgery*. 2013;154(4):697-701; discussion 701-3. URL: <https://pubmed.ncbi.nlm.nih.gov/24011674/>
97. Yeh M, Bauer A, Bernet V, Ferris R, Loevner L, Mandel S, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. *Thyroid*. 2015;25(1):3-14. URL: <https://pubmed.ncbi.nlm.nih.gov/25188202/>
98. Zhao H, Li H. Meta-analysis of ultrasound for cervical lymph nodes in papillary thyroid cancer: Diagnosis of central and lateral compartment nodal metastases. *Eur J Radiol*. 2019;112:14-21. URL: <https://pubmed.ncbi.nlm.nih.gov/30777203/>
99. Wu L, Gu H, Qu X, Zheng J, Zhang W, Yin Y, et al. The accuracy of ultrasonography in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma: A meta-analysis. *Eur J Radiol*. 2012;81(8):1798-805. URL: <https://pubmed.ncbi.nlm.nih.gov/21536396/>
100. Xing Z, Qiu Y, Yang Q, Yu Y, Liu J, Fei Y, et al. Thyroid cancer neck lymph nodes metastasis: Meta-analysis of US and CT diagnosis. *Eur J Radiol*. 2020;129:109103. URL: <https://pubmed.ncbi.nlm.nih.gov/32574937/>

101. Leboulleux S, Girard E, Rose M, Travagli J, Sabbah N, Caillou B, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. *J Clin Endocrinol Metab.* 2007;92(9):3590-4. URL: <https://pubmed.ncbi.nlm.nih.gov/17609301/>
102. Azizi G, Keller J, Mayo M, Piper K, Puett D, Earp K, et al. Shear Wave Elastography and Cervical Lymph Nodes: Predicting Malignancy. *Ultrasound Med Biol.* 2016;42(6):1273-81. URL: <https://pubmed.ncbi.nlm.nih.gov/26976785/>
103. Khokhar M, Day K, Sangal R, Ahmedli N, Pisharodi L, Beland M, et al. Preoperative High-Resolution Ultrasound for the Assessment of Malignant Central Compartment Lymph Nodes in Papillary Thyroid Cancer. *Thyroid.* 2015;25(12):1351-4. URL: <https://pubmed.ncbi.nlm.nih.gov/26431908/>
104. Kim E, Park J, Son K, Kim J, Jeon S, Na D. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. *Thyroid.* 2008;18(4):411-8. URL: <https://pubmed.ncbi.nlm.nih.gov/18358074/>
105. Moreno M, Edeiken-Monroe B, Siegel E, Sherman S, Clayman G. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. *Thyroid.* 2012;22(4):347-55. URL: <https://pubmed.ncbi.nlm.nih.gov/22280230/>
106. Ahuja A, Ying M. Sonographic evaluation of cervical lymph nodes. *AJR Am J Roentgenol.* 2005;184(5):1691-9. URL: <https://pubmed.ncbi.nlm.nih.gov/15855141/>
107. U S V, Shivalli S, Rai S, Haris A, Madhurkar R, Hemraj S. Diagnostic accuracy of high resolution ultrasound to differentiate neoplastic and non neoplastic causes of cervical lymphadenopathy. *J Clin Diagn Res.* 2014;8(9):RC05-7. URL: <https://pubmed.ncbi.nlm.nih.gov/25386501/>
108. Sohn Y, Kwak J, Kim E, Moon H, Kim S, Kim M. Diagnostic approach for evaluation of lymph node metastasis from thyroid cancer using ultrasound and fine-needle aspiration biopsy. *AJR Am J Roentgenol.* 2010;194(1):38-43. URL: <https://pubmed.ncbi.nlm.nih.gov/20028903/>
109. do Rosário P, Fagundes T, Maia F, Franco A, Figueiredo M, Purisch S. Sonography in the diagnosis of cervical recurrence in patients with differentiated thyroid carcinoma. *J Ultrasound Med.* 2004;23(7):915-20; quiz 921-2. URL: <https://pubmed.ncbi.nlm.nih.gov/15292559/>
110. Steinkamp H, Cornehl M, Hosten N, Pegios W, Vogl T, Felix R. Cervical lymphadenopathy: ratio of long- to short-axis diameter as a predictor of malignancy. *Br J Radiol.* 1995;68(807):266-70. URL: <https://pubmed.ncbi.nlm.nih.gov/7735765/>
111. Kuna S, Bracic I, Tesic V, Kuna K, Herceg G, Dodig D. Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. *J Ultrasound Med.* 2006;25(12):1531-7; quiz 1538-40. URL: <https://pubmed.ncbi.nlm.nih.gov/17121947/>
112. Tomoda C, Sugino K, Matsuzu K, Uruno T, Ohkuwa K, Kitagawa W, et al. Cervical Lymph Node Metastases After Thyroidectomy for Papillary Thyroid Carcinoma Usually Remain Stable for Years. *Thyroid.* 2016;26(12):1706-1711. URL: <https://pubmed.ncbi.nlm.nih.gov/27616725/>
113. Kupferman M, Patterson M, Mandel S, LiVolsi V, Weber R. Patterns of lateral neck metastasis in papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg.* 2004;130(7):857-60. URL: <https://pubmed.ncbi.nlm.nih.gov/15262763/>
114. Onoda N, Ishikawa T, Kawajiri H, Takashima T, Hirakawa K. Pattern of initial metastasis in the cervical lymph node from papillary thyroid carcinoma. *Surg Today.* 2013;43(2):178-84. URL: <https://pubmed.ncbi.nlm.nih.gov/22732927/>

115. Desmots F, Fakhry N, Mancini J, Reyre A, Vidal V, Jacquier A, et al. Shear Wave Elastography in Head and Neck Lymph Node Assessment: Image Quality and Diagnostic Impact Compared with B-Mode and Doppler Ultrasonography. *Ultrasound Med Biol*. 2016;42(2):387-98. URL: <https://pubmed.ncbi.nlm.nih.gov/26617244/>
116. Xu J, Xu X, Xu H, Zhang Y, Guo L, Liu L, et al. Prediction of cervical lymph node metastasis in patients with papillary thyroid cancer using combined conventional ultrasound, strain elastography, and acoustic radiation force impulse (ARFI) elastography. *Eur Radiol*. 2016;26(8):2611-22. URL: <https://pubmed.ncbi.nlm.nih.gov/26560715/>
117. Görges R, Eising E, Fotescu D, Renzing-Köhler K, Frilling A, Schmid K, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. *Eur J Ultrasound*. 2003;16(3):191-206. URL: <https://pubmed.ncbi.nlm.nih.gov/12573788/>
118. Giovanella L, Paone G, Ruberto T, Ceriani L, Trimboli P. *Endocrinol Metab* (Seoul). 2019;34(1):63-69. URL: <https://pubmed.ncbi.nlm.nih.gov/30784242/>
119. Schenke S, Seifert P, Zimny M, Winkens T, Binse I, Görges R. Risk Stratification of Thyroid Nodules Using the Thyroid Imaging Reporting and Data System (TIRADS): The Omission of Thyroid Scintigraphy Increases the Rate of Falsely Suspected Lesions. *J Nucl Med*. 2019;60(3):342-347. URL: <https://pubmed.ncbi.nlm.nih.gov/30097501/>
120. Ruhlmann M, Stebner V, Görges R, Farahati J, Simon D, Bockisch A, et al. Diagnosis of hyperfunctional thyroid nodules: impact of US-elastography. *Nuklearmedizin*. 2014;53(5):173-7. URL: <https://pubmed.ncbi.nlm.nih.gov/24898434/>
121. Trimboli P, Paone G, Zatelli M, Ceriani L, Giovanella L. Real-time elastography in autonomously functioning thyroid nodules: relationship with TSH levels, scintigraphy, and ultrasound patterns. *Endocrine*. 2017;58(3):488-494. URL: <https://pubmed.ncbi.nlm.nih.gov/28285385/>
122. COLE W, MAJARAKIS J, SLAUGHTER D. Incidence of carcinoma of the thyroid in nodular goiter. *J Clin Endocrinol Metab*. 1949;9(10):1007-11. URL: <https://pubmed.ncbi.nlm.nih.gov/18142433/>
123. DOBYNS B, SKANSE B, MALOOF F. A method for the preoperative estimation of function in thyroid tumors; its significance in diagnosis and treatment. *J Clin Endocrinol Metab*. 1949;9(11):1171-84, illust. URL: <https://pubmed.ncbi.nlm.nih.gov/15395981/>
124. Schröder S, Marthaler B. [Autonomy and malignancy of thyroid gland tumors A critical analysis of the literature on the existence of hyperfunctioning follicular and papillary thyroid gland carcinomas]. *Pathologe*. 1996;17(5):349-57. URL: <https://pubmed.ncbi.nlm.nih.gov/8992477/>
125. Schicha H, Hellmich M, Lehmacher W, Eschner W, Schmidt M, Kobe C, et al. [Should all patients with thyroid nodules > or = 1 cm undergo fine-needle aspiration biopsy?]. *Nuklearmedizin*. 2009;48(3):79-83. URL: <https://pubmed.ncbi.nlm.nih.gov/19325991/>
126. Belfiore A, La Rosa G, Padova G, Sava L, Ippolito O, Vigneri R. The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area. *Cancer*. 1987;60(12):3096-102. URL: <https://pubmed.ncbi.nlm.nih.gov/3677033/>
127. Christensen S, Bondeson L, Ericsson U, Lindholm K. Prediction of malignancy in the solitary thyroid nodule by physical examination, thyroid scan, fine-needle biopsy and serum thyroglobulin A prospective study of 100 surgically treated patients. *Acta Chir Scand*. 1984;150(6):433-9. URL: <https://pubmed.ncbi.nlm.nih.gov/6495973/>
128. Ross D, Burch H, Cooper D, Greenlee M, Laurberg P, Maia A, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid*. 2016;26(10):1343-1421. URL: <https://pubmed.ncbi.nlm.nih.gov/27521067/>

129. Biondi B, Bartalena L, Cooper D, Hegedüs L, Laurberg P, Kahaly G. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. *Eur Thyroid J.* 2015;4(3):149-63. URL: <https://pubmed.ncbi.nlm.nih.gov/26558232/>
130. Kim H, Yoon J, Kim S, Cho J, Kweon S, Kang H. Higher TSH level is a risk factor for differentiated thyroid cancer. *Clin Endocrinol (Oxf).* 2013;78(3):472-7. URL: <https://pubmed.ncbi.nlm.nih.gov/22924613/>
131. Figuera T, Perez C, Faris N, Scarabotto P, da Silva T, Cavalcanti T, et al. TSH levels are associated with increased risk of thyroid carcinoma in patients with nodular disease. *Endokrynol Pol.* 2015;66(6):480-5. URL: <https://pubmed.ncbi.nlm.nih.gov/26662646/>
132. Batool S, Afridi M, Khoja A, Islam N. Pre-operative serum TSH levels: A risk factor for advanced metastatic differentiated thyroid carcinoma. *Pak J Med Sci.* 2019;35(5):1312-1317. URL: <https://pubmed.ncbi.nlm.nih.gov/31488998/>
133. Boelaert K, Horacek J, Holder R, Watkinson J, Sheppard M, Franklyn J. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *J Clin Endocrinol Metab.* 2006;91(11):4295-301. URL: <https://pubmed.ncbi.nlm.nih.gov/16868053/>
134. Khan M, Malik N, Khan K, Shahzad M. Association of Preoperative Serum Thyroid-stimulating Hormone Levels with Thyroid Cancer in Patients with Nodular Thyroid Disease. *World J Nucl Med.* 2017;16(3):202-205. URL: <https://pubmed.ncbi.nlm.nih.gov/28670178/>
135. Zafón C, Obiols G, Mesa J. Preoperative TSH level and risk of thyroid cancer in patients with nodular thyroid disease: nodule size contribution. *Endocrinol Nutr.* 2015;62(1):24-8. URL: <https://pubmed.ncbi.nlm.nih.gov/25066642/>
136. Huang H, Rusiecki J, Zhao N, Chen Y, Ma S, Yu H, et al. Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study. *Cancer Epidemiol Biomarkers Prev.* 2017;26(8):1209-1218. URL: <https://pubmed.ncbi.nlm.nih.gov/28377419/>
137. Zhu C, Li S, Gao X, Zhu G, Song M, Gao F. Retrospective Analysis of Thyroid Nodules: Thyroid Cancer Risk Factors in Suzhou, China. *Clin Lab.* 2018;64(3):333-338. URL: <https://pubmed.ncbi.nlm.nih.gov/29739119/>
138. Zhao H, Li H, Huang T. High Urinary Iodine, Thyroid Autoantibodies, and Thyroid-Stimulating Hormone for Papillary Thyroid Cancer Risk. *Biol Trace Elem Res.* 2018;184(2):317-324. URL: <https://pubmed.ncbi.nlm.nih.gov/29164514/>
139. Haymart M, Repplinger D, Levenson G, Elson D, Sippel R, Jaume J, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *J Clin Endocrinol Metab.* 2008;93(3):809-14. URL: <https://pubmed.ncbi.nlm.nih.gov/18160464/>
140. Haymart M, Glinberg S, Liu J, Sippel R, Jaume J, Chen H. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. *Clin Endocrinol (Oxf).* 2009;71(3):434-9. URL: <https://pubmed.ncbi.nlm.nih.gov/19067720/>
141. Kim S, Lee B, Lee J, Song S, Kim B, Son S, et al. Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: a single-center experience. *Endocrine.* 2011;39(3):259-65. URL: <https://pubmed.ncbi.nlm.nih.gov/21161440/>
142. Adhami M, Michail P, Rao A, Bhatt C, Grodski S, Serpell J, et al. Anti-Thyroid Antibodies and TSH as Potential Markers of Thyroid Carcinoma and Aggressive Behavior in Patients with

- Indeterminate Fine-Needle Aspiration Cytology. *World J Surg.* 2020;44(2):363-370. URL: <https://pubmed.ncbi.nlm.nih.gov/31502005/>
143. Cappelli C, Pirola I, Gandossi E, Rotondi M, Lombardi D, Casella C, et al. Could Serum TSH Levels Predict Malignancy in Euthyroid Patients Affected by Thyroid Nodules with Indeterminate Cytology?. *Int J Endocrinol.* 2020;2020:7543930. URL: <https://pubmed.ncbi.nlm.nih.gov/32377187/>
 144. Fernández-Trujillo C, Pérez-Zaballos J, Rodríguez-Pérez C, López-Plasencia Y, Marrero-Arencibia D, Cabrera-Galván J, et al. TSH Level and Risk of Malignancy in Patients with Bethesda Category IV Thyroid Nodules. *Horm Cancer.* 2020;11(3-4):200-204. URL: <https://pubmed.ncbi.nlm.nih.gov/32266672/>
 145. Ahn D, Sohn J, Kim J, Shin C, Jeon J, Park J. Preoperative subclinical hypothyroidism in patients with papillary thyroid carcinoma. *Am J Otolaryngol.* 2013;34(4):312-9. URL: <https://pubmed.ncbi.nlm.nih.gov/23357595/>
 146. Fiore E, Rago T, Provenzale M, Scutari M, Ugolini C, Basolo F, et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. *Endocr Relat Cancer.* 2009;16(4):1251-60. URL: <https://pubmed.ncbi.nlm.nih.gov/19528244/>
 147. Paparodis R, Bantouna D, Karvounis E, Imam S, Jaume J. Higher TSH Is Not Associated With Thyroid Cancer Risk in the Presence of Thyroid Autoimmunity. *J Clin Endocrinol Metab.* 2020;105(7): URL: <https://pubmed.ncbi.nlm.nih.gov/32391913/>
 148. Schiffmann L, Kostev K, Kalder M. Association between various thyroid gland diseases, TSH values and thyroid cancer: a case-control study. *J Cancer Res Clin Oncol.* 2020;146(11):2989-2994. URL: <https://pubmed.ncbi.nlm.nih.gov/32518973/>
 149. Su A, Zhao W, Wu W, Wei T, Ruan M, Li Z, et al. The association of preoperative thyroid-stimulating hormone level and the risk of differentiated thyroid cancer in patients with thyroid nodules: A systematic review and meta-analysis. *Am J Surg.* 2020;220(3):634-641. URL: <https://pubmed.ncbi.nlm.nih.gov/31955813/>
 150. Eilsberger F, Pfestroff A, Librizzi D, Luster M. [Follow-up of differentiated thyroid cancer]. *Dtsch Med Wochenschr.* 2020;145(17):1236-1244. URL: <https://pubmed.ncbi.nlm.nih.gov/32634842/>
 151. Suh I, Vriens M, Guerrero M, Griffin A, Shen W, Duh Q, et al. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid. *Am J Surg.* 2010;200(1):41-6. URL: <https://pubmed.ncbi.nlm.nih.gov/20637335/>
 152. Trimboli P, Treglia G, Giovanella L. Preoperative measurement of serum thyroglobulin to predict malignancy in thyroid nodules: a systematic review. *Horm Metab Res.* 2015;47(4):247-52. URL: <https://pubmed.ncbi.nlm.nih.gov/25384015/>
 153. Hulikal N, Re A, Banoth M, Chowhan A, Yutla M, Sachan A. Can preoperative serum thyroglobulin levels predict the risk of malignancy? Results from prospective analysis of biochemical predictors of malignancy in thyroid nodules. *Acta Otorhinolaryngol Ital.* 2020;40(1):33-37. URL: <https://pubmed.ncbi.nlm.nih.gov/32275647/>
 154. Lee E, Chung K, Min H, Kim T, Kim T, Ryu J, et al. Preoperative serum thyroglobulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules. *J Korean Med Sci.* 2012;27(9):1014-8. URL: <https://pubmed.ncbi.nlm.nih.gov/22969246/>
 155. Patel A, Shostrom V, Treude K, Lydiatt W, Smith R, Goldner W. Serum Thyroglobulin: Preoperative Levels and Factors Affecting Postoperative Optimal Timing following Total Thyroidectomy. *Int J Endocrinol.* 2019;2019:1384651. URL: <https://pubmed.ncbi.nlm.nih.gov/30915112/>

156. Kang M, Wang T, Yen T, Doffek K, Evans D, Dream S. The Clinical Utility of Preoperative Thyroglobulin for Surgical Decision Making in Thyroid Disease. *J Surg Res.* 2022;270:230-235. URL: <https://pubmed.ncbi.nlm.nih.gov/34710703/>
157. Petric R, Besic H, Besic N. Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hürthle cell neoplasms of the thyroid gland. *World J Surg Oncol.* 2014;12:282. URL: <https://pubmed.ncbi.nlm.nih.gov/25213012/>
158. Ma Z, Skeaff S. Thyroglobulin as a biomarker of iodine deficiency: a review. *Thyroid.* 2014;24(8):1195-209. URL: <https://pubmed.ncbi.nlm.nih.gov/24762031/>
159. Zimmermann M, Aeberli I, Andersson M, Assey V, Yorg J, Jooste P, et al. Thyroglobulin is a sensitive measure of both deficient and excess iodine intakes in children and indicates no adverse effects on thyroid function in the UIC range of 100-299 µg/L: a UNICEF/ICCIDD study group report. *J Clin Endocrinol Metab.* 2013;98(3):1271-80. URL: <https://pubmed.ncbi.nlm.nih.gov/23345097/>
160. Cheng X, Xu S, Zhu Y, Wu J, Bao J, Yu H, et al. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer. *Eur J Clin Invest.* 2022;52(4):e13721. URL: <https://pubmed.ncbi.nlm.nih.gov/34855206/>
161. Kim H, Park S, Choe J, Kim J, Hahn S, Kim S, et al. Preoperative Serum Thyroglobulin and Its Correlation with the Burden and Extent of Differentiated Thyroid Cancer. *Cancers (Basel).* 2020;12(3). URL: <https://pubmed.ncbi.nlm.nih.gov/32182688/>
162. Wang L, Li H, Yang Z, Guo Z, Zhang Q. Preoperative Serum Thyrotropin to Thyroglobulin Ratio Is Effective for Thyroid Nodule Evaluation in Euthyroid Patients. *Otolaryngol Head Neck Surg.* 2015;153(1):15-9. URL: <https://pubmed.ncbi.nlm.nih.gov/25883100/>
163. Karvounis E, Kappas I, Angelousi A, Makris G, Siamatras T, Kassi E. The diagnostic and predictive accuracy of thyroglobulin to TSH ratio and TSH to thyroglobulin ratio in detecting differentiated thyroid carcinoma in normothyroid patients with thyroid nodules: A retrospective cohort study and systematic review of the literature. *Oncol Rev.* 2020;14(2):439. URL: <https://pubmed.ncbi.nlm.nih.gov/33505608/>
164. Noel J, Thatipamala P, Hung K, Chen J, Shi R, Orloff L. Pre-Operative Antithyroid Antibodies in Differentiated Thyroid Cancer. *Endocr Pract.* 2021;27(11):1114-1118. URL: <https://pubmed.ncbi.nlm.nih.gov/34217894/>
165. Li L, Shan T, Sun X, Lv B, Chen B, Liu N, et al. Positive Thyroid Peroxidase Antibody and Thyroglobulin Antibody are Associated With Better Clinicopathologic Features of Papillary Thyroid Cancer. *Endocr Pract.* 2021;27(4):306-311. URL: <https://pubmed.ncbi.nlm.nih.gov/33645517/>
166. Jo K, Kim M, Ha J, Lim Y, Lee S, Bae J, et al. Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer. *Clin Endocrinol (Oxf).* 2017;87(3):292-299. URL: <https://pubmed.ncbi.nlm.nih.gov/28493284/>
167. Kim E, Lim D, Baek K, Lee J, Kim M, Kwon H, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. *Thyroid.* 2010;20(8):885-91. URL: <https://pubmed.ncbi.nlm.nih.gov/20465529/>
168. Vasileiadis I, Boutzios G, Charitoudis G, Koukouliti E, Karatzas T. Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. *Ann Surg Oncol.* 2014;21(8):2725-32. URL: <https://pubmed.ncbi.nlm.nih.gov/24595799/>
169. Hosseini S, Payne R, Zawawi F, Mlynarek A, Hier M, Tamlia M, et al. Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer?. *J Otolaryngol Head Neck Surg.* 2016;45(1):31. URL: <https://pubmed.ncbi.nlm.nih.gov/27179632/>

170. Jia X, Pang P, Wang L, Zhao L, Jiang L, Song Y, et al. Clinical Analysis of Preoperative Anti-thyroglobulin Antibody in Papillary Thyroid Cancer Between 2011 and 2015 in Beijing, China: A Retrospective Study. *Front Endocrinol (Lausanne)*. 2020;11:452. URL: <https://pubmed.ncbi.nlm.nih.gov/32760349/>
171. Grani G, Calvanese A, Carbotta G, D'Alessandri M, Nesca A, Bianchini M, et al. Thyroid autoimmunity and risk of malignancy in thyroid nodules submitted to fine-needle aspiration cytology. *Head Neck*. 2015;37(2):260-4. URL: <https://pubmed.ncbi.nlm.nih.gov/24375752/>
172. Wong S, Grodski S, Yeung M, Serpell J. Anti-thyroid antibodies as a predictor of thyroid cancer. *ANZ J Surg*. 2015;85(11):849-53. URL: <https://pubmed.ncbi.nlm.nih.gov/24299506/>
173. Karatzas T, Vasileiadis I, Zapanti E, Charitoudis G, Karakostas E, Boutzios G. Thyroglobulin antibodies as a potential predictive marker of papillary thyroid carcinoma in patients with indeterminate cytology. *Am J Surg*. 2016;212(5):946-952. URL: <https://pubmed.ncbi.nlm.nih.gov/27324384/>
174. Knappe L, Giovanella L. Life after thyroid cancer: the role of thyroglobulin and thyroglobulin antibodies for postoperative follow-up. *Expert Rev Endocrinol Metab*. 2021;16(6):273-279. URL: <https://pubmed.ncbi.nlm.nih.gov/34693849/>
175. Lee Y, Park K, Park S, Kim K, Shin D, Nam K, et al. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF. *Head Neck*. 2018;40(10):2271-2279. URL: <https://pubmed.ncbi.nlm.nih.gov/29935011/>
176. Wu X, Lun Y, Jiang H, Gang Q, Xin S, Duan Z, et al. Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer. *Endocrine*. 2014;46(3):554-60. URL: <https://pubmed.ncbi.nlm.nih.gov/24338678/>
177. Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, von Buchwald C. Association between Hashimoto's Thyroiditis and Thyroid Cancer in 64,628 Patients. *Front Oncol*. 2017;7:53. URL: <https://pubmed.ncbi.nlm.nih.gov/28443243/>
178. Boi F, Pani F, Calò P, Lai M, Mariotti S. High prevalence of papillary thyroid carcinoma in nodular Hashimoto's thyroiditis at the first diagnosis and during the follow-up. *J Endocrinol Invest*. 2018;41(4):395-402. URL: <https://pubmed.ncbi.nlm.nih.gov/28875268/>
179. Song E, Oh H, Jeon M, Chung K, Hong S, Ryu J, et al. The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma. *Int J Cancer*. 2019;144(6):1414-1420. URL: <https://pubmed.ncbi.nlm.nih.gov/30357831/>
180. Krátký J, Ježková J, Kosák M, Vítková H, Bartáková J, Mráz M, et al. Positive Antithyroid Antibodies and Nonsuppressed TSH Are Associated with Thyroid Cancer: A Retrospective Cross-Sectional Study. *Int J Endocrinol*. 2018;2018:9793850. URL: <https://pubmed.ncbi.nlm.nih.gov/30258461/>
181. Lai X, Xia Y, Zhang B, Li J, Jiang Y. A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk. *Oncotarget*. 2017;8(37):62414-62424. URL: <https://pubmed.ncbi.nlm.nih.gov/28977955/>
182. Lloyd RV, Osamura RY, Klöppel G, Rosai J, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of endocrine organs. World Health Organization classification of tumours. 2017
183. Accurso A, Rocco N, Palumbo A, Feleppa C. Usefulness of ultrasound-guided fine-needle aspiration cytology in the diagnosis of non-palpable small thyroid nodules: our growing experience. *J Endocrinol Invest*. 2009;32(2):156-9. URL: <https://pubmed.ncbi.nlm.nih.gov/19411815/>

184. Słowińska-Klencka D, Popowicz B, Lewiński A, Sporny S, Klencki M. The fine-needle aspiration biopsy efficacy of small thyroid nodules in the area of recently normalized iodine supply. *Eur J Endocrinol.* 2008;159(6):747-54. URL: <https://pubmed.ncbi.nlm.nih.gov/18794209/>
185. Scheuba C, Kaserer K, Kaczirek K, Asari R, Niederle B. Desmoplastic stromal reaction in medullary thyroid cancer-an intraoperative "marker" for lymph node metastases. *World J Surg.* 2006;30(5):853-9. URL: <https://pubmed.ncbi.nlm.nih.gov/16680600/>
186. Koperek O, Scheuba C, Cherenko M, Neuhold N, De Micco C, Schmid K, et al. Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. *Histopathology.* 2008;52(5):623-30. URL: <https://pubmed.ncbi.nlm.nih.gov/18370959/>
187. Machens A, Dralle H. Clinical relevance of desmoplasia in medullary thyroid carcinoma. *Histopathology.* 2008;53(4):481; author reply 482-3. URL: <https://pubmed.ncbi.nlm.nih.gov/18764881/>
188. Niederle M, Riss P, Selberherr A, Koperek O, Kaserer K, Niederle B, et al. Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction. *Br J Surg.* 2021;108(2):174-181. URL: <https://pubmed.ncbi.nlm.nih.gov/33704404/>
189. Wu M. A comparative study of 200 head and neck FNAs performed by a cytopathologist with versus without ultrasound guidance: evidence for improved diagnostic value with ultrasound guidance. *Diagn Cytopathol.* 2011;39(10):743-51. URL: <https://pubmed.ncbi.nlm.nih.gov/20949470/>
190. Conrad R, Yang S, Chang S, Bhasin M, Sullivan P, Moatamed N, et al. Comparison of Cytopathologist-Performed Ultrasound-Guided Fine-Needle Aspiration With Cytopathologist-Performed Palpation-Guided Fine-Needle Aspiration: A Single Institutional Experience. *Arch Pathol Lab Med.* 2018;142(10):1260-1267. URL: <https://pubmed.ncbi.nlm.nih.gov/29697276/>
191. Taha I, Al-Thani H, El-Menyar A, Asim M, Al-Sulaiti M, Tabea A. Diagnostic accuracy of preoperative palpation- versus ultrasound-guided thyroid fine needle aspiration cytology: an observational study. *Postgrad Med.* 2020;132(5):465-472. URL: <https://pubmed.ncbi.nlm.nih.gov/32163318/>
192. Zhang L, Liu Y, Tan X, Liu X, Zhang H, Qian L. Comparison of Different-Gauge Needles for Fine-Needle Aspiration Biopsy of Thyroid Nodules. *J Ultrasound Med.* 2018;37(7):1713-1716. URL: <https://pubmed.ncbi.nlm.nih.gov/29288581/>
193. İnci M, Özkan F, Yüksel M, Şalk İ, Şahin M. The effects of sonographic and demographic features and needle size on obtaining adequate cytological material in sonography-guided fine-needle aspiration biopsy of thyroid nodules. *Endocrine.* 2013;43(2):424-9. URL: <https://pubmed.ncbi.nlm.nih.gov/22956413/>
194. Moss W, Finegersh A, Pang J, Califano J, Coffey C, Orosco R, et al. Needle Biopsy of Routine Thyroid Nodules Should Be Performed Using a Capillary Action Technique with 24- to 27-Gauge Needles: A Systematic Review and Meta-Analysis. *Thyroid.* 2018;28(7):857-863. URL: <https://pubmed.ncbi.nlm.nih.gov/29742978/>
195. Tanaka A, Hirokawa M, Higuchi M, Kanematsu R, Suzuki A, Kuma S, et al. Optimal needle size for thyroid fine needle aspiration cytology. *Endocr J.* 2019;66(2):143-147. URL: <https://pubmed.ncbi.nlm.nih.gov/30464152/>
196. Pothier D, Narula A. Should we apply suction during fine needle cytology of thyroid lesions? A systematic review and meta-analysis. *Ann R Coll Surg Engl.* 2006;88(7):643-5. URL: <https://pubmed.ncbi.nlm.nih.gov/17132312/>
197. Song H, Wei C, Li D, Hua K, Song J, Maskey N, et al. Comparison of Fine Needle Aspiration and Fine Needle Nonaspiration Cytology of Thyroid Nodules: A Meta-Analysis. *Biomed Res Int.* 2015;2015:796120. URL: <https://pubmed.ncbi.nlm.nih.gov/26491689/>

198. Wang D, Fu H, Xu H, Guo L, Li X, He Y, et al. Comparison of fine needle aspiration and non-aspiration cytology for diagnosis of thyroid nodules: A prospective, randomized, and controlled trial. *Clin Hemorheol Microcirc.* 2017;66(1):67-81. URL: <https://pubmed.ncbi.nlm.nih.gov/28128748/>
199. Nagarajah J, Sheu-Grabellus S, Farahati J, Kamruddin K, Bockisch A, Schmid K, et al. Ultrasound-guided fine-needle aspiration biopsy of clinically suspicious thyroid nodules with an automatic aspirator: a novel technique. *Thyroid.* 2012;22(7):695-8. URL: <https://pubmed.ncbi.nlm.nih.gov/22524469/>
200. Chong Y, Ji S, Kang C, Lee E. Can liquid-based preparation substitute for conventional smear in thyroid fine-needle aspiration? A systematic review based on meta-analysis. *Endocr Connect.* 2017;6(8):817-829. URL: <https://pubmed.ncbi.nlm.nih.gov/29018157/>
201. Nagarajan N, Schneider E, Ali S, Zeiger M, Olson M. How do liquid-based preparations of thyroid fine-needle aspiration compare with conventional smears? An analysis of 5475 specimens. *Thyroid.* 2015;25(3):308-13. URL: <https://pubmed.ncbi.nlm.nih.gov/25420135/>
202. [Public health requirements in punctures and injections]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.* 2011;54(9):1135-44. URL: <https://pubmed.ncbi.nlm.nih.gov/21887628/>
203. Lyle M, Dean D. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients taking novel oral anticoagulants. *Thyroid.* 2015;25(4):373-6. URL: <https://pubmed.ncbi.nlm.nih.gov/25584817/>
204. Khadra H, Kholmatov R, Monlezun D, Kandil E. Do anticoagulation medications increase the risk of haematoma in ultrasound-guided fine needle aspiration of thyroid lesions?. *Cytopathology.* 2018;29(6):565-568. URL: <https://pubmed.ncbi.nlm.nih.gov/29969159/>
205. Kim S, Lee H, Moon J, Kim E, Moon H, Yoon J, et al. Fine-needle aspiration versus core needle biopsy for diagnosis of thyroid malignancy and neoplasm: a matched cohort study. *Eur Radiol.* 2017;27(2):801-811. URL: <https://pubmed.ncbi.nlm.nih.gov/27260342/>
206. Chen J, Morgan T, Liu C, Khanafshar E, Choi H. Cervical Lymph Node Features Predictive of Suboptimal Adequacy During Ultrasound-Guided Fine-Needle Aspiration in Thyroid Cancer Patients. *J Ultrasound Med.* 2022;41(1):135-145. URL: <https://pubmed.ncbi.nlm.nih.gov/33665844/>
207. Suh C, Baek J, Lee J, Choi Y, Kim K, Lee J, et al. The role of core-needle biopsy in the diagnosis of thyroid malignancy in 4580 patients with 4746 thyroid nodules: a systematic review and meta-analysis. *Endocrine.* 2016;54(2):315-328. URL: <https://pubmed.ncbi.nlm.nih.gov/27220941/>
208. Du W, Fang Q, Dai L, Fan J. Fine-needle aspiration biopsy versus frozen section examination in assessing cervical lymph node metastasis in primary clinically positive neck papillary thyroid carcinoma. *Diagn Cytopathol.* 2022;50(5):217-222. URL: <https://pubmed.ncbi.nlm.nih.gov/35103414/>
209. Zhang X, Zhang X, Du W, Dai L, Luo R, Fang Q, et al. Fine Needle Biopsy Versus Core Needle Biopsy Combined With/Without Thyroglobulin or BRAF 600E Mutation Assessment for Detecting Cervical Nodal Metastasis of Papillary Thyroid Carcinoma. *Front Endocrinol (Lausanne).* 2021;12:663720. URL: <https://pubmed.ncbi.nlm.nih.gov/33912138/>
210. Landry C, Grubbs E, Busaidy N, Monroe B, Staerke G, Perrier N, et al. Cystic lymph nodes in the lateral neck as indicators of metastatic papillary thyroid cancer. *Endocr Pract.* 2011;17(2):240-4. URL: <https://pubmed.ncbi.nlm.nih.gov/20713342/>
211. Jiang H, Hsiao P. Clinical application of the ultrasound-guided fine needle aspiration for thyroglobulin measurement to diagnose lymph node metastasis from differentiated thyroid carcinoma-literature review. *Kaohsiung J Med Sci.* 2020;36(4):236-243. URL: <https://pubmed.ncbi.nlm.nih.gov/31909556/>

212. Eun N, Son E, Kim J, Gweon H, Kang J, Youk J. Comparison of the diagnostic performances of ultrasonography, CT and fine needle aspiration cytology for the prediction of lymph node metastasis in patients with lymph node dissection of papillary thyroid carcinoma: A retrospective cohort study. *Int J Surg*. 2018;51:145-150. URL: <https://pubmed.ncbi.nlm.nih.gov/29337176/>
213. Kahramangil B, Kose E, Donmez M, Aydin H, El-Dabh D, Krishnamurthy V, et al. Efficacy of surgeon-performed, ultrasound-guided lymph node fine needle aspiration in patients with thyroid pathologic conditions. *Surgery*. 2018;164(4):657-664. URL: <https://pubmed.ncbi.nlm.nih.gov/30072253/>
214. Ke Z, Liu Y, Zhang Y, Li J, Kuang M, Peng S, et al. Diagnostic value and lymph node metastasis prediction of a custom-made panel (thyroline) in thyroid cancer. *Oncol Rep*. 2018;40(2):659-668. URL: <https://pubmed.ncbi.nlm.nih.gov/29901149/>
215. Jun H, Kim S, Kim B, Lee Y, Chang H, Park C. Overcoming the limitations of fine needle aspiration biopsy: detection of lateral neck node metastasis in papillary thyroid carcinoma. *Yonsei Med J*. 2015;56(1):182-8. URL: <https://pubmed.ncbi.nlm.nih.gov/25510763/>
216. Zhu X, Zhou J, Qian Y, Yang K, Wen Q, Zhang Q, et al. Diagnostic values of thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis diagnostic values of FNA-Tg. *Endocr J*. 2020;67(2):113-123. URL: <https://pubmed.ncbi.nlm.nih.gov/31723088/>
217. Snozek C, Chambers E, Reading C, Sebo T, Sistrunk J, Singh R, et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. *J Clin Endocrinol Metab*. 2007;92(11):4278-81. URL: <https://pubmed.ncbi.nlm.nih.gov/17684045/>
218. Kim D, Jeon S, Kim C. Usefulness of thyroglobulin measurement in needle washouts of fine-needle aspiration biopsy for the diagnosis of cervical lymph node metastases from papillary thyroid cancer before thyroidectomy. *Endocrine*. 2012;42(2):399-403. URL: <https://pubmed.ncbi.nlm.nih.gov/22350587/>
219. Salmaslıoğlu A, Erbil Y, Cıtlak G, Ersöz F, Sarı S, Olmez A, et al. Diagnostic value of thyroglobulin measurement in fine-needle aspiration biopsy for detecting metastatic lymph nodes in patients with papillary thyroid carcinoma. *Langenbecks Arch Surg*. 2011;396(1):77-81. URL: <https://pubmed.ncbi.nlm.nih.gov/21052711/>
220. Uruno T, Miyauchi A, Shimizu K, Tomoda C, Takamura Y, Ito Y, et al. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. *World J Surg*. 2005;29(4):483-5. URL: <https://pubmed.ncbi.nlm.nih.gov/15776292/>
221. Xu Y, Wu D, Wu W, Jiang J, Xi C, Ye N, et al. Diagnostic value of cytology, thyroglobulin, and combination of them in fine-needle aspiration of metastatic lymph nodes in patients with differentiated thyroid cancer: A systematic review and network meta-analysis. *Medicine (Baltimore)*. 2019;98(45):e17859. URL: <https://pubmed.ncbi.nlm.nih.gov/31702649/>
222. Yi K, Kim J, Na D, Seo H, Min H, Won J, et al. Usefulness of core needle biopsy for thyroid nodules with macrocalcifications: comparison with fine-needle aspiration. *Thyroid*. 2015;25(6):657-64. URL: <https://pubmed.ncbi.nlm.nih.gov/25851539/>
223. Na D, Kim D, Kim S, Ryoo J, Jung S. Thyroid nodules with isolated macrocalcification: malignancy risk and diagnostic efficacy of fine-needle aspiration and core needle biopsy. *Ultrasonography*. 2016;35(3):212-9. URL: <https://pubmed.ncbi.nlm.nih.gov/26810196/>
224. Park K, Shin J, Hahn S, Oh Y, Kim S, Kim T, et al. Ultrasound-guided fine-needle aspiration or core needle biopsy for diagnosing follicular thyroid carcinoma?. *Clin Endocrinol (Oxf)*. 2020;92(5):468-474. URL: <https://pubmed.ncbi.nlm.nih.gov/32012326/>

225. Ha E, Baek J, Lee J, Kim J, Song D, Kim W, et al. Core needle biopsy could reduce diagnostic surgery in patients with anaplastic thyroid cancer or thyroid lymphoma. *Eur Radiol*. 2016;26(4):1031-6. URL: <https://pubmed.ncbi.nlm.nih.gov/26201291/>
226. Kim S, Lee S, Jeong S, Pak K, Kim K. Diagnostic Performance of Technetium-99m Methoxy-Isobutyl-Isonitrile for Differentiation of Malignant Thyroid Nodules: A Systematic Review and Meta-Analysis. *Thyroid*. 2018;28(10):1339-1348. URL: <https://pubmed.ncbi.nlm.nih.gov/30129898/>
227. Treglia G, Caldarella C, Saggiorato E, Ceriani L, Orlandi F, Salvatori M, et al. Diagnostic performance of (99m)Tc-MIBI scan in predicting the malignancy of thyroid nodules: a meta-analysis. *Endocrine*. 2013;44(1):70-8. URL: <https://pubmed.ncbi.nlm.nih.gov/23529672/>
228. MIBI-Scintigraphy in Hypofunctioning Thyroid Nodules. *Der Nuklearmediziner*. 2016;39(03):178. URL: [10.1055/s-0042-102525](https://pubmed.ncbi.nlm.nih.gov/27055525/)
229. Update 2019 for MIBI-Scintigraphy in cold thyroid nodules. *Nuklearmediziner*. 2019;42(3):174. URL: [10.1055/a-0916-6238](https://pubmed.ncbi.nlm.nih.gov/31662388/)
230. Wale A, Miles K, Young B, Zammit C, Williams A, Quin J, et al. Combined (99m)Tc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules. *Eur J Nucl Med Mol Imaging*. 2014;41(1):105-15. URL: <https://pubmed.ncbi.nlm.nih.gov/24030667/>
231. Szybiński Z, Huszno B, Gołkowski F, Atneisha A. Technetium 99m-methoxyisobutylisonitrile in early diagnosis of thyroid cancer. *Endokrynol Pol*. 1993;44(4):427-33. URL: <https://pubmed.ncbi.nlm.nih.gov/8055811/>
232. Schenke S, Klett R, Wagner P, Mott S, Zimny M, Feek U, et al. Characteristics of different histological subtypes of thyroid nodules classified with 99mTc-methoxy-isobutyl-isonitrile imaging and Thyroid Imaging Reporting And Data System. *Nucl Med Commun*. 2021;42(1):73-80. URL: <https://pubmed.ncbi.nlm.nih.gov/33122502/>
233. Chen W, Parsons M, Torigian D, Zhuang H, Alavi A. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. *Nucl Med Commun*. 2009;30(3):240-4. URL: <https://pubmed.ncbi.nlm.nih.gov/19262287/>
234. Nishimori H, Tabah R, Hickeson M, How J. Incidental thyroid "PETomas": clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake. *Can J Surg*. 2011;54(2):83-8. URL: <https://pubmed.ncbi.nlm.nih.gov/21251421/>
235. Marcus C, Whitworth P, Surasi D, Pai S, Subramaniam R. PET/CT in the management of thyroid cancers. *AJR Am J Roentgenol*. 2014;202(6):1316-29. URL: <https://pubmed.ncbi.nlm.nih.gov/24848831/>
236. Soelberg K, Bonnema S, Brix T, Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. *Thyroid*. 2012;22(9):918-25. URL: <https://pubmed.ncbi.nlm.nih.gov/22827552/>
237. Pattison D, Bozin M, Gorelik A, Hofman M, Hicks R, Skandarajah A. *J Nucl Med*. 2018;59(5):749-755. URL: <https://pubmed.ncbi.nlm.nih.gov/29025986/>
238. Vriens D, de Wilt J, van der Wilt G, Netea-Maier R, Oyen W, de Geus-Oei L. The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. *Cancer*. 2011;117(20):4582-94. URL: <https://pubmed.ncbi.nlm.nih.gov/21432844/>
239. Wang N, Zhai H, Lu Y. Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A

- meta-analysis of the literature. *J Otolaryngol Head Neck Surg*. 2013;42(1):38. URL: <https://pubmed.ncbi.nlm.nih.gov/24228840/>
240. Vriens D, Adang E, Netea-Maier R, Smit J, de Wilt J, Oyen W, et al. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. *J Clin Endocrinol Metab*. 2014;99(9):3263-74. URL: <https://pubmed.ncbi.nlm.nih.gov/24873995/>
 241. Deandreis D, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, et al. Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology?. *Thyroid*. 2012;22(2):165-72. URL: <https://pubmed.ncbi.nlm.nih.gov/22257371/>
 242. Piccardo A, Puntoni M, Treglia G, Foppiani L, Bertagna F, Paparo F, et al. Thyroid nodules with indeterminate cytology: prospective comparison between 18F-FDG-PET/CT, multiparametric neck ultrasonography, 99mTc-MIBI scintigraphy and histology. *Eur J Endocrinol*. 2016;174(5):693-703. URL: <https://pubmed.ncbi.nlm.nih.gov/26966173/>
 243. Rosario P, Rocha T, Calsolari M. Fluorine-18-fluorodeoxyglucose positron emission tomography in thyroid nodules with indeterminate cytology: a prospective study. *Nucl Med Commun*. 2019;40(2):185-187. URL: <https://pubmed.ncbi.nlm.nih.gov/30444748/>
 244. Urhan M, Velioglu M, Rosenbaum J, Basu S, Alavi A. Imaging for the diagnosis of thyroid cancer. *Expert Opin Med Diagn*. 2009;3(3):237-49. URL: <https://pubmed.ncbi.nlm.nih.gov/23488460/>
 245. Choi W, Chung Y, Han E, Sohn H, Lee S. Clinical value of integrated [18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the preoperative assessment of papillary thyroid carcinoma: comparison with sonography. *J Ultrasound Med*. 2011;30(9):1267-73. URL: <https://pubmed.ncbi.nlm.nih.gov/21876098/>
 246. Morita S, Mizoguchi K, Suzuki M, Iizuka K. The accuracy of (18)[F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography, ultrasonography, and enhanced computed tomography alone in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid carcinoma. *World J Surg*. 2010;34(11):2564-9. URL: <https://pubmed.ncbi.nlm.nih.gov/20645089/>
 247. Kim B, Kim S, Kim I, Pak K, Kim K. Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma. *Thyroid*. 2012;22(7):725-9. URL: <https://pubmed.ncbi.nlm.nih.gov/22524470/>
 248. Wang W, Macapinlac H, Larson S, Yeh S, Akhurst T, Finn R, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. *J Clin Endocrinol Metab*. 1999;84(7):2291-302. URL: <https://pubmed.ncbi.nlm.nih.gov/10404792/>
 249. Chung J, So Y, Lee J, Choi C, Lim S, Lee D, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. *J Nucl Med*. 1999;40(6):986-92. URL: <https://pubmed.ncbi.nlm.nih.gov/10452315/>
 250. Rosenbaum-Krumme S, Görges R, Bockisch A, Binse I. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. *Eur J Nucl Med Mol Imaging*. 2012;39(9):1373-80. URL: <https://pubmed.ncbi.nlm.nih.gov/22718304/>
 251. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, et al. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. *Thyroid*. 2015;25(4):437-44. URL: <https://pubmed.ncbi.nlm.nih.gov/25633259/>

252. Pryma D, Schöder H, Gönen M, Robbins R, Larson S, Yeung H. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. *J Nucl Med*. 2006;47(8):1260-6. URL: <https://pubmed.ncbi.nlm.nih.gov/16883003/>
253. Lowe V, Mullan B, Hay I, McIver B, Kasperbauer J. 18F-FDG PET of patients with Hürthle cell carcinoma. *J Nucl Med*. 2003;44(9):1402-6. URL: <https://pubmed.ncbi.nlm.nih.gov/12960183/>
254. Schoenberger J, Fuchs E, Fertig V, Szikszai A, Maenner P, Eilles C. Clinical value of planar and tomographic dual-isotope scintigraphy using 99mTc-methylene diphosphonate and 131I in patients with thyroid cancer. *Nucl Med Commun*. 2006;27(11):865-71. URL: <https://pubmed.ncbi.nlm.nih.gov/17021426/>
255. Qiu Z, Xue Y, Song H, Luo Q. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. *Nucl Med Commun*. 2012;33(12):1232-42. URL: <https://pubmed.ncbi.nlm.nih.gov/23111353/>
256. Ota N, Kato K, Iwano S, Ito S, Abe S, Fujita N, et al. Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. *Br J Radiol*. 2014;87(1034):20130444. URL: <https://pubmed.ncbi.nlm.nih.gov/24297809/>
257. Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. *J Nucl Med*. 2007;48(6):889-95. URL: <https://pubmed.ncbi.nlm.nih.gov/17504877/>
258. Huellner M, Strobel K. Clinical applications of SPECT/CT in imaging the extremities. *Eur J Nucl Med Mol Imaging*. 2014;41 Suppl 1:S50-8. URL: <https://pubmed.ncbi.nlm.nih.gov/23963296/>
259. Mikhael A, Patell R, Tabet M, Bena J, Berber E, Nasr C. Chest X-ray Prior to Thyroidectomy: Is It Really Needed?. *World J Surg*. 2018;42(5):1403-1407. URL: <https://pubmed.ncbi.nlm.nih.gov/29147894/>
260. Bongers P, Verzijl R, Dzingala M, Vriens M, Yu E, Pasternak J, et al. Preoperative Computed Tomography Changes Surgical Management for Clinically Low-Risk Well-Differentiated Thyroid Cancer. *Ann Surg Oncol*. 2019;26(13):4439-4444. URL: <https://pubmed.ncbi.nlm.nih.gov/31583547/>
261. Ahn J, Lee J, Yi J, Shong Y, Hong S, Lee D, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. *World J Surg*. 2008;32(7):1552-8. URL: <https://pubmed.ncbi.nlm.nih.gov/18408961/>
262. Lesnik D, Cunnane M, Zurakowski D, Acar G, Ecevit C, Mace A, et al. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. *Head Neck*. 2014;36(2):191-202. URL: <https://pubmed.ncbi.nlm.nih.gov/23554058/>
263. Kim H, Kim J, Son E, Youk J, Chung T, Park C, et al. Preoperative prediction of the extrathyroidal extension of papillary thyroid carcinoma with ultrasonography versus MRI: a retrospective cohort study. *Int J Surg*. 2014;12(5):544-8. URL: <https://pubmed.ncbi.nlm.nih.gov/24631554/>
264. Lloyd RVO. WHO classification of tumours of endocrine organs. World Health Organization Classification of Tumours, International Agency for Research on Cancer (IARC). 2017
265. Baloch Z, Asa S, Barletta J, Ghossein R, Juhlin C, Jung C, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. *Endocr Pathol*. 2022;33(1):27-63. URL: <https://pubmed.ncbi.nlm.nih.gov/35288841/>

266. Theurer S, Dralle H, Führer-Sakel D, Herrmann K, Schmid K. [Morphologic diagnostic criteria of noninvasive follicular neoplasia with papillary-like nuclear features (NIFTP) : A diagnostic challenge for the patient's benefit]. 2019;40:220. URL: <http://europepmc.org/abstract/MED/31049677>, <https://doi.org/10.1007/s00292-019-0597-0>
267. Schmid K, Farid N. How to define follicular thyroid carcinoma?. Virchows Arch. 2006;448(4):385-93. URL: <https://pubmed.ncbi.nlm.nih.gov/16506015/>
268. Cooper D, Doherty G, Haugen B, Kloos R, Lee S, Mandel S, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214. URL: <https://pubmed.ncbi.nlm.nih.gov/19860577/>
269. Hermann M, Tonninger K, Kober F, Furtlehner E, Schultheis A, Neuhold N. [Minimally invasive follicular thyroid carcinoma : Not always total thyroidectomy]. Chirurg. 2010;81(7):627-30, 632-5. URL: <https://pubmed.ncbi.nlm.nih.gov/20544166/>
270. Dralle H, Musholt T, Schabram J, Steinmüller T, Frilling A, Simon D, et al. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013;398(3):347-75. URL: <https://pubmed.ncbi.nlm.nih.gov/23456424/>
271. Goffredo P, Cheung K, Roman SA, Sosa JA. Can minimally invasive follicular thyroid cancer be approached as a benign lesion?: a population-level analysis of survival among 1,200 patients. Ann Surg Oncol. 2013;20:767-72. URL: <https://pubmed.ncbi.nlm.nih.gov/23111705/>
272. Jung C, Bychkov A, Kakudo K. Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach. Endocrinol Metab (Seoul). 2022;37(5):703-718. URL: <https://pubmed.ncbi.nlm.nih.gov/36193717/>
273. Abe I, Lam A. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging. Histol Histopathol. 2021;36(3):239-248. URL: <https://pubmed.ncbi.nlm.nih.gov/33170501/>
274. Abiri A, Pang J, Prasad K, Goshtasbi K, Kuan E, Armstrong W, et al. Prognostic Utility of Tumor Stage versus American Thyroid Association Risk Class in Thyroid Cancer. Laryngoscope. 2023;133(1):205-211. URL: <https://pubmed.ncbi.nlm.nih.gov/35716358/>
275. Morosán Allo Y, Bosio L, Morejón A, Parisi C, Faingold M, Ilera V, et al. Comparison of the prognostic value of AJCC cancer staging system 7th and 8th editions for differentiated thyroid cancer. BMC Endocr Disord. 2022;22(1):146. URL: <https://pubmed.ncbi.nlm.nih.gov/35650574/>
276. Bai Y, Kakudo K, Jung C. Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification. Endocrinol Metab (Seoul). 2020;35(4):696-715. URL: <https://pubmed.ncbi.nlm.nih.gov/33261309/>
277. Borda A, Zahan A, Piciu D, Barbuș E, Berger N, Nechifor-Boilă A. A 15 year institutional experience of well-differentiated follicular cell-derived thyroid carcinomas; impact of the new 2017 TNM and WHO Classifications of Tumors of Endocrine Organs on the epidemiological trends and pathological characteristics. Endocrine. 2020;67(3):630-642. URL: <https://pubmed.ncbi.nlm.nih.gov/31838728/>
278. Ito Y, Miyauchi A, Hirokawa M, Yamamoto M, Oda H, Masuoka H, et al. Prognostic value of the 8. Endocr J. 2018;65(6):621-627. URL: <https://pubmed.ncbi.nlm.nih.gov/29618671/>
279. Jeon Y, Gwak H, Lim S, Schneider J, Suh Y. Long-Term Prognosis of Unilateral and Multifocal Papillary Thyroid Microcarcinoma After Unilateral Lobectomy Versus Total Thyroidectomy. Ann Surg Oncol. 2019;26(9):2952-2958. URL: <https://pubmed.ncbi.nlm.nih.gov/31264119/>

280. Scheffel R, de Cristo A, Romitti M, Vargas C, Ceolin L, Zanella A, et al. The BRAF. Arch Endocrinol Metab. 2021;64(6):751-757. URL: <https://pubmed.ncbi.nlm.nih.gov/34033285/>
281. Harries V, Wang L, McGill M, Xu B, Tuttle R, Wong R, et al. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?. Surgery. 2020;167(1):10-17. URL: <https://pubmed.ncbi.nlm.nih.gov/31515125/>
282. Haugen B, Sawka A, Alexander E, Bible K, Caturegli P, Doherty G, et al. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017;27(4):481-483. URL: <https://pubmed.ncbi.nlm.nih.gov/28114862/>
283. Christofer Juhlin C, Mete O, Baloch Z. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2023;30(2): URL: <https://pubmed.ncbi.nlm.nih.gov/36445235/>
284. van Velsen E, Peeters R, Stegenga M, Mäder U, Reiners C, van Kemenade F, et al. Evaluating the use of a two-step age-based cutoff for the UICC/AJCC TNM staging system in patients with papillary or follicular thyroid cancer. Eur J Endocrinol. 2022;186(3):389-397. URL: <https://pubmed.ncbi.nlm.nih.gov/35038308/>
285. Tuttle R, Haugen B, Perrier N. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?. Thyroid. 2017;27(6):751-756. URL: <https://pubmed.ncbi.nlm.nih.gov/28463585/>
286. Schmid K, Synoracki S, Dralle H, Wittekind C. [Proposal for an extended pTNM classification of thyroid carcinoma : Commentary on deficits of the 8th edition of the TNM classification (German version)]. Pathologe. 2018;39(1):49-56. URL: <https://pubmed.ncbi.nlm.nih.gov/29372307/>
287. Su H, Wenig B, Haser G, Rowe M, Asa S, Baloch Z, et al. Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma. Thyroid. 2016;26(4):512-7. URL: <https://pubmed.ncbi.nlm.nih.gov/26953223/>
288. Clain J, Scherl S, Dos Reis L, Turk A, Wenig B, Mehra S, et al. Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management. Thyroid. 2014;24(6):951-7. URL: <https://pubmed.ncbi.nlm.nih.gov/24443878/>
289. Machens A, Dralle H. Breach of the thyroid capsule and lymph node capsule in node-positive papillary and medullary thyroid cancer: Different biology. Eur J Surg Oncol. 2015;41(6):766-72. URL: <https://pubmed.ncbi.nlm.nih.gov/25468749/>
290. Roh J, Park J, Jeong J, Gong G, Cho K, Choi S, et al. Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma. J Surg Oncol. 2017;116(4):450-458. URL: <https://pubmed.ncbi.nlm.nih.gov/28608492/>
291. Schmid K, Synoracki S, Dralle H, Wittekind C. Proposal for an extended pTNM classification of thyroid carcinoma : Commentary on deficits of the 8th edition of the TNM classification. Pathologe. 2019;40(Suppl 1):18-24. URL: <https://pubmed.ncbi.nlm.nih.gov/29459993/>
292. Nagarajan N, Najafian A, Schneider E, Zeiger M, Olson M. Conventional smears versus liquid-based preparations for thyroid fine-needle aspirates: a systematic review and meta-analysis. J Am Soc Cytopathol. 2015;4(5):253-260. URL: <https://pubmed.ncbi.nlm.nih.gov/31051762/>
293. Burch H. Drug Effects on the Thyroid. N Engl J Med. 2019;381(8):749-761. URL: <https://pubmed.ncbi.nlm.nih.gov/31433922/>

294. Weber A, Rahemtullah A, Ferry J. Hodgkin and non-Hodgkin lymphoma of the head and neck: clinical, pathologic, and imaging evaluation. *Neuroimaging Clin N Am*. 2003;13(3):371-92. URL: <https://pubmed.ncbi.nlm.nih.gov/14631680/>
295. Hart J, Mandavilli S. Epithelioid angiosarcoma: a brief diagnostic review and differential diagnosis. *Arch Pathol Lab Med*. 2011;135(2):268-72. URL: <https://pubmed.ncbi.nlm.nih.gov/21284449/>
296. Sen R, Gupta S, Batra A, Gill M, Gupta V, Marwah N. Acute lymphoblastic leukaemia (ALL) with infiltration of the thyroid: a cytological diagnosis. *Endocr Pathol*. 2012;23(4):268-9. URL: <https://pubmed.ncbi.nlm.nih.gov/22562766/>
297. Yang G, Zhao D, Zhang W, Meng J, Li J, Li X, et al. Role of ultrasound evaluation for the diagnosis and monitoring of thyroid tuberculosis: A case report and review of the literature. *Oncol Lett*. 2015;9(1):227-230. URL: <https://pubmed.ncbi.nlm.nih.gov/25435964/>
298. Okuma H, Hashimoto K, Wang X, Ohkiba N, Murooka N, Akizuki N, et al. Systemic Sarcoidosis with Thyroid Involvement. *Intern Med*. 2017;56(16):2181-2186. URL: <https://pubmed.ncbi.nlm.nih.gov/28781308/>
299. Tjahjono R, Phung D, Gurney H, Gupta R, Riffat F, Palme C. Thyroid gland metastasis from renal cell carcinoma: a case series and literature review. *ANZ J Surg*. 2021;91(4):708-715. URL: <https://pubmed.ncbi.nlm.nih.gov/33319504/>
300. Cibas E, Ali S. The Bethesda System for Reporting Thyroid Cytopathology. *Thyroid*. 2009;19(11):1159-65. URL: <https://pubmed.ncbi.nlm.nih.gov/19888858/>
301. Cibas E, Ali S. The 2017 Bethesda System for Reporting Thyroid Cytopathology. *Thyroid*. 2017;27(11):1341-1346. URL: <https://pubmed.ncbi.nlm.nih.gov/29091573/>
302. Guidance on the Reporting of Thyroid Cytology Specimens. 2nd ed. Royal College of Pathologists. 2016
303. Nardi F, Basolo F, Crescenzi A, Fadda G, Frasoldati A, Orlandi F, et al. Italian consensus for the classification and reporting of thyroid cytology. *J Endocrinol Invest*. 2014;37(6):593-9. URL: <https://pubmed.ncbi.nlm.nih.gov/24789536/>
304. Ting S, Synoracki S, Bockisch A, Führer D, Schmid K. [Clinical importance of thyroid gland cytology]. *Pathologe*. 2015;36(6):543-52. URL: <https://pubmed.ncbi.nlm.nih.gov/26462485/>
305. Alhashem M, Alabidi A, Aly M. The Bethesda System for Reporting Thyroid Cytopathology: A Retrospective Review of its Diagnostic Utility at Johns Hopkins Aramco Healthcare, Saudi Arabia. *Am J Otolaryngol*. 2021;42(6):103088. URL: <https://pubmed.ncbi.nlm.nih.gov/34090018/>
306. Linhares S, Handelsman R, Picado O, Farrá J, Lew J. Fine needle aspiration and the Bethesda system: Correlation with histopathology in 1,228 surgical patients. *Surgery*. 2021;170(5):1364-1368. URL: <https://pubmed.ncbi.nlm.nih.gov/34134896/>
307. Madgar O, Avior G, Shochat I, Joshua B, Baraf L, Avidor Y, et al. Thyroid malignancy rates according to the Bethesda reporting system in Israel - A multicenter study. *Eur J Surg Oncol*. 2021;47(6):1370-1375. URL: <https://pubmed.ncbi.nlm.nih.gov/33745793/>
308. Cherella C, Angell T, Richman D, Frates M, Benson C, Moore F, et al. Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults. *Thyroid*. 2019;29(8):1097-1104. URL: <https://pubmed.ncbi.nlm.nih.gov/31298618/>
309. Vivero M, Renshaw A, Krane J. Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only. *Cancer Cytopathol*. 2017;125(7):534-543. URL: <https://pubmed.ncbi.nlm.nih.gov/28388017/>

310. Goldner W, Angell T, McAdoo S, Babiarz J, Sadow P, Nabhan F, et al. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules. *Thyroid*. 2019;29(11):1594-1605. URL: <https://pubmed.ncbi.nlm.nih.gov/31469053/>
311. Musholt T, Clerici T, Dralle H, Frilling A, Goretzki P, Hermann M, et al. German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. *Langenbecks Arch Surg*. 2011;396(5):639-49. URL: <https://pubmed.ncbi.nlm.nih.gov/21424798/>
312. Synoracki S, Ting S, Siebolts U, Dralle H, Koperek O, Schmid K. [Intraoperative frozen sections of the thyroid gland]. *Pathologe*. 2015;36(4):362-71. URL: <https://pubmed.ncbi.nlm.nih.gov/26055332/>
313. Der intraoperative Gefrierschnitt von Schilddrüsenknoten. *Viszeralchirurgie*. 2005;40(3):174-179. URL: <https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-2005-836556>
314. Schmid K, Ladurner D, Zechmann W, Feichtinger H. Clinicopathologic management of tumors of the thyroid gland in an endemic goiter area Combined use of preoperative fine needle aspiration biopsy and intraoperative frozen section. *Acta Cytol*. 1989;33(1):27-30. URL: <https://pubmed.ncbi.nlm.nih.gov/2916368/>
315. Rosen Y, Rosenblatt P, Saltzman E. Intraoperative pathologic diagnosis of thyroid neoplasms Report on experience with 504 specimens. *Cancer*. 1990;66(9):2001-6. URL: <https://pubmed.ncbi.nlm.nih.gov/2146011/>
316. Shaha A, Gleich L, Di Maio T, Jaffe B. Accuracy and pitfalls of frozen section during thyroid surgery. *J Surg Oncol*. 1990;44(2):84-92. URL: <https://pubmed.ncbi.nlm.nih.gov/2355746/>
317. de Micco C. [Anatomo-pathology and histological prognosis of follicular thyroid carcinoma]. *Ann Endocrinol (Paris)*. 1997;58(3):172-82. URL: <https://pubmed.ncbi.nlm.nih.gov/9239238/>
318. Schmid K, Ladurner D. [Intraoperative diagnostic frozen section of the thyroid gland]. *Pathologe*. 1997;18(1):98-101. URL: <https://pubmed.ncbi.nlm.nih.gov/9157412/>
319. Chadwick D, Harrison B. The role of fine-needle aspiration cytology and frozen section histology in management of differentiated thyroid cancer: the UK experience. *Langenbecks Arch Surg*. 1998;383(2):164-6. URL: <https://pubmed.ncbi.nlm.nih.gov/9641891/>
320. DeMay R. Frozen section of thyroid? Just say no. *Am J Clin Pathol*. 1998;110(4):423-4. URL: <https://pubmed.ncbi.nlm.nih.gov/9763027/>
321. McHenry C, Thomas S, Slusarczyk S, Khiyami A. Follicular or Hürthle cell neoplasm of the thyroid: can clinical factors be used to predict carcinoma and determine extent of thyroidectomy?. *Surgery*. 1999;126(4):798-802; discussion 802-4. URL: <https://pubmed.ncbi.nlm.nih.gov/10520931/>
322. Shaha A. Controversies in the management of thyroid nodule. *Laryngoscope*. 2000;110(2 Pt 1):183-93. URL: <https://pubmed.ncbi.nlm.nih.gov/10680914/>
323. Leteurtre E, Leroy X, Pattou F, Wacrenier A, Carnaille B, Proye C, et al. Why do frozen sections have limited value in encapsulated or minimally invasive follicular carcinoma of the thyroid?. *Am J Clin Pathol*. 2001;115(3):370-4. URL: <https://pubmed.ncbi.nlm.nih.gov/11242793/>
324. Caraci P, Aversa S, Mussa A, Pancani G, Ondolo C, Conticello S. Role of fine-needle aspiration biopsy and frozen-section evaluation in the surgical management of thyroid nodules. *Br J Surg*. 2002;89(6):797-801. URL: <https://pubmed.ncbi.nlm.nih.gov/12027995/>

325. Dosen D, Turić M, Smalcelj J, Janusić R, Grgić M, Separović V. The value of frozen section in intraoperative surgical management of thyroid follicular carcinoma. *Head Neck*. 2003;25(7):521-8. URL: <https://pubmed.ncbi.nlm.nih.gov/12808654/>
326. Grannan K, Snyder J, McDonough S, Engel A, Farnum J. Operative decision-making for follicular thyroid lesions: a community hospital system experience. *Am Surg*. 2011;77(4):443-6. URL: <https://pubmed.ncbi.nlm.nih.gov/21679553/>
327. Marshall R, Alexander D, Fleming J, Grayson J, Peters G, Buczek E. Utility of intraoperative frozen sections of thyroid tissue in the age of molecular testing. *Clin Otolaryngol*. 2021;46(5):991-997. URL: <https://pubmed.ncbi.nlm.nih.gov/33811452/>
328. Sanabria A, Zafereo M, Thompson L, Hernandez-Prera J, Kowalski L, Nixon I, et al. Frozen section in thyroid gland follicular neoplasms: It's high time to abandon it!. *Surg Oncol*. 2021;36:76-81. URL: <https://pubmed.ncbi.nlm.nih.gov/33316682/>
329. Staubitz J, Elmrich I, Musholt P, Cámara R, Watzka F, Dralle H, et al. Targeted use of intraoperative frozen-section analysis lowers the frequency of completion thyroidectomy. *BJS Open*. 2021;5(2): URL: <https://pubmed.ncbi.nlm.nih.gov/33851986/>
330. Goemann I, Paixão F, Migliavacca A, Guimarães J, Scheffel R, Maia A. Intraoperative frozen section performance for thyroid cancer diagnosis. *Arch Endocrinol Metab*. 2022;66(1):50-57. URL: <https://pubmed.ncbi.nlm.nih.gov/35263048/>
331. Lee S, Han B, Ko E, Oh Y, Choe J, Shin J. The ultrasonography features of hyalinizing trabecular tumor of the thyroid are more consistent with its benign behavior than cytology or frozen section readings. *Thyroid*. 2011;21(3):253-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21190434/>
332. Ting S, Puttinger C, Schmid K, Sheu-Grabellus S. [Hyalinizing trabecular tumor of the thyroid An overcautious designation of a benign thyroid tumour?]. *Pathologe*. 2012;33(2):135-41. URL: <https://pubmed.ncbi.nlm.nih.gov/21842215/>
333. Sung S, Shen H, Hsieh C, Duh Q, Su T, Chan D, et al. Hyalinizing trabecular tumor of thyroid: does frozen section prevent unnecessarily aggressive operation? Six new cases and a literature review. *J Chin Med Assoc*. 2014;77(11):573-7. URL: <https://pubmed.ncbi.nlm.nih.gov/25278150/>
334. Schenke S, Kreissl M, Grunert M, Hach A, Haghighi S, Kandror T, et al. Distribution of Functional Status of Thyroid Nodules and Malignancy Rates of Hyperfunctioning and Hypofunctioning Thyroid Nodules in Germany. *Nuklearmedizin*. 2022;61(5):376-384. URL: <https://pubmed.ncbi.nlm.nih.gov/35917825/>
335. Li H, Goh J, Anand K, Bundele M, Fu E, Gan J, et al. Routine intraoperative frozen section adds little value to the management of thyroid nodules with Bethesda III cytology. *Ann Acad Med Singap*. 2021;50(11):865-867. URL: <https://pubmed.ncbi.nlm.nih.gov/34877593/>
336. De Schutter H, Van Damme N, Colpaert C, Galant C, Lambein K, Cornelis A, et al. Quality of pathology reporting is crucial for cancer care and registration: a baseline assessment for breast cancers diagnosed in Belgium in 2008. *Breast*. 2015;24(2):143-52. URL: <https://pubmed.ncbi.nlm.nih.gov/25572136/>
337. Ellis D. Surgical pathology reporting at the crossroads: beyond synoptic reporting. *Pathology*. 2011;43(5):404-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21753714/>
338. Ellis D, Srigley J. Does standardised structured reporting contribute to quality in diagnostic pathology? The importance of evidence-based datasets. *Virchows Arch*. 2016;468(1):51-9. URL: <https://pubmed.ncbi.nlm.nih.gov/26316184/>
339. Aumann K, Niermann K, Asberger J, Wellner U, Bronsert P, Erbes T, et al. Structured reporting ensures complete content and quick detection of essential data in pathology

- reports of oncological breast resection specimens. *Breast Cancer Res Treat.* 2016;156(3):495-500. URL: <https://pubmed.ncbi.nlm.nih.gov/27059032/>
340. Słodkowska J, Cierniak S, Patera J, Kopik J, Baranowski W, Markiewicz T, et al. Functional Assessment of Synoptic Pathology Reporting for Ovarian Cancer. *Pathobiology.* 2016;83(2-3):70-8. URL: <https://pubmed.ncbi.nlm.nih.gov/27100104/>
 341. Sluijter C, van Lonkhuijzen L, van Slooten H, Nagtegaal I, Overbeek L. The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review. *Virchows Arch.* 2016;468(6):639-49. URL: <https://pubmed.ncbi.nlm.nih.gov/27097810/>
 342. Baranov N, Nagtegaal I, van Grieken N, Verhoeven R, Voorham Q, Rosman C, et al. Synoptic reporting increases quality of upper gastrointestinal cancer pathology reports. *Virchows Arch.* 2019;475(2):255-259. URL: <https://pubmed.ncbi.nlm.nih.gov/31144018/>
 343. Tsan C, Serpell J, Poh Y. The impact of synoptic cytology reporting on fine-needle aspiration cytology of thyroid nodules. *ANZ J Surg.* 2007;77(11):991-5. URL: <https://pubmed.ncbi.nlm.nih.gov/17931264/>
 344. Kahn C, Simonella L, Sywak M, Boyages S, Ung O, O'Connell D. Postsurgical pathology reporting of thyroid cancer in New South Wales, Australia. *Thyroid.* 2012;22(6):604-10. URL: <https://pubmed.ncbi.nlm.nih.gov/22524497/>
 345. Lam E, Vy N, Bajdik C, Strugnell S, Walker B, Wiseman S. Synoptic pathology reporting for thyroid cancer: a review and institutional experience. *Expert Rev Anticancer Ther.* 2013;13(9):1073-9. URL: <https://pubmed.ncbi.nlm.nih.gov/24053206/>
 346. Wells S, Asa S, Dralle H, Elisei R, Evans D, Gagel R, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid.* 2015;25(6):567-610. URL: <https://pubmed.ncbi.nlm.nih.gov/25810047/>
 347. Xu B, Ghossein R. Critical Prognostic Parameters in the Anatomic Pathology Reporting of Differentiated Follicular Cell-Derived Thyroid Carcinoma. *Cancers (Basel).* 2019;11(8): URL: <https://pubmed.ncbi.nlm.nih.gov/31382401/>
 348. Bible K, Kebebew E, Brierley J, Brito J, Cabanillas M, Clark T, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. *Thyroid.* 2021;31(3):337-386. URL: <https://pubmed.ncbi.nlm.nih.gov/33728999/>
 349. Ghossein R, Barletta J, Bullock M, Johnson S, Kakudo K, Lam A, et al. Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. *Hum Pathol.* 2021;110:62-72. URL: <https://pubmed.ncbi.nlm.nih.gov/32920035/>
 350. Cibas E, Ali S. The 2017 Bethesda System for Reporting Thyroid Cytopathology. *J Am Soc Cytopathol.* 2017;6(6):217-222. URL: <https://pubmed.ncbi.nlm.nih.gov/31043290/>
 351. Musholt TJ, Bockisch A, Clerici T, Dotzenrath C, Dralle H, Goretzki PE, et al. Aktualisierung der S2k-Leitlinie. 2018;89:699. URL: <https://doi.org/10.1007/s00104-018-0653-y>
 352. Robbins K, Shaha A, Medina J, Califano J, Wolf G, Ferlito A, et al. Consensus statement on the classification and terminology of neck dissection. *Arch Otolaryngol Head Neck Surg.* 2008;134(5):536-8. URL: <https://pubmed.ncbi.nlm.nih.gov/18490577/>
 353. Carty S, Cooper D, Doherty G, Duh Q, Kloos R, Mandel S, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. *Thyroid.* 2009;19(11):1153-8. URL: <https://pubmed.ncbi.nlm.nih.gov/19860578/>
 354. Dralle H, Damm I, Scheumann G, Kotzerke J, Kupsch E, Geerlings H, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. *Surg Today.* 1994;24(2):112-21. URL: <https://pubmed.ncbi.nlm.nih.gov/8054788/>

355. Dralle H, Lorenz K, Machens A. Chirurgie der Schilddrüsenkarzinome. 2009;80:1069. URL: <https://doi.org/10.1007/s00104-009-1769-x>
356. Dralle H, Machens A, Lorenz K. [Hereditary thyroid cancer]. Chirurg. 2008;79(11):1017-28. URL: <https://pubmed.ncbi.nlm.nih.gov/18818894/>
357. Praktische Anatomie. Hals. 1955;Volume 1 / 2
358. Lehrbuch Lymphologie. Für Mediziner und Physiotherapeuten. 1989
359. Shonka D, Ho A, Chintakuntlawar A, Geiger J, Park J, Seetharamu N, et al. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head Neck. 2022;44(6):1277-1300. URL: <https://pubmed.ncbi.nlm.nih.gov/35274388/>
360. Kelley S, Beck A, Weigel R, Howe J, Sugg S, Lal G. Influence of endocrine multidisciplinary tumor board on patient management and treatment decision making. Am J Surg. 2022;223(1):76-80. URL: <https://pubmed.ncbi.nlm.nih.gov/34303521/>
361. El Saghir N, Keating N, Carlson R, Khoury K, Fallowfield L. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book. 2014;;e461-6. URL: <https://pubmed.ncbi.nlm.nih.gov/24857140/>
362. Lamb B, Green J, Benn J, Brown K, Vincent C, Sevdalis N. Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients. J Am Coll Surg. 2013;217(3):412-20. URL: <https://pubmed.ncbi.nlm.nih.gov/23891067/>
363. Chan S, Karamali K, Kolodziejczyk A, Oikonomou G, Watkinson J, Paleri V, et al. Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer. Eur Thyroid J. 2020;9(2):73-84. URL: <https://pubmed.ncbi.nlm.nih.gov/32257956/>
364. Zhang C, Li Y, Li J, Chen X. Total thyroidectomy versus lobectomy for papillary thyroid cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(6):e19073. URL: <https://pubmed.ncbi.nlm.nih.gov/32028431/>
365. Sarquis M, Moraes D, Bastos-Rodrigues L, Azevedo P, Ramos A, Reis F, et al. Germline Mutations in Familial Papillary Thyroid Cancer. Endocr Pathol. 2020;31(1):14-20. URL: <https://pubmed.ncbi.nlm.nih.gov/32034658/>
366. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601-5; discussion 605-7. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25203876>
367. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787-803. URL: <https://pubmed.ncbi.nlm.nih.gov/16728537/>
368. Guidelines for the management of thyroid cancer. Second edition. 2007; URL: <http://www.british-thyroid-association.org>
369. National evidence-based guideline. 2007;Version 1.0.: URL: <http://www.oncoline.nl>
370. Mitchell A, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S150-S160. URL: <https://pubmed.ncbi.nlm.nih.gov/27841128/>
371. Reiners C, Hänscheid H, Luster M, Lassmann M, Verburg F. Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol. 2011;7(10):589-95. URL: <https://pubmed.ncbi.nlm.nih.gov/21826102/>

372. Passler C, Scheuba C, Asari R, Kaczirek K, Kaserer K, Niederle B. Importance of tumour size in papillary and follicular thyroid cancer. *Br J Surg.* 2005;92(2):184-9. URL: <https://pubmed.ncbi.nlm.nih.gov/15685703/>
373. Bilimoria K, Bentrem D, Ko C, Stewart A, Winchester D, Talamonti M, et al. Extent of surgery affects survival for papillary thyroid cancer. *Ann Surg.* 2007;246(3):375-81; discussion 381-4. URL: <https://pubmed.ncbi.nlm.nih.gov/17717441/>
374. Perros P, Boelaert K, Colley S, Evans C, Evans R, Gerrard Ba G, et al. Guidelines for the management of thyroid cancer. *Clin Endocrinol (Oxf).* 2014;81 Suppl 1:1-122. URL: <https://pubmed.ncbi.nlm.nih.gov/24989897/>
375. Mendelsohn A, Elashoff D, Abemayor E, St John M. Surgery for papillary thyroid carcinoma: is lobectomy enough?. *Arch Otolaryngol Head Neck Surg.* 2010;136(11):1055-61. URL: <https://pubmed.ncbi.nlm.nih.gov/21079156/>
376. Barney B, Hitchcock Y, Sharma P, Shrieve D, Tward J. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. *Head Neck.* 2011;33(5):645-9. URL: <https://pubmed.ncbi.nlm.nih.gov/20687168/>
377. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. *World J Surg.* 2014;38(1):68-79. URL: <https://pubmed.ncbi.nlm.nih.gov/24081532/>
378. Nixon I, Ganly I, Patel S, Palmer F, Whitcher M, Tuttle R, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. *Surgery.* 2012;151(4):571-9. URL: <https://pubmed.ncbi.nlm.nih.gov/22001636/>
379. WHO Classification of tumors. Pathology and Genetics of Tumors of Endocrine Organs. 2004;49
380. Carling T, Ocal I, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer?. *World J Surg.* 2007;31(5):916-23. URL: <https://pubmed.ncbi.nlm.nih.gov/17345120/>
381. Liu Z, Zeng W, Chen T, Guo Y, Zhang C, Liu C, et al. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis. *Oncotarget.* 2017;8(4):6222-6232. URL: <https://pubmed.ncbi.nlm.nih.gov/28009980/>
382. Wang X, Cheng W, Liu C, Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. *Oncotarget.* 2016;7(26):40792-40799. URL: <https://pubmed.ncbi.nlm.nih.gov/27008708/>
383. Chereau N, Giudicelli X, Pattou F, Lifante J, Triponez F, Mirallié E, et al. Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study. *J Clin Endocrinol Metab.* 2016;101(12):4603-4610. URL: <https://pubmed.ncbi.nlm.nih.gov/27626975/>
384. Yan B, Hou Y, Chen D, He J, Jiang Y. Risk factors for contralateral central lymph node metastasis in unilateral cN0 papillary thyroid carcinoma: A meta-analysis. *Int J Surg.* 2018;59:90-98. URL: <https://pubmed.ncbi.nlm.nih.gov/30342280/>
385. Sun W, Zheng B, Wang Z, Dong W, Qin Y, Zhang H. Meta-analysis of risk factors for CCLNM in patients with unilateral cN0 PTC. *Endocr Connect.* 2020;9(5):387-395. URL: <https://pubmed.ncbi.nlm.nih.gov/32272445/>
386. Dralle H, Lorenz K, Schabram P, Musholt T, Dotzenrath C, Goretzki P, et al. [Intraoperative neuromonitoring in thyroid surgery Recommendations of the Surgical Working Group for Endocrinology]. *Chirurg.* 2013;84(12):1049-56. URL: <https://pubmed.ncbi.nlm.nih.gov/24337220/>

387. Machens A, Dralle H. Prediction of Mediastinal Lymph Node Metastasis in Papillary Thyroid Cancer. 2009;16:171. URL: <https://doi.org/10.1245/s10434-008-0201-y>
388. Giordano D, Valcavi R, Thompson G, Pedroni C, Renna L, Gradoni P, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. *Thyroid*. 2012;22(9):911-7. URL: <https://pubmed.ncbi.nlm.nih.gov/22827494/>
389. Moo T, Umunna B, Kato M, Butriago D, Kundel A, Lee J, et al. Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. *Ann Surg*. 2009;250(3):403-8. URL: <https://pubmed.ncbi.nlm.nih.gov/19661784/>
390. Sadowski B, Snyder S, Lairmore T. Routine bilateral central lymph node clearance for papillary thyroid cancer. *Surgery*. 2009;146(4):696-703; discussion 703-5. URL: <https://pubmed.ncbi.nlm.nih.gov/19789029/>
391. Hughes D, Rosen J, Evans D, Grubbs E, Wang T, Solórzano C. Prophylactic Central Compartment Neck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence. *Ann Surg Oncol*. 2018;25(9):2526-2534. URL: <https://pubmed.ncbi.nlm.nih.gov/29786126/>
392. Kim S, Park I, Woo J, Lee J, Choe J, Kim J, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: Analysis of 8,676 patients at a single institution. *Surgery*. 2017;161(2):485-492. URL: <https://pubmed.ncbi.nlm.nih.gov/27593085/>
393. Tang J, Gui C, Qiu S, Wang M. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?. *World J Surg Oncol*. 2018;16(1):100. URL: <https://pubmed.ncbi.nlm.nih.gov/29855303/>
394. Manzella L, Stella S, Pennisi M, Tirrò E, Massimino M, Romano C, et al. New Insights in Thyroid Cancer and p53 Family Proteins. *Int J Mol Sci*. 2017;18(6): URL: <https://pubmed.ncbi.nlm.nih.gov/28635633/>
395. Liu L, Liang J, Li J, Liu X, Jiang L, Long J, et al. The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. *Eur Arch Otorhinolaryngol*. 2017;274(3):1327-1338. URL: <https://pubmed.ncbi.nlm.nih.gov/27645473/>
396. Hartl D, Leboulleux S, Al Ghuzlan A, Baudin E, Chami L, Schlumberger M, et al. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. *Ann Surg*. 2012;255(4):777-83. URL: <https://pubmed.ncbi.nlm.nih.gov/22418010/>
397. Raffaelli M, De Crea C, Sessa L, Giustacchini P, Revelli L, Bellantone C, et al. Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma. *Surgery*. 2012;152(6):957-64. URL: <https://pubmed.ncbi.nlm.nih.gov/23158170/>
398. Barczyński M, Konturek A, Stopa M, Nowak W. Prophylactic central neck dissection for papillary thyroid cancer. *Br J Surg*. 2013;100(3):410-8. URL: <https://pubmed.ncbi.nlm.nih.gov/23188784/>
399. Lee Y, Lim Y, Lee J, Wang S, Kim I, Lee B. Clinical implication of the number of central lymph node metastasis in papillary thyroid carcinoma: preliminary report. *World J Surg*. 2010;34(11):2558-63. URL: <https://pubmed.ncbi.nlm.nih.gov/20703463/>
400. Scherl S, Mehra S, Clain J, Dos Reis L, Persky M, Turk A, et al. The effect of surgeon experience on the detection of metastatic lymph nodes in the central compartment and the pathologic features of clinically unapparent metastatic lymph nodes: what are we missing when we don't perform a prophylactic dissection of central compartment lymph nodes in

- papillary thyroid cancer?. *Thyroid*. 2014;24(8):1282-8. URL: <https://pubmed.ncbi.nlm.nih.gov/24787362/>
401. Ji Y, Lee D, Song C, Kim K, Park C, Tae K. Accuracy of intraoperative determination of central node metastasis by the surgeon in papillary thyroid carcinoma. *Otolaryngol Head Neck Surg*. 2014;150(4):542-7. URL: <https://pubmed.ncbi.nlm.nih.gov/24429357/>
 402. Kaczka K, Celnik A, Luks B, Jasion J, Pomorski L. Sentinel lymph node biopsy techniques in thyroid pathologies--a meta-analysis. *Endokrynol Pol*. 2012;63(3):222-31. URL: <https://pubmed.ncbi.nlm.nih.gov/22744629/>
 403. Portinari M, Carcoforo P. Radioguided sentinel lymph node biopsy in patients with papillary thyroid carcinoma. *Gland Surg*. 2016;5(6):591-602. URL: <https://pubmed.ncbi.nlm.nih.gov/28149805/>
 404. Albers M, Nordenström E, Wohlfahrt J, Bergenfelz A, Almquist M. Sentinel Lymph Node Biopsy in Thyroid Cancer. *World J Surg*. 2020;44(1):142-147. URL: <https://pubmed.ncbi.nlm.nih.gov/31583456/>
 405. Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso J, Al Ghuzlan A, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. *J Clin Endocrinol Metab*. 2009;94(4):1162-7. URL: <https://pubmed.ncbi.nlm.nih.gov/19116234/>
 406. So Y, Son Y, Hong S, Seo M, Baek C, Jeong H, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. *Surgery*. 2010;148(3):526-31. URL: <https://pubmed.ncbi.nlm.nih.gov/20189620/>
 407. Pereira J, Jimeno J, Miquel J, Iglesias M, Munné A, Sancho J, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. *Surgery*. 2005;138(6):1095-100, discussion 1100-1. URL: <https://pubmed.ncbi.nlm.nih.gov/16360396/>
 408. White M, Gauger P, Doherty G. Central lymph node dissection in differentiated thyroid cancer. *World J Surg*. 2007;31(5):895-904. URL: <https://pubmed.ncbi.nlm.nih.gov/17347896/>
 409. Mazzaferri E, Doherty G, Steward D. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. *Thyroid*. 2009;19(7):683-9. URL: <https://pubmed.ncbi.nlm.nih.gov/19583485/>
 410. Shen W, Ogawa L, Ruan D, Suh I, Duh Q, Clark O. Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. *Surgery*. 2010;148(2):398-403. URL: <https://pubmed.ncbi.nlm.nih.gov/20451230/>
 411. Zetoune T, Keutgen X, Buitrago D, Aldailami H, Shao H, Mazumdar M, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. *Ann Surg Oncol*. 2010;17(12):3287-93. URL: <https://pubmed.ncbi.nlm.nih.gov/20596784/>
 412. Popadich A, Levin O, Lee J, Smooke-Praw S, Ro K, Fazel M, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. *Surgery*. 2011;150(6):1048-57. URL: <https://pubmed.ncbi.nlm.nih.gov/22136820/>
 413. Cooper D, Tufano R. Prophylactic central neck dissection in differentiated thyroid cancer: a procedure in search of an indication. *Thyroid*. 2012;22(4):341-3. URL: <https://pubmed.ncbi.nlm.nih.gov/22458971/>
 414. Takami H, Ito Y, Okamoto T, Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. *World J Surg*. 2011;35(1):111-21. URL: <https://pubmed.ncbi.nlm.nih.gov/21042913/>

415. Gonçalves Filho J, Zafereo M, Ahmad F, Nixon I, Shaha A, Vander Poorten V, et al. Decision making for the central compartment in differentiated thyroid cancer. *Eur J Surg Oncol*. 2018;44(11):1671-1678. URL: <https://pubmed.ncbi.nlm.nih.gov/30145001/>
416. Lang B, Ng S, Lau L, Cowling B, Wong K, Wan K. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. *Thyroid*. 2013;23(9):1087-98. URL: <https://pubmed.ncbi.nlm.nih.gov/23402640/>
417. Chen L, Wu Y, Lee C, Chen H, Loh E, Tam K. Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis. *World J Surg*. 2018;42(9):2846-2857. URL: <https://pubmed.ncbi.nlm.nih.gov/29488066/>
418. Zhao W, Luo H, Zhou Y, Dai W, Zhu J. Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for cN0 papillary thyroid carcinoma: An updated meta-analysis. *Eur J Surg Oncol*. 2017;43(11):1989-2000. URL: <https://pubmed.ncbi.nlm.nih.gov/28807633/>
419. Kayser C, Tittelbach-Helmrich D, Meyer S, Thomusch O. Indikation und Ausmaß der zervikalen Lymphadenektomie beim differenzierten Schilddrüsenkarzinom. 2010/08/01;135
420. Liang J, Li Z, Fang F, Yu T, Li S. Is prophylactic central neck dissection necessary for cN0 differentiated thyroid cancer patients at initial treatment? A meta-analysis of the literature. *Acta Otorhinolaryngol Ital*. 2017;37(1):1-8. URL: <https://pubmed.ncbi.nlm.nih.gov/28374865/>
421. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. *Surgery*. 2006;140(6):1000-5; discussion 1005-7. URL: <https://pubmed.ncbi.nlm.nih.gov/17188149/>
422. Shan C, Zhang W, Jiang D, Zheng X, Liu S, Qiu M. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. *Laryngoscope*. 2012;122(4):797-804. URL: <https://pubmed.ncbi.nlm.nih.gov/22294492/>
423. Moo T, McGill J, Allendorf J, Lee J, Fahey T, Zarnegar R. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. *World J Surg*. 2010;34(6):1187-91. URL: <https://pubmed.ncbi.nlm.nih.gov/20130868/>
424. Chisholm E, Kulinskaya E, Tolley N. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. *Laryngoscope*. 2009;119(6):1135-9. URL: <https://pubmed.ncbi.nlm.nih.gov/19358241/>
425. Mulla M, Schulte K. Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment. *Clin Endocrinol (Oxf)*. 2012;76(1):131-6. URL: <https://pubmed.ncbi.nlm.nih.gov/21722150/>
426. Wang T, Cheung K, Farrokhyar F, Roman S, Sosa J. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. *Ann Surg Oncol*. 2013;20(11):3477-83. URL: <https://pubmed.ncbi.nlm.nih.gov/23846784/>
427. Zhu W, Zhong M, Ai Z. Systematic evaluation of prophylactic neck dissection for the treatment of papillary thyroid carcinoma. *Jpn J Clin Oncol*. 2013;43(9):883-8. URL: <https://pubmed.ncbi.nlm.nih.gov/23858039/>
428. Lorenz K, Raffaeli M, Barczyński M, Lorente-Poch L, Sancho J. Volume, outcomes, and quality standards in thyroid surgery: an evidence-based analysis-European Society of Endocrine Surgeons (ESES) positional statement. *Langenbecks Arch Surg*. 2020;405(4):401-425. URL: <https://pubmed.ncbi.nlm.nih.gov/32524467/>

429. Sancho J, Lennard T, Paunovic I, Triponez F, Sitges-Serra A. Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbecks Arch Surg*. 2014;399(2):155-63. URL: <https://pubmed.ncbi.nlm.nih.gov/24352594/>
430. Xing M. BRAF mutation in thyroid cancer. *Endocr Relat Cancer*. 2005;12(2):245-62. URL: <https://pubmed.ncbi.nlm.nih.gov/15947100/>
431. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. *J Clin Endocrinol Metab*. 2010;95(9):4197-205. URL: <https://pubmed.ncbi.nlm.nih.gov/20631031/>
432. O'Neill C, Bullock M, Chou A, Sidhu S, Delbridge L, Robinson B, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. *Surgery*. 2010;148(6):1139-45; discussion 1145-6. URL: <https://pubmed.ncbi.nlm.nih.gov/21134544/>
433. Kim S, Lee K, Myong J, Park J, Jeon Y, Min H, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. *World J Surg*. 2012;36(2):310-7. URL: <https://pubmed.ncbi.nlm.nih.gov/22190222/>
434. Ricarte-Filho J, Ganly I, Rivera M, Katabi N, Fu W, Shaha A, et al. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. *Thyroid*. 2012;22(6):575-84. URL: <https://pubmed.ncbi.nlm.nih.gov/22471242/>
435. Li C, Lee K, Schneider E, Zeiger M. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. *J Clin Endocrinol Metab*. 2012;97(12):4559-70. URL: <https://pubmed.ncbi.nlm.nih.gov/23055546/>
436. Ma B, Wang Y, Yang S, Ji Q. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: A systematic review and meta-analysis. *Int J Surg*. 2016;28:153-61. URL: <https://pubmed.ncbi.nlm.nih.gov/26944586/>
437. Song J, Sun S, Dong F, Huang T, Wu B, Zhou J. Predictive Value of BRAF. *Curr Med Sci*. 2018;38(5):785-797. URL: <https://pubmed.ncbi.nlm.nih.gov/30341513/>
438. Qu H, Sun G, Liu Y, He Q. Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. 2015;83(1):124-32. URL: <https://pubmed.ncbi.nlm.nih.gov/25130203/>
439. Yang J, Gong Y, Yan S, Chen H, Qin S, Gong R. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis. *Endocrine*. 2020;67(1):44-57. URL: <https://pubmed.ncbi.nlm.nih.gov/31655978/>
440. Bournaud C, Descotes F, Decaussin-Petrucci M, Berthiller J, de la Fouchardière C, Giraudet A, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. *Eur J Cancer*. 2019;108:41-49. URL: <https://pubmed.ncbi.nlm.nih.gov/30648628/>
441. Vuong H, Duong U, Altibi A, Ngo H, Pham T, Tran H, et al. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. *Endocr Connect*. 2017;6(3):R8-R17. URL: <https://pubmed.ncbi.nlm.nih.gov/28219937/>
442. Ito Y, Miyauchi A, Kudo T, Kihara M, Fukushima M, Miya A. The Effectiveness of Prophylactic Modified Neck Dissection for Reducing the Development of Lymph Node Recurrence of Papillary Thyroid Carcinoma. *World J Surg*. 2017;41(9):2283-2289. URL: <https://pubmed.ncbi.nlm.nih.gov/28429089/>

443. Malandrino P, Russo M, Regalbuto C, Pellegriti G, Moleti M, Caff A, et al. Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis. *Thyroid*. 2016;26(9):1285-92. URL: <https://pubmed.ncbi.nlm.nih.gov/27349273/>
444. Shin C, Roh J, Song D, Cho K, Choi S, Nam S, et al. Prognostic value of tumor size and minimal extrathyroidal extension in papillary thyroid carcinoma. *Am J Surg*. 2020;220(4):925-931. URL: <https://pubmed.ncbi.nlm.nih.gov/32081409/>
445. Ron E, Lubin J, Shore R, Mabuchi K, Modan B, Pottern L, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. *Radiat Res*. 1995;141(3):259-77. URL: <https://pubmed.ncbi.nlm.nih.gov/7871153/>
446. Vuong H, Altibi A, Duong U, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. *Clin Endocrinol (Oxf)*. 2017;87(5):411-417. URL: <https://pubmed.ncbi.nlm.nih.gov/28666074/>
447. Ito Y, Hirokawa M, Miyauchi A, Higashiyama T, Kihara M, Miya A. Prognostic Significance of the Proportion of Tall Cell Components in Papillary Thyroid Carcinoma. *World J Surg*. 2017;41(3):742-747. URL: <https://pubmed.ncbi.nlm.nih.gov/27807709/>
448. Lim Y, Choi E, Yoon Y, Koo B. Occult lymph node metastases in neck level V in papillary thyroid carcinoma. *Surgery*. 2010;147(2):241-5. URL: <https://pubmed.ncbi.nlm.nih.gov/19910012/>
449. Madenci A, Caragacianu D, Boeckmann J, Stack B, Shin J. Lateral neck dissection for well-differentiated thyroid carcinoma: a systematic review. *Laryngoscope*. 2014;124(7):1724-34. URL: <https://pubmed.ncbi.nlm.nih.gov/24390830/>
450. Ito Y, Miyauchi A. Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks. *World J Surg*. 2007;31(5):905-15. URL: <https://pubmed.ncbi.nlm.nih.gov/17219265/>
451. Machens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. *Surgery*. 2009;145(2):176-81. URL: <https://pubmed.ncbi.nlm.nih.gov/19167972/>
452. Chung Y, Kim J, Bae J, Song B, Kim J, Jeon H, et al. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. *Thyroid*. 2009;19(3):241-6. URL: <https://pubmed.ncbi.nlm.nih.gov/19265495/>
453. Ito Y, Tomoda C, Urano T, Takamura Y, Miya A, Kobayashi K, et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. *World J Surg*. 2005;29(7):917-20. URL: <https://pubmed.ncbi.nlm.nih.gov/15951927/>
454. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. *World J Surg*. 2007;31(11):2085-91. URL: <https://pubmed.ncbi.nlm.nih.gov/17885787/>
455. Caron N, Tan Y, Ogilvie J, Triponez F, Reiff E, Kebebew E, et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?. *World J Surg*. 2006;30(5):833-40. URL: <https://pubmed.ncbi.nlm.nih.gov/16555024/>
456. van Wilgen C, Dijkstra P, van der Laan B, Plukker J, Roodenburg J. Shoulder complaints after nerve sparing neck dissections. *Int J Oral Maxillofac Surg*. 2004;33(3):253-7. URL: <https://pubmed.ncbi.nlm.nih.gov/15287308/>
457. Kupferman M, Patterson D, Mandel S, LiVolsi V, Weber R. Safety of modified radical neck dissection for differentiated thyroid carcinoma. *Laryngoscope*. 2004;114(3):403-6. URL: <https://pubmed.ncbi.nlm.nih.gov/15091209/>

458. Roh J, Kim D, Park C. Prospective identification of chyle leakage in patients undergoing lateral neck dissection for metastatic thyroid cancer. *Ann Surg Oncol*. 2008;15(2):424-9. URL: <https://pubmed.ncbi.nlm.nih.gov/17999116/>
459. Lorenz K, Abuazab M, Sekulla C, Nguyen-Thanh P, Brauckhoff M, Dralle H. Management of lymph fistulas in thyroid surgery. *Langenbecks Arch Surg*. 2010;395(7):911-7. URL: <https://pubmed.ncbi.nlm.nih.gov/20652586/>
460. McGarvey A, Chiarelli P, Osmotherly P, Hoffman G. Physiotherapy for accessory nerve shoulder dysfunction following neck dissection surgery: a literature review. *Head Neck*. 2011;33(2):274-80. URL: <https://pubmed.ncbi.nlm.nih.gov/20222043/>
461. Attard A, Paladino N, Lo Monte A, Falco N, Melfa G, Rotolo G, et al. Skip metastases to lateral cervical lymph nodes in differentiated thyroid cancer: a systematic review. *BMC Surg*. 2019;18(Suppl 1):112. URL: <https://pubmed.ncbi.nlm.nih.gov/31074393/>
462. Wada N, Masudo K, Nakayama H, Suganuma N, Matsuzu K, Hirakawa S, et al. Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age. *Eur J Surg Oncol*. 2008;34(2):202-7. URL: <https://pubmed.ncbi.nlm.nih.gov/18023321/>
463. Xiao G, Gao L. Central lymph node metastasis: is it a reliable indicator of lateral node involvement in papillary thyroid carcinoma?. *World J Surg*. 2010;34(2):237-41. URL: <https://pubmed.ncbi.nlm.nih.gov/20041247/>
464. Park J, Lee Y, Kim B, Chang H, Park C. Skip lateral neck node metastases in papillary thyroid carcinoma. *World J Surg*. 2012;36(4):743-7. URL: <https://pubmed.ncbi.nlm.nih.gov/22354485/>
465. Xiang D, Xie L, Xu Y, Li Z, Hong Y, Wang P. Papillary thyroid microcarcinomas located at the middle part of the middle third of the thyroid gland correlates with the presence of neck metastasis. *Surgery*. 2015;157(3):526-33. URL: <https://pubmed.ncbi.nlm.nih.gov/25433730/>
466. Zhao H, Huang T, Li H. Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer. *Surgery*. 2019;166(1):55-60. URL: <https://pubmed.ncbi.nlm.nih.gov/30876667/>
467. Zhan X, Xue S, Yin Y, Chen G. [Related factors on skip metastasis of neck lymph node in papillary thyroid carcinoma]. *Zhonghua Wai Ke Za Zhi*. 2017;55(8):599-602. URL: <https://pubmed.ncbi.nlm.nih.gov/28789510/>
468. Moritani S. Impact of superior mediastinal metastasis on the prognosis of papillary thyroid carcinoma. *Endocr J*. 2016;63(4):349-57. URL: <https://pubmed.ncbi.nlm.nih.gov/26765269/>
469. Gartland R, Lubitz C. Impact of Extent of Surgery on Tumor Recurrence and Survival for Papillary Thyroid Cancer Patients. *Ann Surg Oncol*. 2018;25(9):2520-2525. URL: <https://pubmed.ncbi.nlm.nih.gov/29855833/>
470. Rajjoub S, Yan H, Calcaterra N, Kuchta K, Wang C, Lutfi W, et al. Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers. *Surgery*. 2018;163(5):1134-1143. URL: <https://pubmed.ncbi.nlm.nih.gov/29426618/>
471. Glockzin G, Hornung M, Kienle K, Thelen K, Boin M, Schreyer A, et al. Completion thyroidectomy: effect of timing on clinical complications and oncologic outcome in patients with differentiated thyroid cancer. *World J Surg*. 2012;36(5):1168-73. URL: <https://pubmed.ncbi.nlm.nih.gov/22366982/>
472. Sosa J, Bowman H, Tielsch J, Powe N, Gordon T, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. *Ann Surg*. 1998;228(3):320-30. URL: <https://pubmed.ncbi.nlm.nih.gov/9742915/>

473. Sosa J, Mehta P, Wang T, Boudourakis L, Roman S. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost?. *J Am Coll Surg*. 2008;206(6):1097-105. URL: <https://pubmed.ncbi.nlm.nih.gov/18501806/>
474. Papaleontiou M, Gauger P, Haymart M. REFERRAL OF OLDER THYROID CANCER PATIENTS TO A HIGH-VOLUME SURGEON: RESULTS OF A MULTIDISCIPLINARY PHYSICIAN SURVEY. *Endocr Pract*. 2017;23(7):808-815. URL: <https://pubmed.ncbi.nlm.nih.gov/28534681/>
475. Youngwirth L, Adam M, Scheri R, Roman S, Sosa J. Patients Treated at Low-Volume Centers have Higher Rates of Incomplete Resection and Compromised Outcomes: Analysis of 31,129 Patients with Papillary Thyroid Cancer. *Ann Surg Oncol*. 2016;23(2):403-9. URL: <https://pubmed.ncbi.nlm.nih.gov/26416710/>
476. Kim M, Chung W. Yonsei Experience of 5000 Gasless Transaxillary Robotic Thyroidectomies: Reply. *World J Surg*. 2018;42(7):2281-2282. URL: <https://pubmed.ncbi.nlm.nih.gov/29362890/>
477. Baerbock N, Mittelstädt A, Jähne J. Morbidity and long-term survival in patients with cervical re-exploration for papillary thyroid carcinoma. *Innov Surg Sci*. 2019;4(3):91-99. URL: <https://pubmed.ncbi.nlm.nih.gov/31709300/>
478. Gulcelik M, Dogan L, Akgul G, Güven E, Ersöz Gulcelik N. Completion Thyroidectomy: Safer than Thought. *Oncol Res Treat*. 2018;41(6):386-390. URL: <https://pubmed.ncbi.nlm.nih.gov/29734197/>
479. Nicholson K, Teng C, McCoy K, Carty S, Yip L. Completion thyroidectomy: A risky undertaking?. *Am J Surg*. 2019;218(4):695-699. URL: <https://pubmed.ncbi.nlm.nih.gov/31345503/>
480. Untch B, Palmer F, Ganly I, Patel S, Michael Tuttle R, Shah J, et al. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. *Ann Surg Oncol*. 2014;21(4):1374-8. URL: <https://pubmed.ncbi.nlm.nih.gov/24366419/>
481. Randolph G, Daniels G. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. *Thyroid*. 2002;12(11):989-96. URL: <https://pubmed.ncbi.nlm.nih.gov/12490076/>
482. Barbesino G, Goldfarb M, Parangi S, Yang J, Ross D, Daniels G. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up. *Thyroid*. 2012;22(4):369-76. URL: <https://pubmed.ncbi.nlm.nih.gov/22385290/>
483. Santra A, Bal S, Mahargan S, Bal C. Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer. *Nucl Med Commun*. 2011;32(1):52-8. URL: <https://pubmed.ncbi.nlm.nih.gov/21063234/>
484. Giovannella L, Piccardo A, Paone G, Foppiani L, Treglia G, Ceriani L. Thyroid lobe ablation with iodine- ¹³¹I in patients with differentiated thyroid carcinoma: a randomized comparison between 11 and 37 GBq activities. *Nucl Med Commun*. 2013;34(8):767-70. URL: <https://pubmed.ncbi.nlm.nih.gov/23652210/>
485. Piazza C, Del Bon F, Barbieri D, Grazioli P, Paderno A, Perotti P, et al. Tracheal and Crico-Tracheal Resection and Anastomosis for Malignancies Involving the Thyroid Gland and the Airway. *Ann Otol Rhinol Laryngol*. 2016;125(2):97-104. URL: <https://pubmed.ncbi.nlm.nih.gov/26296930/>
486. Kim H, Jung H, Lee S, Kwon T, Kim K, Sung M, et al. Prognostic factors of locally invasive well-differentiated thyroid carcinoma involving the trachea. *Eur Arch Otorhinolaryngol*. 2016;273(7):1919-26. URL: <https://pubmed.ncbi.nlm.nih.gov/26198285/>

487. Nixon I, Simo R, Newbold K, Rinaldo A, Suarez C, Kowalski L, et al. Management of Invasive Differentiated Thyroid Cancer. *Thyroid*. 2016;26(9):1156-66. URL: <https://pubmed.ncbi.nlm.nih.gov/27480110/>
488. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. *World J Surg*. 2006;30(5):780-6. URL: <https://pubmed.ncbi.nlm.nih.gov/16411013/>
489. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. *Thyroid*. 2009;19(7):707-16. URL: <https://pubmed.ncbi.nlm.nih.gov/19348581/>
490. Rivera M, Ricarte-Filho J, Tuttle R, Ganly I, Shaha A, Knauf J, et al. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. *Thyroid*. 2010;20(10):1085-93. URL: <https://pubmed.ncbi.nlm.nih.gov/20860430/>
491. Fukushima M, Ito Y, Hirokawa M, Miya A, Shimizu K, Miyauchi A. Prognostic impact of extrathyroid extension and clinical lymph node metastasis in papillary thyroid carcinoma depend on carcinoma size. *World J Surg*. 2010;34(12):3007-14. URL: <https://pubmed.ncbi.nlm.nih.gov/20824274/>
492. Brauckhoff M, Meinicke A, Bilkenroth U, Lorenz K, Brauckhoff K, Gimm O, et al. Long-term results and functional outcome after cervical evisceration in patients with thyroid cancer. *Surgery*. 2006;140(6):953-9. URL: <https://pubmed.ncbi.nlm.nih.gov/17188144/>
493. Brauckhoff M, Dralle H. Zervikoviszzerale Resektionen beim organüberschreitenden Schilddrüsenkarzinom. 2009;80:88. URL: <https://doi.org/10.1007/s00104-008-1610-y>
494. Musholt T, Musholt P, Behrend M, Raab R, Scheumann G, Klempnauer J. Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon. *Surgery*. 1999;126(6):1078-87; discussion 1087-8. URL: <https://pubmed.ncbi.nlm.nih.gov/10598191/>
495. Brauckhoff M, Machens A, Thanh P, Lorenz K, Schmeil A, Stratmann M, et al. Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival. *Surgery*. 2010;148(6):1257-66. URL: <https://pubmed.ncbi.nlm.nih.gov/21134559/>
496. Miyauchi A, Kudo T, Ito Y, Oda H, Sasai H, Higashiyama T, et al. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. *Surgery*. 2018;163(1):48-52. URL: <https://pubmed.ncbi.nlm.nih.gov/29103582/>
497. Miyauchi A. Chronology of Thyroid Cancer. *World J Surg*. 2023;47(2):288-295. URL: <https://pubmed.ncbi.nlm.nih.gov/36153411/>
498. Bibbins-Domingo K, Grossman D, Curry S, Barry M, Davidson K, Doubeni C, et al. Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2017;317(18):1882-1887. URL: <https://pubmed.ncbi.nlm.nih.gov/28492905/>
499. Krebs in Deutschland für 2017/2018. Zentrum für Krebsregisterdaten. 2018; URL: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_inhalt.html?nn=2378942
500. Christakis I, Dimas S, Kafetzis I, Roukounakis N. Risk stratification of 282 differentiated thyroid cancers found incidentally in 1369 total thyroidectomies according to the 2015 ATA guidelines; implications for management and treatment. *Ann R Coll Surg Engl*. 2018;100(5):357-365. URL: <https://pubmed.ncbi.nlm.nih.gov/29484944/>
501. Miyauchi A, Ito Y, Oda H. Insights into the Management of Papillary Microcarcinoma of the Thyroid. *Thyroid*. 2018;28(1):23-31. URL: <https://pubmed.ncbi.nlm.nih.gov/28629253/>

502. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. *Eur J Surg Oncol*. 2018;44(3):307-315. URL: <https://pubmed.ncbi.nlm.nih.gov/28343733/>
503. Venkatesh S, Pasternak J, Beninato T, Drake F, Kluijfhout W, Liu C, et al. Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer. *Surgery*. 2017;161(1):116-126. URL: <https://pubmed.ncbi.nlm.nih.gov/27839930/>
504. Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, Shindo H, et al. Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma. *Thyroid*. 2021;31(2):183-192. URL: <https://pubmed.ncbi.nlm.nih.gov/33023426/>
505. Oh H, Ha J, Kim H, Kim T, Kim W, Lim D, et al. Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea. *Thyroid*. 2018;28(12):1587-1594. URL: <https://pubmed.ncbi.nlm.nih.gov/30226447/>
506. Sugitani I, Ito Y, Miyauchi A, Imai T, Suzuki S. Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma in Japan. *Thyroid*. 2019;29(11):1563-1571. URL: <https://pubmed.ncbi.nlm.nih.gov/31441377/>
507. Jeon M, Kim W, Kwon H, Kim M, Park S, Oh H, et al. Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid microcarcinoma. *Eur J Endocrinol*. 2017;177(1):25-31. URL: <https://pubmed.ncbi.nlm.nih.gov/28432268/>
508. Ng S, Kuo S, Chen S, Hsueh C, Huang B, Lin J. Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors. *Int J Endocrinol*. 2017;2017:4208178. URL: <https://pubmed.ncbi.nlm.nih.gov/28642790/>
509. Chien M, Yang P, Lee J, Wang T, Hsu Y, Cheng S. Recurrence-associated genes in papillary thyroid cancer: An analysis of data from The Cancer Genome Atlas. *Surgery*. 2017;161(6):1642-1650. URL: <https://pubmed.ncbi.nlm.nih.gov/28237646/>
510. Tong M, Li S, Li Y, Li Y, Feng Y, Che Y. Efficacy and safety of radiofrequency, microwave and laser ablation for treating papillary thyroid microcarcinoma: a systematic review and meta-analysis. *Int J Hyperthermia*. 2019;36(1):1278-1286. URL: <https://pubmed.ncbi.nlm.nih.gov/31826684/>
511. Chen J, Cao J, Qiu F, Huang P. The Efficacy and The Safety of Ultrasound-guided Ablation Therapy for Treating Papillary Thyroid Microcarcinoma. *J Cancer*. 2019;10(21):5272-5282. URL: <https://pubmed.ncbi.nlm.nih.gov/31602278/>
512. Sullivan M, Graham P, Alexander E, Ruan D, Nehs M, Gawande A, et al. Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer. *J Am Coll Surg*. 2017;224(6):1021-1027. URL: <https://pubmed.ncbi.nlm.nih.gov/28017809/>
513. Joseph K, Edirimanne S, Eslick G. Multifocality as a prognostic factor in thyroid cancer: A meta-analysis. *Int J Surg*. 2018;50:121-125. URL: <https://pubmed.ncbi.nlm.nih.gov/29337178/>
514. Liu Z, Zhao Q, Liu C, Zeng W, Ming J, Chen C, et al. Is biopsy enough for papillary thyroid microcarcinoma?: An analysis of the SEER database 2004 to 2013 with propensity score matching. *Medicine (Baltimore)*. 2018;97(31):e11791. URL: <https://pubmed.ncbi.nlm.nih.gov/30075609/>
515. Adam M, Thomas S, Hyslop T, Scheri R, Roman S, Sosa J. Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems. *J Clin Oncol*. 2016;34(36):4415-4420. URL: <https://pubmed.ncbi.nlm.nih.gov/27998233/>

516. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk B, Chirlaque M, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCare-5. *Eur J Cancer*. 2017;77:140-152. URL: <https://pubmed.ncbi.nlm.nih.gov/28410490/>
517. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. *World J Surg*. 2008;32(5):747-53. URL: <https://pubmed.ncbi.nlm.nih.gov/18264828/>
518. Kwon H, Jeon M, Kim W, Park S, Kim M, Song D, et al. A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. *Eur J Endocrinol*. 2017;176(4):371-378. URL: <https://pubmed.ncbi.nlm.nih.gov/28089996/>
519. Wu Z, Yan X, Su R, Ma Z, Xie B, Cao F. How Many Contralateral Carcinomas in Patients with Unilateral Papillary Thyroid Microcarcinoma are Preoperatively Misdiagnosed as Benign?. *World J Surg*. 2017;41(1):129-135. URL: <https://pubmed.ncbi.nlm.nih.gov/27541032/>
520. Ding Y, Mao Z, Ruan J, Su X, Li L, Fahey T, et al. Nomogram-Based New Recurrence Predicting System in Early-Stage Papillary Thyroid Cancer. *Int J Endocrinol*. 2019;2019:1029092. URL: <https://pubmed.ncbi.nlm.nih.gov/31582973/>
521. Wang F, Yu X, Shen X, Zhu G, Huang Y, Liu R, et al. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. *J Clin Endocrinol Metab*. 2017;102(9):3241-3250. URL: <https://pubmed.ncbi.nlm.nih.gov/28582521/>
522. Dong S, Xie X, Xia Q, Wu Y. Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis. *Am J Cancer Res*. 2019;9(8):1786-1795. URL: <https://pubmed.ncbi.nlm.nih.gov/31497359/>
523. Kim K, Kim S, Tan J, Shen X, Viola D, Elisei R, et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. *Eur J Cancer*. 2020;124:161-169. URL: <https://pubmed.ncbi.nlm.nih.gov/31790974/>
524. Chen B, Zhang Z, Wang K, Shang M, Zhao S, Ding W, et al. A multivariable model of BRAF. *Cancer Manag Res*. 2019;11:7211-7217. URL: <https://pubmed.ncbi.nlm.nih.gov/31440100/>
525. Liu W, Cheng R, Su Y, Diao C, Qian J, Zhang J, et al. Risk factors of central lymph node metastasis of papillary thyroid carcinoma: A single-center retrospective analysis of 3273 cases. *Medicine (Baltimore)*. 2017;96(43):e8365. URL: <https://pubmed.ncbi.nlm.nih.gov/29069024/>
526. Sun W, Lan X, Zhang H, Dong W, Wang Z, He L, et al. Risk Factors for Central Lymph Node Metastasis in CNO Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. *PLoS One*. 2015;10:e0139021. URL: <https://pubmed.ncbi.nlm.nih.gov/26431346/>
527. Wang Y, Guan Q, Xiang J. Nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma: A retrospective cohort study of 8668 patients. *Int J Surg*. 2018;55:98-102. URL: <https://pubmed.ncbi.nlm.nih.gov/29803769/>
528. Xu Y, Xu L, Wang J. Clinical predictors of lymph node metastasis and survival rate in papillary thyroid microcarcinoma: analysis of 3607 patients at a single institution. *J Surg Res*. 2018;221:128-134. URL: <https://pubmed.ncbi.nlm.nih.gov/29229118/>
529. Liu Z, Wang L, Yi P, Wang CY, Huang T. Risk factors for central lymph node metastasis of patients with papillary thyroid microcarcinoma: a meta-analysis. *Int J Clin Exp Pathol*. 2014;7:932-7. URL: <https://pubmed.ncbi.nlm.nih.gov/24696711/>
530. Qu N, Zhang L, Ji Q, Chen J, Zhu Y, Cao Y, et al. Risk Factors for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Meta-Analysis. *World J Surg*. 2015;39(10):2459-70. URL: <https://pubmed.ncbi.nlm.nih.gov/26099728/>

531. Slijepcevic N, Zivaljevic V, Diklic A, Jovanovic M, Oluic B, Paunovic I. Risk factors associated with intrathyroid extension of thyroid microcarcinomas. *Langenbecks Arch Surg.* 2018;403(5):615-622. URL: <https://pubmed.ncbi.nlm.nih.gov/29770856/>
532. Wei X, Wang M, Wang X, Zheng X, Li Y, Pan Y, et al. Prediction of cervical lymph node metastases in papillary thyroid microcarcinoma by sonographic features of the primary site. *Cancer Biol Med.* 2019;16(3):587-594. URL: <https://pubmed.ncbi.nlm.nih.gov/31565487/>
533. Feng J, Gan X, Shen F, Cai W, Xu B. The role of two tumor foci for predicting central lymph node metastasis in papillary thyroid carcinoma: A meta-analysis. *Int J Surg.* 2018;52:166-170. URL: <https://pubmed.ncbi.nlm.nih.gov/29481991/>
534. Zheng W, Wang K, Wu J, Wang W, Shang J. Multifocality is associated with central neck lymph node metastases in papillary thyroid microcarcinoma. *Cancer Manag Res.* 2018;10:1527-1533. URL: <https://pubmed.ncbi.nlm.nih.gov/29942154/>
535. Zhao Q, Ming J, Liu C, Shi L, Xu X, Nie X, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. *Ann Surg Oncol.* 2013;20(3):746-52. URL: <https://pubmed.ncbi.nlm.nih.gov/22972508/>
536. Hu J, Wen D, Ma B, Zhang T, Liao T, Shi X, et al. The extent of lymph node yield in central neck dissection can be affected by preoperative and intraoperative assessment and alter the prognosis of papillary thyroid carcinoma. *Cancer Med.* 2020;9(3):1017-1024. URL: <https://pubmed.ncbi.nlm.nih.gov/31854077/>
537. Qiu Y, Fei Y, Liu J, Liu C, He X, Zhu N, et al. Prevalence, Risk Factors And Location Of Skip Metastasis In Papillary Thyroid Carcinoma: A Systematic Review And Meta-Analysis. *Cancer Manag Res.* 2019;11:8721-8730. URL: <https://pubmed.ncbi.nlm.nih.gov/31576174/>
538. Pawelczak M, David R, Franklin B, Kessler M, Lam L, Shah B. Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following ¹³¹I treatment: a systematic review. *Thyroid.* 2010;20(10):1095-101. URL: <https://pubmed.ncbi.nlm.nih.gov/20860418/>
539. Francis G, Waguespack S, Bauer A, Angelos P, Benvenga S, Cerutti J, et al. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid.* 2015;25(7):716-59. URL: <https://pubmed.ncbi.nlm.nih.gov/25900731/>
540. Baumgarten H, Jenks C, Isaza A, Bhatti T, Mostoufi-Moab S, Kazahaya K, et al. Bilateral papillary thyroid cancer in children: Risk factors and frequency of postoperative diagnosis. *J Pediatr Surg.* 2020;55(6):1117-1122. URL: <https://pubmed.ncbi.nlm.nih.gov/32171533/>
541. Chen J, Huang N, Ji Q, Wang Y, Zhu Y, Li D. Multifocal papillary thyroid cancer in children and adolescents: 12-year experience in a single center. *Gland Surg.* 2019;8(5):507-515. URL: <https://pubmed.ncbi.nlm.nih.gov/31741881/>
542. Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. *World J Surg.* 2010;34:1192-202. URL: <https://pubmed.ncbi.nlm.nih.gov/20087589/>
543. Balachandar S, La Quaglia M, Tuttle R, Heller G, Ghossein R, Sklar C. Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes. *Thyroid.* 2016;26(2):219-26. URL: <https://pubmed.ncbi.nlm.nih.gov/26854950/>
544. Onder S, Ozturk Sari S, Yegen G, Sormaz I, Yilmaz I, Poyrazoglu S, et al. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. *Endocr Pathol.* 2016;27(2):153-61. URL: <https://pubmed.ncbi.nlm.nih.gov/26951110/>

545. Vassilopoulou-Sellin R, Goepfert H, Raney B, Schultz P. Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. *Head Neck*. 1998;20(6):549-55. URL: <https://pubmed.ncbi.nlm.nih.gov/9702543/>
546. Al-Qurayshi Z, Hauch A, Srivastav S, Aslam R, Friedlander P, Kandil E. A National Perspective of the Risk, Presentation, and Outcomes of Pediatric Thyroid Cancer. *JAMA Otolaryngol Head Neck Surg*. 2016;142(5):472-8. URL: <https://pubmed.ncbi.nlm.nih.gov/27031884/>
547. Leboulleux S, Baudin E, Hartl D, Travagli J, Schlumberger M. Follicular cell-derived thyroid cancer in children. *Horm Res*. 2005;63(3):145-51. URL: <https://pubmed.ncbi.nlm.nih.gov/15802922/>
548. Machens A, Lorenz K, Nguyen Thanh P, Brauckhoff M, Dralle H. Papillary thyroid cancer in children and adolescents does not differ in growth pattern and metastatic behavior. *J Pediatr*. 2010;157(4):648-52. URL: <https://pubmed.ncbi.nlm.nih.gov/20553841/>
549. Machens A, Elwerr M, Thanh P, Lorenz K, Schneider R, Dralle H. Impact of central node dissection on postoperative morbidity in pediatric patients with suspected or proven thyroid cancer. *Surgery*. 2016;160(2):484-92. URL: <https://pubmed.ncbi.nlm.nih.gov/27117577/>
550. Farahati J, Reiners C, Demidchik E. Is the UICC/AJCC classification of primary tumor in childhood thyroid carcinoma valid?. *J Nucl Med*. 1999;40(12):2125. URL: <https://pubmed.ncbi.nlm.nih.gov/10616895/>
551. Dralle H. [Thyroid gland surgery: risk factor surgeon]. *Chirurg*. 2012;83(3):280-1. URL: <https://pubmed.ncbi.nlm.nih.gov/22349789/>
552. Hundahl S, Cady B, Cunningham M, Mazzaferri E, McKee R, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996 US and German Thyroid Cancer Study Group An American College of Surgeons Commission on Cancer Patient Care Evaluation study. *Cancer*. 2000;89(1):202-17. URL: <https://pubmed.ncbi.nlm.nih.gov/10897019/>
553. Clerici T, Kolb W, Beutner U, Bareck E, Dotzenrath C, Kull C, et al. Diagnosis and treatment of small follicular thyroid carcinomas. *Br J Surg*. 2010;97(6):839-44. URL: <https://pubmed.ncbi.nlm.nih.gov/20473996/>
554. Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M, et al. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. *Ann Surg*. 2009;249(6):1023-31. URL: <https://pubmed.ncbi.nlm.nih.gov/19474675/>
555. O'Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Delbridge LW, Sywak MS. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. *Eur J Surg Oncol*. 2011;37:181-5
556. Schmid K, Sheu S, G6rges R, Ensinger C, T6tsch M. [Thyroid tumors]. *Pathologe*. 2003;24(5):357-72. URL: <https://pubmed.ncbi.nlm.nih.gov/12961024/>
557. LiVolsi VA. Papillary thyroid carcinoma: an update. 2011;24:S1. URL: <https://doi.org/10.1038/modpathol.2010.129>
558. Udelsman R, Westra W, Donovan P, Sohn T, Cameron J. Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. *Ann Surg*. 2001;233(5):716-22. URL: <https://pubmed.ncbi.nlm.nih.gov/11323510/>
559. Miller M, Rubin C, Cunnane M, Bibbo M, Miller J, Keane W, et al. Intraoperative pathologic examination: cost effectiveness and clinical value in patients with cytologic diagnosis of cellular follicular thyroid lesion. *Thyroid*. 2007;17(6):557-65. URL: <https://pubmed.ncbi.nlm.nih.gov/17614777/>

560. Lin J, Chao T, Hsueh C. Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas. Clin Endocrinol (Oxf). 2007;66(2):224-8. URL: <https://pubmed.ncbi.nlm.nih.gov/17223992/>
561. Baloch Z, LiVolsi V, Jain P, Jain R, Aljada I, Mandel S, et al. Role of repeat fine-needle aspiration biopsy (FNAB) in the management of thyroid nodules. Diagn Cytopathol. 2003;29(4):203-6. URL: <https://pubmed.ncbi.nlm.nih.gov/14506672/>
562. Dionigi G, Kraimps J, Schmid K, Hermann M, Sheu-Grabellus S, De Wailly P, et al. Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399(2):165-84. URL: <https://pubmed.ncbi.nlm.nih.gov/24233345/>
563. Huang C, Hsueh C, Liu F, Chao T, Lin J. Diagnostic and therapeutic strategies for minimally and widely invasive follicular thyroid carcinomas. Surg Oncol. 2011;20(1):1-6. URL: <https://pubmed.ncbi.nlm.nih.gov/19596568/>
564. Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, et al. Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid. 2011;21(7):751-7. URL: <https://pubmed.ncbi.nlm.nih.gov/21615311/>
565. Luster M, Clarke S, Dietlein M, Lassmann M, Lind P, Oyen W, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941-59. URL: <https://pubmed.ncbi.nlm.nih.gov/18670773/>
566. Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B, et al. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)]. Nuklearmedizin. 2007;46(5):213-9. URL: <https://pubmed.ncbi.nlm.nih.gov/17938757/>
567. Dralle H, Lorenz K, Machens A. [Surgery of thyroid carcinoma]. Chirurg. 2009;80(11):1069-82; quiz 1083. URL: <https://pubmed.ncbi.nlm.nih.gov/19902289/>
568. Machens A, Holzhausen H, Lautenschläger C, Thanh P, Dralle H. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. Cancer. 2003;98(4):712-9. URL: <https://pubmed.ncbi.nlm.nih.gov/12910514/>
569. Carling T, Udelsman R. Follicular neoplasms of the thyroid: what to recommend. Thyroid. 2005;15(6):583-7. URL: <https://pubmed.ncbi.nlm.nih.gov/16029125/>
570. Besic N, Hocevar M, Zgajnar J, Petric R, Pilko G. Aggressiveness of therapy and prognosis of patients with Hürthle cell papillary thyroid carcinoma. Thyroid. 2006;16(1):67-72. URL: <https://pubmed.ncbi.nlm.nih.gov/16487016/>
571. Montone K, Baloch Z, LiVolsi V. The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med. 2008;132(8):1241-50. URL: <https://pubmed.ncbi.nlm.nih.gov/18684023/>
572. Guerrero M, Suh I, Vriens M, Shen W, Gosnell J, Kebebew E, et al. Age and tumor size predicts lymph node involvement in Hürthle Cell Carcinoma. J Cancer. 2010;1:23-6. URL: <https://pubmed.ncbi.nlm.nih.gov/20842220/>
573. Lopez-Penabad L, Chiu A, Hoff A, Schultz P, Gaztambide S, Ordoñez N, et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer. 2003;97(5):1186-94. URL: <https://pubmed.ncbi.nlm.nih.gov/12599224/>
574. Carcangiu M. Hürthle cell carcinoma: clinic-pathological and biological aspects. Tumori. 2003;89(5):529-32. URL: <https://pubmed.ncbi.nlm.nih.gov/14870778/>
575. Kushchayeva Y, Duh Q, Kebebew E, Clark O. Prognostic indications for Hürthle cell cancer. World J Surg. 2004;28(12):1266-70. URL: <https://pubmed.ncbi.nlm.nih.gov/15517492/>

576. Sanders E, LiVolsi V, Brierley J, Shin J, Randolph G. An evidence-based review of poorly differentiated thyroid cancer. *World J Surg.* 2007;31(5):934-45. URL: <https://pubmed.ncbi.nlm.nih.gov/17431717/>
577. Poorly differentiated and undifferentiated thyroid cancer. In: *Endocrine Surgery.* 2009;121
578. Walczyk A, Kopczyński J, Gąsior-Perczak D, Pałyga I, Kowalik A, Chrapek M, et al. Poorly differentiated thyroid cancer in the context of the revised 2015 American Thyroid Association Guidelines and the Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System (eighth edition). *Clin Endocrinol (Oxf).* 2019;91(2):331-339. URL: <https://pubmed.ncbi.nlm.nih.gov/30525210/>
579. Patel K, Shaha A. Poorly differentiated thyroid cancer. *Curr Opin Otolaryngol Head Neck Surg.* 2014;22(2):121-6. URL: <https://pubmed.ncbi.nlm.nih.gov/24492853/>
580. Ibrahimasic T, Ghossein R, Shah JP, Ganly I. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. *Thyroid.* 2019;29:311-321. URL: <https://pubmed.ncbi.nlm.nih.gov/30747050/>
581. Hescot S, Al Ghuzlan A, Henry T, Sheikh-Alard H, Lamartina L, Borget I, et al. Prognostic of recurrence and survival in poorly differentiated thyroid cancer. *Endocr Relat Cancer.* 2022;29(11):625-634. URL: <https://pubmed.ncbi.nlm.nih.gov/36040800/>
582. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. *Cancer.* 2004;100(5):950-7. URL: <https://pubmed.ncbi.nlm.nih.gov/14983490/>
583. Akaishi J, Kondo T, Sugino K, Ogimi Y, Masaki C, Hames K, et al. Prognostic Impact of the Turin Criteria in Poorly Differentiated Thyroid Carcinoma. *World J Surg.* 2019;43(9):2235-2244. URL: <https://pubmed.ncbi.nlm.nih.gov/31098668/>
584. Volante M, Collini P, Nikiforov Y, Sakamoto A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. *Am J Surg Pathol.* 2007;31(8):1256-64. URL: <https://pubmed.ncbi.nlm.nih.gov/17667551/>
585. Volante M, Papotti M. Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours. *Endocr Pathol.* 2010;21(1):1-6. URL: <https://pubmed.ncbi.nlm.nih.gov/19960273/>
586. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. *Cancer.* 2006;106:1286-95. URL: <https://pubmed.ncbi.nlm.nih.gov/16470605/>
587. Wong K, Lorch J, Alexander E, Marqusee E, Cho N, Nehs M, et al. Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. *Thyroid.* 2019;29(9):1255-1261. URL: <https://pubmed.ncbi.nlm.nih.gov/31397224/>
588. Lam K, Lo C, Chan K, Wan K. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. *Ann Surg.* 2000;231(3):329-38. URL: <https://pubmed.ncbi.nlm.nih.gov/10714625/>
589. Dettmer M, Schmitt A, Steinert H, Haldemann A, Meili A, Moch H, et al. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed?. *Am J Surg Pathol.* 2011;35(12):1866-72. URL: <https://pubmed.ncbi.nlm.nih.gov/21989341/>
590. Chao TC, Lin JD, Chen MF. Insular carcinoma: infrequent subtype of thyroid cancer with aggressive clinical course. *World J Surg.* 2004;28:393-6. URL: <https://pubmed.ncbi.nlm.nih.gov/14994145/>

591. Patel K, Shaha A. Poorly differentiated and anaplastic thyroid cancer. *Cancer Control*. 2006;13(2):119-28. URL: <https://pubmed.ncbi.nlm.nih.gov/16735986/>
592. Jung T, Kim T, Kim K, Oh Y, Park D, Cho B, et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. *Endocr J*. 2007;54(2):265-74. URL: <https://pubmed.ncbi.nlm.nih.gov/17379963/>
593. Walczyk A, Kopczyński J, Gąsior-Perczak D, Pałyga I, Kowalik A, Chrapek M, et al. Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients. *PLoS One*. 2020;15(2):e0229264. URL: <https://pubmed.ncbi.nlm.nih.gov/32092093/>
594. de la Fouchardière C, Decaussin-Petrucci M, Berthiller J, Descotes F, Lopez J, Lifante J, et al. Predictive factors of outcome in poorly differentiated thyroid carcinomas. *Eur J Cancer*. 2018;92:40-47. URL: <https://pubmed.ncbi.nlm.nih.gov/29413688/>
595. Ho A, Luu M, Barrios L, Chen I, Melany M, Ali N, et al. Incidence and Mortality Risk Spectrum Across Aggressive Variants of Papillary Thyroid Carcinoma. *JAMA Oncol*. 2020;6(5):706-713. URL: <https://pubmed.ncbi.nlm.nih.gov/32134428/>
596. Dralle H, Sekulla C, Haerting J, Timmermann W, Neumann H, Kruse E, et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. *Surgery*. 2004;136(6):1310-22. URL: <https://pubmed.ncbi.nlm.nih.gov/15657592/>
597. Maneck M, Dotzenrath C, Dralle H, Fahlenbrach C, Paschke R, Steinmüller T, et al. [Complications after thyroid gland operations in Germany : A routine data analysis of 66,902 AOK patients]. *Chirurg*. 2017;88(1):50-57. URL: <https://pubmed.ncbi.nlm.nih.gov/27510155/>
598. Adam M, Thomas S, Youngwirth L, Hyslop T, Reed S, Scheri R, et al. Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes?. *Ann Surg*. 2017;265(2):402-407. URL: <https://pubmed.ncbi.nlm.nih.gov/28059969/>
599. Godballe C, Madsen A, Sørensen C, Schytte S, Trolle W, Helweg-Larsen J, et al. Risk factors for recurrent nerve palsy after thyroid surgery: a national study of patients treated at Danish departments of ENT Head and Neck Surgery. *Eur Arch Otorhinolaryngol*. 2014;271(8):2267-76. URL: <https://pubmed.ncbi.nlm.nih.gov/24132654/>
600. Hauch A, Al-Qurayshi Z, Friedlander P, Kandil E. Association of socioeconomic status, race, and ethnicity with outcomes of patients undergoing thyroid surgery. *JAMA Otolaryngol Head Neck Surg*. 2014;140(12):1173-83. URL: <https://pubmed.ncbi.nlm.nih.gov/25187970/>
601. Maneck M, Dotzenrath C, Dralle H, Fahlenbrach C, Steinmüller T, Simon D, et al. [Case volume and complications after thyroid gland surgery in Germany: an analysis of routine data from 48,387 AOK patients]. *Chirurg*. 2021;92(1):40-48. URL: <https://pubmed.ncbi.nlm.nih.gov/32430544/>
602. Schneider R. Invited Commentary: Intraoperative Neural Monitoring for Early Vocal Cord Function Assessment After Thyroid Surgery-A Systematic Review and Meta-Analysis. *World J Surg*. 2021;45(11):3328-3329. URL: <https://pubmed.ncbi.nlm.nih.gov/34414465/>
603. Cirocchi R, Arezzo A, D'Andrea V, Abraha I, Popivanov G, Avenia N, et al. Intraoperative neuromonitoring versus visual nerve identification for prevention of recurrent laryngeal nerve injury in adults undergoing thyroid surgery. *Cochrane Database Syst Rev*. 2019;1(1):CD012483. URL: <https://pubmed.ncbi.nlm.nih.gov/30659577/>
604. Barczyński M, Konturek A, Cichoń S. Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal nerves during thyroidectomy. *Br J Surg*. 2009;96(3):240-6. URL: <https://pubmed.ncbi.nlm.nih.gov/19177420/>
605. Barczyński M, Konturek A, Stopa M, Honowska A, Nowak W. Randomized controlled trial of visualization versus neuromonitoring of the external branch of the superior laryngeal nerve

- during thyroidectomy. *World J Surg.* 2012;36(6):1340-7. URL: <https://pubmed.ncbi.nlm.nih.gov/22402975/>
606. Lee H, Lee J, Dionigi G, Bae J, Kim H. The Efficacy of Intraoperative Neuromonitoring During Robotic Thyroidectomy: A Prospective, Randomized Case-Control Evaluation. *J Laparoendosc Adv Surg Tech A.* 2015;25(11):908-14. URL: <https://pubmed.ncbi.nlm.nih.gov/26575249/>
607. Sarı S, Erbil Y, Sümer A, Agcaoglu O, Bayraktar A, Issever H, et al. Evaluation of recurrent laryngeal nerve monitoring in thyroid surgery. *Int J Surg.* 2010;8(6):474-8. URL: <https://pubmed.ncbi.nlm.nih.gov/20601257/>
608. Hei H, Zhou B, Qin J, Song Y. Intermittent intraoperative nerve monitoring in thyroid reoperations: Preliminary results of a randomized, single-surgeon study. *Head Neck.* 2016;38 Suppl 1:E1993-7. URL: <https://pubmed.ncbi.nlm.nih.gov/26829763/>
609. Schneider R, Sekulla C, Machens A, Lorenz K, Nguyen Thanh P, Dralle H. Postoperative vocal fold palsy in patients undergoing thyroid surgery with continuous or intermittent nerve monitoring. *Br J Surg.* 2015;102(11):1380-7. URL: <https://pubmed.ncbi.nlm.nih.gov/26333134/>
610. Barczyński M, Konturek A, Pragacz K, Papier A, Stopa M, Nowak W. Intraoperative nerve monitoring can reduce prevalence of recurrent laryngeal nerve injury in thyroid reoperations: results of a retrospective cohort study. *World J Surg.* 2014;38(3):599-606. URL: <https://pubmed.ncbi.nlm.nih.gov/24081538/>
611. Calò P, Pisano G, Medas F, Pittau M, Gordini L, Demontis R, et al. Identification alone versus intraoperative neuromonitoring of the recurrent laryngeal nerve during thyroid surgery: experience of 2034 consecutive patients. *J Otolaryngol Head Neck Surg.* 2014;43(1):16. URL: <https://pubmed.ncbi.nlm.nih.gov/24942225/>
612. De Falco M, Santangelo G, Del Giudice S, Gallucci F, Parmeggiani U. Double probe intraoperative neuromonitoring with a standardized method in thyroid surgery. *Int J Surg.* 2014;12 Suppl 1:S140-4. URL: <https://pubmed.ncbi.nlm.nih.gov/24862671/>
613. Cavicchi O, Burgio L, Cioccoloni E, Piccin O, Macrì G, Schiavon P, et al. Intraoperative intermittent neuromonitoring of inferior laryngeal nerve and staged thyroidectomy: our experience. *Endocrine.* 2018;62(3):560-565. URL: <https://pubmed.ncbi.nlm.nih.gov/30173330/>
614. Lombardi C, De Waure C, Mariani M, Carnassale G, D'Amore A, Traini E, et al. Efficacy of continuous neuromonitoring in thyroid surgery: preliminary report of a single-center experience. *Gland Surg.* 2019;8(4):336-342. URL: <https://pubmed.ncbi.nlm.nih.gov/31538057/>
615. Sedlmaier A, Steinmüller T, Hermanns M, Nawka T, Weikert S, Sedlmaier B, et al. Continuous versus intermittent intraoperative neuromonitoring in complex benign thyroid surgery: A retrospective analysis and prospective follow-up. *Clin Otolaryngol.* 2019;44(6):1071-1079. URL: <https://pubmed.ncbi.nlm.nih.gov/31565844/>
616. Schneider R, Randolph G, Sekulla C, Phelan E, Thanh P, Bucher M, et al. Continuous intraoperative vagus nerve stimulation for identification of imminent recurrent laryngeal nerve injury. *Head Neck.* 2013;35(11):1591-8. URL: <https://pubmed.ncbi.nlm.nih.gov/23169450/>
617. Schneider R, Satioglu I, Lorenz K. Operationstechnik: Neuromonitoring bei Schilddrüsenoperationen (cIONM, iIONM). 2021;1. URL: https://doi.org/10.1007/978-3-662-61724-3_7-1
618. Staubitz J, van der Sluis P, Berth F, Watzka F, Dette F, Läßig A, et al. Recurrent laryngeal nerve monitoring during totally robot-assisted Ivor Lewis esophagectomy. *Langenbecks Arch Surg.* 2020;405(8):1091-1099. URL: <https://pubmed.ncbi.nlm.nih.gov/32970189/>

619. Smith J, Douglas J, Smith B, Dougherty T, Ayshford C. Assessment of recurrent laryngeal nerve function during thyroid surgery. *Ann R Coll Surg Engl*. 2014;96(2):130-5. URL: <https://pubmed.ncbi.nlm.nih.gov/24780671/>
620. Melin M, Schwarz K, Pearson M, Lammers B, Goretzki P. Postoperative vocal cord dysfunction despite normal intraoperative neuromonitoring: an unexpected complication with the risk of bilateral palsy. *World J Surg*. 2014;38(10):2597-602. URL: <https://pubmed.ncbi.nlm.nih.gov/24867468/>
621. Justiz Bd. Gesetz zum Schutz vor der schädlichen Wirkung ionisierender Strahlung (Strahlenschutzgesetz - StrlSchG) Strahlenschutzgesetz vom 27 Juni 1971 (BGBl I S 1966), das zuletzt durch die Bekanntmachung vom 3 Januar 2022 (BGBl I S 15) geändert worden ist. 2017
622. Justiz Bd. Verordnung zur weiteren Modernisierung des Strahlenschutzrechts. 2018
623. Strahlenschutzkommission. Therapeutische Verfahren in der Nuklearmedizin. 2022
624. Eilsberger F, Kreissl MC, Luster M, Pfestroff A. [Therapy concepts for thyroid carcinoma]. *Nuklearmedizin*. 2022;61:223-230. URL: <https://pubmed.ncbi.nlm.nih.gov/34644802/>
625. Krajewska J, Jarzab M, Kukulska A, Czarniecka A, Roskosz J, Puch Z, et al. Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma. *Nucl Med Mol Imaging*. 2019;53:320-327
626. Yu F, Li X, Ji Y, Tan J, Zhang G, Wang P, et al. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer. *Front Endocrinol (Lausanne)*. 2021;12:743310. URL: <https://pubmed.ncbi.nlm.nih.gov/34858329/>
627. Schmid KW, Synoracki S, Dralle H, Wittekind C. [Proposal for an extended pTNM classification of thyroid carcinoma : Commentary on deficits of the 8th edition of the TNM classification (German version)]. *Pathologe*. 2018;39:49-56
628. Schmid KW, Synoracki S, Dralle H, Wittekind C. Proposal for an extended pTNM classification of thyroid carcinoma. *Der Pathologe*. 2019;40:18-24. URL: <https://doi.org/10.1007/s00292-018-0418-x>
629. Li J, Liang J, Zhao T, Lin Y. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy. *Eur J Nucl Med Mol Imaging*. 2016;43:1034-9
630. Orosco R, Hussain T, Noel J, Chang D, Dosiou C, Mittra E, et al. Radioactive iodine in differentiated thyroid cancer: a national database perspective. *Endocr Relat Cancer*. 2019;26(10):795-802. URL: <https://pubmed.ncbi.nlm.nih.gov/31443087/>
631. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A comparison of different staging systems predictability of patient outcome Thyroid carcinoma as an example. *Cancer*. 1997;79:2414-23. URL: <https://pubmed.ncbi.nlm.nih.gov/9191532/>
632. Tanase K, Thies ED, Mäder U, Reiners C, Verburg FA. The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer. *Clin Endocrinol (Oxf)*. 2016;84:284-291
633. Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. *Thyroid*. 2016;26:373-80. URL: <https://pubmed.ncbi.nlm.nih.gov/26914539/>
634. Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, Consensus, and Collaboration in the Use of (131)I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear

Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. *Thyroid*. 2019;29:461-470

635. Orosco RK, Hussain T, Brumund KT, Oh DK, Chang DC, Bouvet M. Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database. *Thyroid*. 2015;25:125-32. URL: <https://pubmed.ncbi.nlm.nih.gov/25369076/>
636. van Velsen EFS, Visser WE, Stegenga MT, Mäder U, Reiners C, van Kemenade FJ, et al. Finding the Optimal Age Cutoff for the UICC/AJCC TNM Staging System in Patients with Papillary or Follicular Thyroid Cancer. *Thyroid*. 2021;31:1041-1049. URL: <https://pubmed.ncbi.nlm.nih.gov/33487121/>
637. Luster M, Aktolun C, Amendoeira I, Barczyński M, Bible KC, Duntas LH, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. *Thyroid*. 2019;29:7-26
638. Verburg FA, Flux G, Giovanella L, van Nostrand D, Muylle K, Luster M. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. *Eur J Nucl Med Mol Imaging*. 2020;47:78-83
639. (IARC) IAFRoC. Cancer incidence in five continents. XI
640. Pontius LN, Youngwirth LM, Thomas SM, Scheri RP, Roman SA, Sosa JA. Lymphovascular invasion is associated with survival for papillary thyroid cancer. *Endocr Relat Cancer*. 2016;23:555-62
641. Zhu GD. Clinical significance of the BRAF V600E mutation in PTC and its effect on radioiodine therapy. *Endocrine Connections*. 2019;8:754-763. URL: <https://pubmed.ncbi.nlm.nih.gov/31071680/>
642. Schmidt M, Bartenstein P, Bucerius J, Dietlein M, Drzezga A, Herrmann K, et al. Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine. *Nuklearmedizin*. 2022;61:87-96
643. Sawka AM, Thephamongkhon K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2004;89:3668-76
644. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. *Endocrinol Metab Clin North Am*. 2008;37:457-80, x
645. Sun Y, Gong J, Guo B, Shang J, Cheng Y, Xu H. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer. *Oral Oncology*. 2018;87:152-157. URL: <https://pubmed.ncbi.nlm.nih.gov/30527231/>
646. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. *Thyroid*. 2006;16:1229-42. URL: <https://pubmed.ncbi.nlm.nih.gov/17199433/>
647. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, et al. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. *J Clin Endocrinol Metab*. 2015;100:3270-9. URL: <https://pubmed.ncbi.nlm.nih.gov/26171797/>
648. Yang Z, Flores J, Katz S, Nathan CA, Mehta V. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated

- Thyroid Carcinoma. *Thyroid*. 2017;27:944-952. URL: <https://pubmed.ncbi.nlm.nih.gov/28446057/>
649. Ruel E, Thomas S, Perkins JM, Roman SA, Sosa JA. The Impact of Pathologically Positive Lymph Nodes in the Clinically Negative Neck: An Analysis of 39,301 Patients with Papillary Thyroid Cancer. *Annals of Surgical Oncology*. 2017;24:1935-1942. URL: <https://pubmed.ncbi.nlm.nih.gov/28127652/>
 650. Tang J, Kong D, Cui Q, Wang K, Zhang D, Liao X, et al. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. *OncoTargets and therapy*. 2018;11:3551-3560. URL: <https://pubmed.ncbi.nlm.nih.gov/29950860/>
 651. Verburg FA, Mäder U, Tanase K, Thies ED, Diessl S, Buck AK, et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. *J Clin Endocrinol Metab*. 2013;98:172-80
 652. Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. *Journal of Clinical Endocrinology & Metabolism*. 2015;100:1529-36. URL: <https://pubmed.ncbi.nlm.nih.gov/25642591/>
 653. Liu XF. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study. *Updates in Surgery*. 2020;72:871-884
 654. MacKinney E, Kuchta K, Winchester D, Khokar A, Holoubek S, Moo-Young T, et al. Overall survival is improved with total thyroidectomy and radiation for male patients and patients older than 55 with T2N0M0 Stage 1 classic papillary thyroid cancer. *Surgery*. 2022;171(1):197-202. URL: <https://pubmed.ncbi.nlm.nih.gov/34666913/>
 655. Zhao MS. Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis. *Computational and Mathematical Methods in Medicine*. 2022;Volume 2022 | Article ID 8028846
 656. Sutton W, Canner J, Segev D, Zeiger M, Mathur A. Treatment Variation in Older Adults With Differentiated Thyroid Cancer. *J Surg Res*. 2020;254:154-164. URL: <https://pubmed.ncbi.nlm.nih.gov/32445931/>
 657. Hu G, Zhu W, Yang W, Wang H, Shen L, Zhang H. The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis. *World Journal of Surgery*. 2016;40:100-9. URL: <https://pubmed.ncbi.nlm.nih.gov/26578322/>
 658. Harach HR, Franssila KO, Wasenius V. Occult papillary carcinoma of the thyroid A "normal" finding in Finland A systematic autopsy study. *Cancer*. 1985;56:531-538. URL: <https://pubmed.ncbi.nlm.nih.gov/2408737/>
 659. Krajewska J, Kukulska A, Oczko-Wojciechowska M, Kotecka-Blicharz A, Drosik-Rutowicz K, Haras-Gil M, et al. Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival. *Front Endocrinol (Lausanne)*. 2020;11:571421
 660. Miyauchi A, Kudo T, Ito Y, Oda H, Sasai H, Higashiyama T, et al. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. *Surgery*. 2018;163:48-52
 661. Buffet C, Golmard JL, Hoang C, Trésallet C, Du Pasquier Fédiaevsky L, Fierrard H, et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. *Eur J Endocrinol*. 2012;167:267-75. URL: <https://pubmed.ncbi.nlm.nih.gov/22648965/>

662. Creach KM, Siegel BA, Nussenbaum B, Grigsby PW. Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma. *ISRN Endocrinol.* 2012;2012:816386. URL: <https://pubmed.ncbi.nlm.nih.gov/22462017/>
663. Noguchi S, Yamashita H, Murakami N, Nakayama I, Toda M, Kawamoto H. Small carcinomas of the thyroid A long-term follow-up of 867 patients. *Arch Surg.* 1996;131:187-91
664. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. *Eur J Endocrinol.* 2008;159:659-73
665. Qu N, Zhang L, Ji QH, Chen JY, Zhu YX, Cao YM, et al. Risk Factors for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Meta-Analysis. *World J Surg.* 2015;39:2459-70
666. Lee KJ, Cho YJ, Kim SJ, Lee SC, Kim JG, Ahn CJ, et al. Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size. *World J Surg.* 2011;35:318-23
667. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. *Cancer.* 2005;103:2269-73
668. Verburg FA, Mäder U, Luster M, Reiners C. Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. *Clin Endocrinol (Oxf).* 2009;71:291-7
669. Goran M, Markovic I, Buta M, Gavrilovic D, Cvetkovic A, Santrac N, et al. The influence of papillary thyroid microcarcinomas size on the occurrence of lymph node metastases. *J buon.* 2019;24:2120-2126. URL: <https://pubmed.ncbi.nlm.nih.gov/31786884/>
670. Gao X, Zhang X, Zhang Y, Hua W, Maimaiti Y, Gao Z. Is papillary thyroid microcarcinoma an indolent tumor?: A retrospective study on 280 cases treated with radioiodine. *Medicine (Baltimore).* 2016;95:e5067. URL: <https://pubmed.ncbi.nlm.nih.gov/27749574/>
671. Gong Y, Li G, Lei J, You J, Jiang K, Li Z, et al. A favorable tumor size to define papillary thyroid microcarcinoma: an analysis of 1176 consecutive cases. *Cancer Manag Res.* 2018;10:899-906. URL: <https://pubmed.ncbi.nlm.nih.gov/29740219/>
672. Al-Qurayshi Z, Nilubol N, Tufano RP, Kandil E. Wolf in Sheep's Clothing: Papillary Thyroid Microcarcinoma in the US. *J Am Coll Surg.* 2020;230:484-491. URL: <https://www.ncbi.nlm.nih.gov/pubmed/32220437>
673. Huang Y, Yin Y, Zhou W. Risk Factors for Central and Lateral Lymph Node Metastases in Patients With Papillary Thyroid Micro-Carcinoma: Retrospective Analysis on 484 Cases. *Front Endocrinol (Lausanne).* 2021;12:640565. URL: <https://pubmed.ncbi.nlm.nih.gov/33746905/>
674. Baudin E, Travaglini JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. *Cancer.* 1998;83:553-9. URL: <https://pubmed.ncbi.nlm.nih.gov/9690549/>
675. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. *J Clin Endocrinol Metab.* 2012;97:4390-8. URL: <https://pubmed.ncbi.nlm.nih.gov/23066120/>
676. Malandrino P, Pellegri G, Attard M, Violi MA, Giordano C, Sciacca L, et al. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. *J Clin Endocrinol Metab.* 2013;98:1427-34
677. Mehanna H, Al-Maqbili T, Carter B, Martin E, Campain N, Watkinson J, et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. *J Clin Endocrinol Metab.* 2014;99:2834-43

678. Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, et al. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. *N Engl J Med*. 2022;386:923-932
679. Genpeng L, Jianyong L, Jiaying Y, Ke J, Zhihui L, Rixiang G, et al. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer. *Medicine*. 2018;97:e9619. URL: <https://pubmed.ncbi.nlm.nih.gov/29384841/>
680. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. *N Engl J Med*. 2005;352:2406-12
681. Pillai S, Gopalan V, Smith RA, Lam AK. Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology. *Crit Rev Oncol Hematol*. 2015;94:64-73
682. Liu Z, Zeng W, Huang L, Wang Z, Wang M, Zhou L, et al. Prognosis of FTC compared to PTC and FVPTC: findings based on SEER database using propensity score matching analysis. *Am J Cancer Res*. 2018;8(8):1440-1448. URL: <https://pubmed.ncbi.nlm.nih.gov/30210915/>
683. Liu C, Liu Y, Zhang L, Dong Y, Hu S, Xia Y, et al. Risk factors for high-volume lymph node metastases in cN0 papillary thyroid microcarcinoma. *Gland Surg*. 2019;8:550-556
684. De Leo S, Trevisan M, Colombo C, Gazzano G, Palazzo S, Vicentini L, et al. Post-Surgical Ablative or Adjuvant Radioiodine Therapy Has No Impact on Outcome in 1-4 cm Differentiated Thyroid Cancers without Extrathyroidal Extension. *J Clin Med*. 2021;10: URL: <https://pubmed.ncbi.nlm.nih.gov/34640469/>
685. Tuncel M, Vrachimis A, Campenni A, de Keizer B, Verburg FA, Kreissl MC, et al. To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment. *Eur J Nucl Med Mol Imaging*. 2022;49:3316-3319
686. Thompson AM, Turner RM, Hayen A, Aniss A, Jalaty S, Learoyd DL, et al. A preoperative nomogram for the prediction of ipsilateral central compartment lymph node metastases in papillary thyroid cancer. *Thyroid*. 2014;24:675-82
687. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med*. 1994;97:418-28
688. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. *J Clin Endocrinol Metab*. 1992;75:714-20
689. Chow SM, Yau S, Kwan CK, Poon PC, Law SC. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. *Endocr Relat Cancer*. 2006;13:1159-72. URL: <https://pubmed.ncbi.nlm.nih.gov/17158761/>
690. Alzahrani AS, Xing M. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. *Endocr Relat Cancer*. 2013;20:13-22. URL: <https://www.ncbi.nlm.nih.gov/pubmed/23132792>
691. Wang LY, Ganly I. Nodal metastases in thyroid cancer: prognostic implications and management. *Future Oncol*. 2016;12:981-94. URL: <https://pubmed.ncbi.nlm.nih.gov/26948758/>
692. Schmidt M, Görges R, Drzezga A, Dietlein M. A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?. *J Nucl Med*. 2018;59:1195-1201
693. Wang JB, Sun YY, Shi LH, Xie L. Predictive factors for non-small-volume central lymph node metastases (more than 5 or ≥ 2 mm) in clinically node-negative papillary thyroid carcinoma. *Medicine (Baltimore)*. 2019;98:e14028. URL: <https://pubmed.ncbi.nlm.nih.gov/30608456/>

694. Lei J, Zhong J, Jiang K, Li Z, Gong R, Zhu J. Skip lateral lymph node metastasis leaping over the central neck compartment in papillary thyroid carcinoma. *Oncotarget*. 2017;8:27022-27033
695. Nie X, Tan Z, Ge M. Skip metastasis in papillary thyroid carcinoma is difficult to predict in clinical practice. *BMC Cancer*. 2017;17:702
696. Pereira JA, Jimeno J, Miquel J, Iglesias M, Munné A, Sancho JJ, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. *Surgery*. 2005;138:1095-100, discussion 1100-1
697. Fama F, Cicciù M, Giudice GL, Sindoni A, Palella J, Piquard A, et al. Pattern of nodal involvement in papillary thyroid cancer: a challenge of quantitative analysis. *Int J Clin Exp Pathol*. 2015;8:11629-34. URL: <https://pubmed.ncbi.nlm.nih.gov/26617901/>
698. Robinson TJ, Thomas S, Dinan MA, Roman S, Sosa JA, Hyslop T. How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer. *J Clin Oncol*. 2016;34:3434-9
699. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. *Thyroid*. 2012;22:1144-52
700. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. *Am Surg*. 2005;71:731-4
701. Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, et al. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. *J Clin Oncol*. 2015;33:2370-5. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26077238>
702. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. *J Clin Endocrinol Metab*. 2006;91:313-9. URL: <https://pubmed.ncbi.nlm.nih.gov/16263822/>
703. Wang S, Xiong Y, Zhao Q, Song H, Yi P, Liu C. Columnar cell papillary thyroid carcinoma prognosis: findings from the SEER database using propensity score matching analysis. *Am J Transl Res*. 2019;11:6262-6270. URL: <https://pubmed.ncbi.nlm.nih.gov/31632592/>
704. Gonzalez-Gonzalez R, Bologna-Molina R, Carreon-Burciaga RG, Gómezpalacio-Gastelum M, Molina-Frechero N, Salazar-Rodríguez S. Papillary thyroid carcinoma: differential diagnosis and prognostic values of its different variants: review of the literature. *ISRN Oncol*. 2011;2011:915925. URL: <https://pubmed.ncbi.nlm.nih.gov/22432054/>
705. Jiang C, Cheng T, Zheng X, Hong S, Liu S, Liu J, et al. Clinical behaviors of rare variants of papillary thyroid carcinoma are associated with survival: a population-level analysis. *Cancer Manag Res*. 2018;10:465-472. URL: <https://pubmed.ncbi.nlm.nih.gov/29563836/>
706. Lam AK, Saremi N. Cribriform-morular variant of papillary thyroid carcinoma: a distinctive type of thyroid cancer. *Endocr Relat Cancer*. 2017;24:R109-r121
707. Ito Y, Miyauchi A, Ishikawa H, Hirokawa M, Kudo T, Tomoda C, et al. Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients. *Endocr J*. 2011;58:685-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21670544/>
708. Yu XM, Schneider DF, Levenson G, Chen H, Sippel RS. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. *Thyroid*. 2013;23:1263-8. URL: <https://pubmed.ncbi.nlm.nih.gov/23477346/>
709. Koo JS, Hong S, Park CS. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. *Thyroid*. 2009;19:1225-31

710. Fukushima M, Ito Y, Hirokawa M, Akasu H, Shimizu K, Miyauchi A. Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. *World J Surg.* 2009;33:958-62. URL: <https://pubmed.ncbi.nlm.nih.gov/19198928/>
711. Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. *Thyroid.* 2011;21:383-9
712. Coca-Pelaz A, Shah JP, Hernandez-Prera JC, Ghossein RA, Rodrigo JP, Hartl DM, et al. Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review. *Adv Ther.* 2020;37:3112-3128. URL: <https://pubmed.ncbi.nlm.nih.gov/32488657/>
713. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. *Am J Surg Pathol.* 2001;25:1478-84
714. Nikiforov Y, Gnepp DR, Fagin JA. Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. *J Clin Endocrinol Metab.* 1996;81:9-14
715. Reiners C, Biko J, Haenscheid H, Hebestreit H, Kirinjuk S, Baranowski O, et al. Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* 2013;98:3039-48
716. Vuong HG, Odate T, Duong UNP, Mochizuki K, Nakazawa T, Katoh R, et al. Prognostic importance of solid variant papillary thyroid carcinoma: A systematic review and meta-analysis. *Head Neck.* 2018;40:1588-1597
717. Ohashi R, Kawahara K, Namimatsu S, Igarashi T, Sakatani T, Sugitani I, et al. Clinicopathological significance of a solid component in papillary thyroid carcinoma. *Histopathology.* 2017;70:775-781
718. Chang H, Kim SM, Chun KW, Kim BW, Lee YS, Chang HS, et al. Clinicopathologic features of solid variant papillary thyroid cancer. *ANZ J Surg.* 2014;84:380-2. URL: <https://pubmed.ncbi.nlm.nih.gov/23826897/>
719. Cartwright S, Fingeret A. Contemporary evaluation and management of tall cell variant of papillary thyroid carcinoma. *Curr Opin Endocrinol Diabetes Obes.* 2020;27:351-357. URL: <https://pubmed.ncbi.nlm.nih.gov/32701516/>
720. Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. *Ann Surg Oncol.* 2012;19:1874-80
721. Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. *Laryngoscope.* 2008;118:32-8
722. Longheu A, Canu GL, Cappellacci F, Erdas E, Medas F, Calò PG. Tall Cell Variant versus Conventional Papillary Thyroid Carcinoma: A Retrospective Analysis in 351 Consecutive Patients. *J Clin Med.* 2020;10
723. Xu J, Zhang Y, Liu J, Qiu S, Wang M. A population-based study of the three major variants of papillary thyroid carcinoma. *J Int Med Res.* 2021;49:300060520984618. URL: <https://pubmed.ncbi.nlm.nih.gov/33535844/>
724. Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. *Hum Pathol.* 2007;38:212-9
725. Holoubek SA, Yan H, Khokar AH, Kuchta KM, Winchester DJ, Prinz RA, et al. Aggressive variants of papillary thyroid microcarcinoma are associated with high-risk features, but not

- decreased survival. *Surgery*. 2020;167:19-27. URL: <https://pubmed.ncbi.nlm.nih.gov/31627846/>
726. Holoubek S, MacKinney E, Khokar A, Kuchta K, Winchester D, Prinz R, et al. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm. *Surgery*. 2022;171(1):203-211. URL: <https://pubmed.ncbi.nlm.nih.gov/34384604/>
 727. Limberg J, Ullmann TM, Stefanova D, Buicko JL, Finnerty BM, Zarnegar R, et al. Does Aggressive Variant Histology Without Invasive Features Predict Overall Survival in Papillary Thyroid Cancer?: A National Cancer Database Analysis. *Ann Surg*. 2021;274:e276-e281
 728. Regalbuto C, Malandrino P, Frasca F, Pellegriti G, Le Moli R, Vigneri R, et al. The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. *J Endocrinol Invest*. 2013;36:249-54
 729. Wei S, Gao M, Zhao C, Pan Y, Li H, Li J, et al. Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma. *Int J Clin Oncol*. 2014;19:800-4
 730. Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. *Head Neck*. 2011;33:1052-9
 731. Wong KS, Higgins SE, Marqusee E, Nehs MA, Angell T, Barletta JA. Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis. *Endocr Pathol*. 2019;30:43-48
 732. Chen JH, Faquin WC, Lloyd RV, Nosé V. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. *Mod Pathol*. 2011;24:739-49. URL: <https://pubmed.ncbi.nlm.nih.gov/21358618/>
 733. Nath MC, Erickson LA. Aggressive Variants of Papillary Thyroid Carcinoma: Hobnail, Tall Cell, Columnar, and Solid. *Adv Anat Pathol*. 2018;25:172-179
 734. Song E, Jeon MJ, Oh HS, Han M, Lee YM, Kim TY, et al. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?. *Eur J Endocrinol*. 2018;179:135-142
 735. Wenig BM, Thompson LD, Adair CF, Shmookler B, Heffess CS. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. *Cancer*. 1998;82:740-53
 736. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma A clinicopathologic, immunohistochemical, and molecular study of eight cases. *Am J Surg Pathol*. 2010;34:44-52. URL: <https://pubmed.ncbi.nlm.nih.gov/19956062/>
 737. Mohapatra D, Naik S, Das P, Agrawala S. Metastatic hobnail variant of papillary thyroid carcinoma: A diagnostic challenge in cell block preparation. *Indian J Pathol Microbiol*. 2021;64:358-361
 738. Asioli S, Erickson LA, Righi A, Lloyd RV. Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior. *Hum Pathol*. 2013;44:320-8. URL: <https://pubmed.ncbi.nlm.nih.gov/23036367/>
 739. Lubitz CC, Economopoulos KP, Pawlak AC, Lynch K, Dias-Santagata D, Faquin WC, et al. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. *Thyroid*. 2014;24:958-65
 740. Donaldson LB, Yan F, Morgan PF, Kaczmar JM, Fernandes JK, Nguyen SA, et al. Hobnail variant of papillary thyroid carcinoma: a systematic review and meta-analysis. *Endocrine*. 2021;72:27-39. URL: <https://pubmed.ncbi.nlm.nih.gov/33025563/>

741. Morandi LR. Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma. *Endocrine-related Cancer*. 2017;24:107-117
742. Gross M, Eliashar R, Ben-Yaakov A, Weinberger JM, Maly B. Clinicopathologic features and outcome of the oncocytic variant of papillary thyroid carcinoma. *Ann Otol Rhinol Laryngol*. 2009;118:374-81. URL: <https://pubmed.ncbi.nlm.nih.gov/19548388/>
743. Herrera MF, Hay ID, Wu PS, Goellner JR, Ryan JJ, Ebersold JR, et al. Hürthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. *World J Surg*. 1992;16:669-74; discussion 774-5. URL: <https://pubmed.ncbi.nlm.nih.gov/1413835/>
744. Hong JH, Yi HS, Yi S, Kim HW, Lee J, Kim KS. Implications of oncocytic change in papillary thyroid cancer. *Clin Endocrinol (Oxf)*. 2016;85:797-804. URL: <https://pubmed.ncbi.nlm.nih.gov/27234487/>
745. Carr AA, Yen TWF, Ortiz DI, Hunt BC, Fareau G, Massey BL, et al. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls. *Thyroid*. 2018;28:1462-1467. URL: <https://pubmed.ncbi.nlm.nih.gov/30215297/>
746. Liu C, Zhao Q, Zeng W, Chen C, Ming J, Wang S, et al. Do patients with oxyphilic cell papillary thyroid carcinoma have a poor prognosis? Analysis of the surveillance, epidemiology, and end results database 2004-2013 with propensity score matching. *Oncotarget*. 2017;8:77075-77085. URL: <https://pubmed.ncbi.nlm.nih.gov/29100371/>
747. Wenter V, Jellinek A, Unterrainer M, Ahmaddy F, Lehner S, Albert NL, et al. Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy. *Eur J Nucl Med Mol Imaging*. 2019;46:2526-2535
748. Goffredo P, Sosa JA, Roman SA. Differentiated thyroid cancer presenting with distant metastases: a population analysis over two decades. *World Journal of Surgery*. 2013;37:1599-605. URL: <https://pubmed.ncbi.nlm.nih.gov/23525600/>
749. Beckner ME, Heffess CS, Oertel JE. Oxyphilic papillary thyroid carcinomas. *Am J Clin Pathol*. 1995;103:280-7. URL: <https://pubmed.ncbi.nlm.nih.gov/7872249/>
750. Cipriani NA, Nagar S, Kaplan SP, White MG, Antic T, Sadow PM, et al. Follicular Thyroid Carcinoma: How Have Histologic Diagnoses Changed in the Last Half-Century and What Are the Prognostic Implications?. *Thyroid*. 2015;25:1209-16. URL: <https://pubmed.ncbi.nlm.nih.gov/26440366/>
751. Yamazaki H, Katoh R, Sugino K, Matsuzu K, Masaki C, Akaishi J, et al. Encapsulated Angioinvasive Follicular Thyroid Carcinoma: Prognostic Impact of the Extent of Vascular Invasion. *Ann Surg Oncol*. 2022; URL: <https://pubmed.ncbi.nlm.nih.gov/35169976/>
752. Ito Y, Hirokawa M, Masuoka H, Yabuta T, Kihara M, Higashiyama T, et al. Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. *Endocr J*. 2013;60:637-42. URL: <https://pubmed.ncbi.nlm.nih.gov/23327839/>
753. D'Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, et al. Follicular thyroid carcinoma: histology and prognosis. *Cancer*. 2004;100:1123-9. URL: <https://pubmed.ncbi.nlm.nih.gov/15022277/>
754. Peth S, Hummel R, Schreckenberger M, Schad A, Raabe R, Weber T. [Is there an indication for thyroidectomy in cases of minimally invasive follicular thyroid carcinoma?]. *Chirurg*. 2022;93:509-512
755. Wu MH, Lee YY, Lu YL, Lin SF. Risk Factors and Prognosis for Metastatic Follicular Thyroid Cancer. *Front Endocrinol (Lausanne)*. 2022;13:791826. URL: <https://pubmed.ncbi.nlm.nih.gov/35299967/>

756. Janovitz T, Barletta JA. Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma. *Endocr Pathol.* 2018;29:357-364. URL: <https://pubmed.ncbi.nlm.nih.gov/30238434/>
757. Vogrin A, Besic H, Besic N, Music MM. Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms. *Radiol Oncol.* 2016;50:269-73
758. Oluic B, Paunovic I, Loncar Z, Djukic V, Diklic A, Jovanovic M, et al. Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience. *BMC Cancer.* 2017;17:371
759. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 [see commetns]. *Cancer.* 1998;83:2638-48. URL: <https://pubmed.ncbi.nlm.nih.gov/9874472/>
760. Haigh PI, Urbach DR. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. *Surgery.* 2005;138:1152-7; discussion 1157-8. URL: <https://pubmed.ncbi.nlm.nih.gov/16360403/>
761. Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H, et al. Does Hürthle cell carcinoma of the thyroid have a poorer prognosis than ordinary follicular thyroid carcinoma?. *Ann Surg Oncol.* 2013;20:2944-50
762. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. *Cancer.* 2003;97:1186-94
763. Jillard CL, Youngwirth L, Scheri RP, Roman S, Sosa JA. Radioactive Iodine Treatment Is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma. *Thyroid.* 2016;26:959-64. URL: <https://pubmed.ncbi.nlm.nih.gov/27150319/>
764. Ibrahimasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, Shaha AR, et al. Outcomes in patients with poorly differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* 2014;99:1245-52. URL: <https://pubmed.ncbi.nlm.nih.gov/24512493/>
765. Dettmer MS, Schmitt A, Komminoth P, Perren A. Poorly differentiated thyroid carcinoma : An underdiagnosed entity. *Pathologe.* 2020;41:1-8. URL: <https://pubmed.ncbi.nlm.nih.gov/31273418/>
766. Grawe F, Cahya A, Fabritius MP, Beyer L, Wenter V, Ruebenthaler J, et al. Course of Disease and Clinical Management of Patients with Poorly Differentiated Thyroid Carcinoma. *Cancers (Basel).* 2021;13: URL: <https://pubmed.ncbi.nlm.nih.gov/34771473/>
767. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. *Cancer.* 2004;100:950-7
768. Sanders EM, LiVolsi VA, Brierley J, Shin J, Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. *World J Surg.* 2007;31:934-45
769. Xu L, Zou Q, Jiao J, Zhang Y. Postoperative radioiodine therapy impact on survival in poorly differentiated thyroid carcinoma: a population-based study. *Nucl Med Commun.* 2022;43:145-151. URL: <https://pubmed.ncbi.nlm.nih.gov/34711774/>
770. Park EK, Chung JK, Lim IH, Park DJ, Lee DS, Lee MC, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. *Eur J Nucl Med Mol Imaging.* 2009;36:172-9
771. Robenshtok E, Grewal RK, Fish S, Sabra M, Tuttle RM. A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients. *Thyroid.* 2013;23:436-42

772. Prabhu M, Samson S, Reddy A, Venkataramanarao SH, Chandrasekhar NH, Pillai V, et al. Role of Preablative Stimulated Thyroglobulin in Prediction of Nodal and Distant Metastasis on Iodine Whole-Body Scan. *Indian J Nucl Med.* 2018;33:93-98
773. Giovanella L, Suriano S, Ceriani L, Verburg FA. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. *Clin Nucl Med.* 2011;36:109-12. URL: <https://pubmed.ncbi.nlm.nih.gov/21220971/>
774. Matrone A, Gambale C, Piaggi P, Viola D, Giani C, Agate L, et al. Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restrification and Decision to Perform 131I Ablation. *J Clin Endocrinol Metab.* 2017;102:893-902
775. 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients. *Oncotarget.* 2018;9:17491-17500. URL: <https://pubmed.ncbi.nlm.nih.gov/29707123/>
776. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. *New England journal of medicine.* 2012;366:1674-1685. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00814146/full>, <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1109589?articleTools=true>
777. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. *N Engl J Med.* 1983;309:937-41
778. Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging.* 2010;37:270-5. URL: <https://pubmed.ncbi.nlm.nih.gov/19760413/>
779. Jentzen W, Verschure F, van Zon A, van de Kolk R, Wierts R, Schmitz J, et al. 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer. *J Nucl Med.* 2016;57:1499-1504. URL: <https://pubmed.ncbi.nlm.nih.gov/27199362/>
780. Klubo-Gwiedzinska J, Van Nostrand D, Atkins F, Burman K, Jonklaas J, Mete M, et al. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. *J Clin Endocrinol Metab.* 2011;96:3217-25
781. Hänscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II Dosimetry prior to radioiodine therapy of benign thyroid diseases. *Eur J Nucl Med Mol Imaging.* 2013;40:1126-34. URL: <https://pubmed.ncbi.nlm.nih.gov/23576099/>
782. Pacini F, Brianzoni E, Durante C, Elisei R, Ferdeghini M, Fugazzola L, et al. Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology. *J Endocrinol Invest.* 2016;39:341-7
783. Robinson PS, Barker P, Campbell A, Henson P, Surveyor I, Young PR. Iodine-131 in breast milk following therapy for thyroid carcinoma. *J Nucl Med.* 1994;35:1797-801
784. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. *J Nucl Med.* 1996;37:606-12
785. Metallo M, Groza L, Brunaud L, Klein M, Weryha G, Feigerlova E. Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I(131) during Adolescence and Young Adulthood. *Int J Endocrinol.* 2016;2016:7586482

786. Kim HO, Lee K, Lee SM, Seo GH. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer. *JAMA Intern Med.* 2020;180:54-61
787. Mazzaferri EL. Gonadal damage from ¹³¹I therapy for thyroid cancer. *Clin Endocrinol (Oxf).* 2002;57:313-4
788. Pacini F, Gasperi M, Fugazzola L, Ceccarelli C, Lippi F, Centoni R, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. *J Nucl Med.* 1994;35:1418-22
789. Wichers M, Benz E, Palmedo H, Biersack HJ, Grünwald F, Klingmüller D. Testicular function after radioiodine therapy for thyroid carcinoma. *Eur J Nucl Med.* 2000;27:503-7
790. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following I(¹³¹) therapy for thyroid cancer. *Clin Endocrinol (Oxf).* 2002;56:755-8. URL: <https://pubmed.ncbi.nlm.nih.gov/12072044/>
791. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with ¹³¹I for thyroid cancer. *J Nucl Med.* 1976;17:460-4
792. Rosário PW, Barroso AL, Rezende LL, Padrão EL, Borges MA, Guimarães VC, et al. Testicular function after radioiodine therapy in patients with thyroid cancer. *Thyroid.* 2006;16:667-70
793. Canale D, Ceccarelli C, Caglieresi C, Moscatelli A, Gavioli S, Santini P, et al. Effects of radioiodine treatment for differentiated thyroid cancer on testis function. *Clin Endocrinol (Oxf).* 2015;82:295-9. URL: <https://pubmed.ncbi.nlm.nih.gov/25138547/>
794. Howell RW, Wessels BW, Loevinger R, Watson EE, Bolch WE, Brill AB, et al. The MIRD perspective 1999 Medical Internal Radiation Dose Committee. *J Nucl Med.* 1999;40:3s-10s. URL: <https://pubmed.ncbi.nlm.nih.gov/9935082/>
795. Anderson C, Engel SM, Weaver MA, Zevallos JP, Nichols HB. Birth rates after radioactive iodine treatment for differentiated thyroid cancer. *Int J Cancer.* 2017;141:2291-2295. URL: <https://www.ncbi.nlm.nih.gov/pubmed/28791691>
796. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L. Assessment of female fertility and carcinogenesis after iodine-¹³¹ therapy for differentiated thyroid carcinoma. *J Nucl Med.* 1995;36:21-7. URL: <https://pubmed.ncbi.nlm.nih.gov/7799075/>
797. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. *Postgrad Med J.* 2002;78:92-3
798. Wu JX, Young S, Ro K, Li N, Leung AM, Chiu HK, et al. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer. *Thyroid.* 2015;25:133-8. URL: <https://pubmed.ncbi.nlm.nih.gov/25289542/>
799. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbé M, Ceccarelli C, et al. Therapeutic administration of ¹³¹I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. *J Nucl Med.* 2008;49:845-52. URL: <https://pubmed.ncbi.nlm.nih.gov/18413399/>
800. Piek M, Postma E, van Leeuwen R, de Boer J, Bos A, Lok C, et al. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis. *Thyroid.* 2021;31(4):658-668. URL: <https://pubmed.ncbi.nlm.nih.gov/33012254/>
801. Raymond JP, Izembart M, Marliac V, Dagousset F, Merceron RE, Vulpillat M, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. *J Clin Endocrinol Metab.* 1989;69:186-90

802. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. ¹³¹I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. *J Clin Endocrinol Metab.* 2001;86:3512-5. URL: <https://pubmed.ncbi.nlm.nih.gov/11502772/>
803. Rosario PW, Fagundes TA, Fagundes AV, Barraso AL, Rezende LL, Padrao EL, et al. Radioiodine therapy and age at menopause in patients with thyroid cancer. *Clin Endocrinol (Oxf).* 2006;64:225-6
804. Sawka AM, Ibrahim-Zada I, Galacgac P, Tsang RW, Brierley JD, Ezzat S, et al. Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review. *Thyroid.* 2010;20:1129-38
805. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. *Clin Endocrinol (Oxf).* 2003;58:428-35
806. Sohn SY, Choi JY, Jang HW, Kim HJ, Jin SM, Kim SW, et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. *Thyroid.* 2013;23:741-7
807. Dobrenic M, Huic D, Zuvic M, Grosev D, Petrovic R, Samardzic T. Usefulness of low iodine diet in managing patients with differentiated thyroid cancer - initial results. *Radiol Oncol.* 2011;45:189-95. URL: <https://pubmed.ncbi.nlm.nih.gov/22933955/>
808. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. *J Clin Endocrinol Metab.* 2003;88:4110-5. URL: <https://pubmed.ncbi.nlm.nih.gov/12970272/>
809. Lan W, Renjie W, Qichang W, Feiyue T, Qingjie M, Bin J. Preoperative Use of Intravenous Contrast Media Is Associated With Decreased Excellent Response Rates in Intermediate-Risk DTC Patients Who Subsequently Receive Total Thyroidectomy and Low-Dose RAI Therapy. *Front Oncol.* 2020;10:1297
810. Petrulea MS, Lencu C, Piciu D, Lisencu CI, Georgescu CE. Challenges of thyroid cancer management in amiodarone-treated patients: a case report. *Clujul Med.* 2015;88:550-4
811. Puchalski AR, Chopra IJ. Radioiodine treatment of differentiated thyroid cancer despite history of 'iodine allergy'. *Endocrinol Diabetes Metab Case Rep.* 2014;2014:130084
812. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?. *J Nucl Med.* 2005;46:261-6
813. Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic (¹²⁴I) PET/(CT) dosimetry confirms low average absorbed doses per administered (¹³¹I) activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging.* 2010;37:884-95. URL: <https://pubmed.ncbi.nlm.nih.gov/20069293/>
814. Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using ¹²⁴I PET/(CT) imaging. *Eur J Nucl Med Mol Imaging.* 2010;37:2298-306. URL: <https://pubmed.ncbi.nlm.nih.gov/20625723/>
815. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. *J Nucl Med.* 2006;47:648-54. URL: <https://pubmed.ncbi.nlm.nih.gov/16595499/>
816. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human

- thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. *Journal of clinical endocrinology and metabolism*. 2006;91:926-932. URL: <https://pubmed.ncbi.nlm.nih.gov/16384850/>
817. Vaiano A, Claudio Traino A, Boni G, Grosso M, Lazzeri P, Colato C, et al. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal. *Nuclear medicine communications*. 2007;28:215-223. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00578094/full>
 818. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, et al. Low-activity (20 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. *European journal of endocrinology*. 2009;160:431-436. URL: <https://pubmed.ncbi.nlm.nih.gov/19074463/>
 819. Emmanouilidis N, Müller JA, Jäger MD, Kaaden S, Helfritz FA, Güner Z, et al. Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH. *European journal of endocrinology*. 2009;161:763-769. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00721059/full>, <https://eje.bioscientifica.com/downloadpdf/journals/eje/161/5/763.pdf>
 820. Emmanouilidis N, Schrem H, Winkler M, Klempnauer J, Scheumann GFW. Long-term results after treatment of very low-, low-, and high-risk thyroid cancers in a combined setting of thyroidectomy and radio ablation therapy in euthyroidism. *International journal of endocrinology*. 2013;2013: URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00919074/full>, <http://downloads.hindawi.com/journals/ije/2013/769473.pdf>
 821. Taïeb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. *Clinical endocrinology*. 2009;71:115-123. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00719883/full>, <https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2265.2008.03424.x>
 822. Waissi F, Kist JW, Lodewijk L, de Wit AG, van der Hage JA, van Dalen T, et al. Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial). *Clinical Nuclear Medicine*. 2019;44:272-275. URL: <https://pubmed.ncbi.nlm.nih.gov/30562195/>
 823. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. *N Engl J Med*. 2012;366:1663-73
 824. Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Kim EE, et al. The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials. *Journal of Korean Medical Science*. 2014;29:811-7. URL: <https://pubmed.ncbi.nlm.nih.gov/24932083/>
 825. Tu J, Wang S, Huo Z, Lin Y, Li X, Wang S. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. *Radiotherapy & Oncology*. 2014;110:25-30. URL: <https://pubmed.ncbi.nlm.nih.gov/24485353/>
 826. Fu H, Ma C, Tang L, Wu F, Liu B, Wang H. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis. *The Quarterly Journal of Nuclear Medicine & Molecular Imaging*. 2015;59:121-8. URL: <https://pubmed.ncbi.nlm.nih.gov/24844252/>
 827. Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, et al. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid

- Cancer: results From the Randomized Phase III ESTIMABL Trial. *Journal of clinical oncology*. 2015;33:2885-2892. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01108762/full>
828. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. *J Clin Endocrinol Metab*. 2009;94:4171-9. URL: <https://pubmed.ncbi.nlm.nih.gov/19850694/>
 829. Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. *Nuclear medicine communications*. 2012;33:275-282. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00971363/full>
 830. Zagar I, Schwarzbartl-Pavec AA, Videgar-Kralj B, Horvat R, Besic N. Recombinant human thyrotropin-aided radioiodine therapy in patients with metastatic differentiated thyroid carcinoma. *J Thyroid Res*. 2012;2012:670180. URL: <https://pubmed.ncbi.nlm.nih.gov/21876838/>
 831. Vrachimis A, Riemann B, Mäder U, Reiners C, Verburg FA. Endogenous TSH levels at the time of (131)I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. *Eur J Nucl Med Mol Imaging*. 2016;43:224-231
 832. Duranton F, Lacoste A, Faurous P, Deshayes E, Ribstein J, Avignon A, et al. Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism. *Clin Kidney J*. 2013;6:478-83. URL: <https://pubmed.ncbi.nlm.nih.gov/26064512/>
 833. Lee SJ, Lee HY, Lee WW, Kim SE. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy. *Nucl Med Commun*. 2014;35:727-32
 834. Coura-Filho GB, Willegaignon J, Buchpiguel CA, Sapienza MT. Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer. *Thyroid*. 2015;25:1291-1296. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01200793/full>
 835. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. *Eur J Nucl Med Mol Imaging*. 2003;30:1371-7
 836. Taïeb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, et al. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. *J Clin Endocrinol Metab*. 2010;95:3283-90
 837. Bacher R, Hohberg M, Dietlein M, Wild M, Kobe C, Drzezga A, et al. Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH. *J Nucl Med*. 2019;60:631-637. URL: <https://pubmed.ncbi.nlm.nih.gov/30315143/>
 838. Vrachimis A, Riemann B, Gerss J, Maier T, Schober O. Peace of mind for patients with differentiated thyroid cancer?. *Nuklearmedizin*. 2013;52:115-20
 839. Piccardo A, Trimboli P, Bottoni G, Giovannella L. Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis. *J Nucl Med*. 2020;61:1730-1735

840. Klain M, Nappi C, Zampella E, Cantoni V, Green R, Piscopo L, et al. Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis. *Eur J Nucl Med Mol Imaging*. 2021;48:4437-4444
841. Abdulrezzak U, Tutus A, Isik I, Kurt Y, Kula M. Quantitative comparison of low dose and standard dose radioiodine therapy effectiveness in patients with low risk differentiated thyroid cancer. *Q J Nucl Med Mol Imaging*. 2017;61:314-322. URL: <https://www.ncbi.nlm.nih.gov/pubmed/25600659>
842. Elrasad SAA, Abdelhafeez Y, Hussein MA, Amin RAA, Elrefaei S. Thyroid remnant ablation of differentiated thyroid carcinoma: a comparison of ablation success with high and low doses of radioiodine (I-131). *European journal of nuclear medicine and molecular imaging*. 2015;42:S328. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01136120/full>, <https://link.springer.com/content/pdf/10.1007%2Fs00259-015-3198-z.pdf>
843. Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, et al. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. *Journal of Clinical Endocrinology & Metabolism*. 2013;98:1353-60. URL: <https://pubmed.ncbi.nlm.nih.gov/23436920/>
844. Ma C, Tang L, Fu H, Li J, Wang H. rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis. *Nuclear Medicine Communications*. 2013;34:1150-6. URL: <https://pubmed.ncbi.nlm.nih.gov/24025918/>
845. Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: A large randomized clinical trial []. *Nuclear Medicine Communications*. 2011;25: URL: <https://pubmed.ncbi.nlm.nih.gov/22124360/>
846. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. *Journal of Clinical Endocrinology & Metabolism*. 2007;92:28-38. URL: <https://pubmed.ncbi.nlm.nih.gov/17032718/>
847. Kusacic Kuna S, Samardzic T, Medvedec M, Horvatic Herceg G, Bracic I, Despot M, et al. Thyroid remnant ablation with idifferent activities of radioiodine. *Nuklearmedizin*. 2011;50:A148. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01028699/full>
848. Song X, Meng Z, Jia Q, Zhang L, Xu K, Tan J, et al. Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer: A Meta-analysis. *Clinical Nuclear Medicine*. 2015;40:774-9. URL: <https://pubmed.ncbi.nlm.nih.gov/26204220/>
849. Gómez-Pérez AM, García-Alemán J, Molina-Vega M, Sebastián Ochoa A, Pérez García P, Mancha Doblas I, et al. Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis. *J Clin Med*. 2020;9: URL: <https://pubmed.ncbi.nlm.nih.gov/32098039/>
850. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. *PLoS ONE [Electronic Resource]*. 2008;3:e1885. URL: <https://pubmed.ncbi.nlm.nih.gov/18382668/>
851. Zaman M, Toor R, Kamal S, Maqbool M, Habib S, Niaz K. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers. *JPMa. The journal of the pakistan medical association*. 2006;56:353-356. URL: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00585898/full>

852. Kukulska A, Krajewska J, Gawkowska-Suwinska M, Puch Z, Paliczka-Cieslik E, Roskosz J, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. *Thyroid research*. 2010;3:9. URL: <https://pubmed.ncbi.nlm.nih.gov/21040579/>
853. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. *Clinical Endocrinology*. 2000;52:765-73. URL: <https://pubmed.ncbi.nlm.nih.gov/10848882/>
854. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity. *Eur Thyroid J*. 2017;6:187-196. URL: <https://pubmed.ncbi.nlm.nih.gov/28868259/>
855. Jentzen W, Moldovan AS, Ruhlmann M, Görges R, Bockisch A, Rosenbaum-Krumme S. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients Dosimetry-based model for estimation. *Nuklearmedizin*. 2015;54:137-43. URL: <https://pubmed.ncbi.nlm.nih.gov/25987357/>
856. Verburg FA, Mäder U, Reiners C, Hänscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. *J Clin Endocrinol Metab*. 2014;99:4487-96
857. Miller JE, Al-Attar NC, Brown OH, Shaughnessy GG, Rosculet NP, Avram AM, et al. Location and Causation of Residual Lymph Node Metastasis After Surgical Treatment of Regionally Advanced Differentiated Thyroid Cancer. *Thyroid*. 2018;28:593-600
858. Spanu A, Nuvoli S, Marongiu A, Gelo I, Mele L, Piras B, et al. Neck lymph node metastasis detection in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: a (131)I-SPECT/CT study. *BMC Cancer*. 2020;20:239
859. Avram AM, Fig LM, Frey KA, Gross MD, Wong KK. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging?. *J Clin Endocrinol Metab*. 2013;98:1163-71. URL: <https://pubmed.ncbi.nlm.nih.gov/23430789/>
860. Avram AM, Dewaraja YK. Thyroid Cancer Radiotheragnostics: the case for activity adjusted (131)I therapy. *Clin Transl Imaging*. 2018;6:335-346. URL: <https://pubmed.ncbi.nlm.nih.gov/30911535/>
861. Szujo S, Sira L, Bajnok L, Bodis B, Gyory F, Nemes O, et al. The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study. *Oncotarget*. 2017;8:79825-79834
862. Avram AM, Zukotynski K, Nadel HR, Giovanella L. Management of Differentiated Thyroid Cancer: The Standard of Care. *Journal of Nuclear Medicine*. 2022;63:189-195. URL: <https://jnm.snmjournals.org/content/jnumed/63/2/189.full.pdf>
863. Banerjee M, Wiebel JL, Guo C, Gay B, Haymart MR. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence. *Bmj*. 2016;354:i3839. URL: <https://pubmed.ncbi.nlm.nih.gov/27443325/>
864. Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, Verburg F. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. *J Clin Endocrinol Metab*. 2014;99(2):440-7. URL: <https://pubmed.ncbi.nlm.nih.gov/24285679/>
865. Bundesministerium für Umwelt N. Richtlinie zur Strahlenschutzverordnung. 2011
866. Verburg FA, Stokkel MP, Düren C, Verkooijen RB, Mäder U, van Isselt JW, et al. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging*. 2010;37:276-83

867. Kita T, Yokoyama K, Higuchi T, Kinuya S, Taki J, Nakajima K, et al. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. *Ann Nucl Med*. 2004;18:345-9
868. Pashnehsaz M, Takavar A, Izadyar S, Zakariaee SS, Mahmoudi M, Paydar R, et al. Gastrointestinal Side Effects of the Radioiodine Therapy for the Patients with Differentiated Thyroid Carcinoma Two Days after Prescription. *World J Nucl Med*. 2016;15:173-8
869. Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. *J Nucl Med*. 1986;27:1519-27
870. Clement SC, Peeters RP, Ronckers CM, Links TP, van den Heuvel-Eibrink MM, Nieveen van Dijkum EJ, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review. *Cancer Treat Rev*. 2015;41:925-34. URL: <https://pubmed.ncbi.nlm.nih.gov/26421813/>
871. Lu L, Shan F, Li W, Lu H. Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer. *Biomed Res Int*. 2016;2016:4376720
872. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. *J Nucl Med*. 1998;39:1551-4. URL: <https://www.ncbi.nlm.nih.gov/pubmed/9744341>
873. Mendoza A, Shaffer B, Karakla D, Mason ME, Elkins D, Goffman TE. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. *Thyroid*. 2004;14:133-40
874. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. *Clin Oncol (R Coll Radiol)*. 2007;19:83-6. URL: <https://pubmed.ncbi.nlm.nih.gov/17305259/>
875. Adramerinas M, Andreadis D, Vahtsevanos K, Pouloupoulos A, Pazaitou-Panayiotou K. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?. *Hormones (Athens)*. 2021;20(4):669-678. URL: <https://pubmed.ncbi.nlm.nih.gov/34143403/>
876. Rosário PW, Maia FF, Barroso A, Padrão EL, Rezende L, Purisch S. [Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer]. *Arq Bras Endocrinol Metabol*. 2004;48:310-4
877. Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. *Thyroid*. 2013;23:617-9
878. Dietlein M, Drzezga A. [Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer - be aware of side effects by antidepressants and sedatives Vorschädigung durch Antidepressiva und Sedativa beachten]. *Nuklearmedizin*. 2017;56:125-131. URL: <https://pubmed.ncbi.nlm.nih.gov/28715040/>
879. Fard-Esfahani A, Mirshekarpour H, Fallahi B, Eftekhari M, Saghari M, Beiki D, et al. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. *Clin Nucl Med*. 2007;32:696-9. URL: <https://pubmed.ncbi.nlm.nih.gov/17710021/>
880. Grünwald F, Schomburg A, Menzel C, Steinecker S, Späth G, Bockisch A, et al. [Changes in the blood picture after radioiodine therapy of thyroid cancer]. *Med Klin (Munich)*. 1994;89:522-8. URL: <https://pubmed.ncbi.nlm.nih.gov/7808352/>
881. Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. *J Nucl Med*. 1986;27:637-40. URL: <https://pubmed.ncbi.nlm.nih.gov/3712081/>

882. Holmquest DL, Lake P. Sudden hemorrhage in metastatic thyroid carcinoma of the brain during treatment with iodine-131. *J Nucl Med.* 1976;17:307-9. URL: <https://pubmed.ncbi.nlm.nih.gov/3632/>
883. Orita Y, Sugitani I, Matsuura M, Ushijima M, Tsukahara K, Fujimoto Y, et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. *Surgery.* 2010;147:424-31
884. An YS, Yoon JK, Lee SJ, Song HS, Yoon SH, Jo KS. Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer. *Ann Nucl Med.* 2013;27:386-91. URL: <https://www.ncbi.nlm.nih.gov/pubmed/23389626>
885. Jeong S, Kim H, Lee S, Ahn B, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. *Thyroid.* 2013;23(5):609-16. URL: <https://pubmed.ncbi.nlm.nih.gov/23153322/>
886. Klein Hesselink EN, Brouwers AH, de Jong JR, van der Horst-Schrivers AN, Coppes RP, Lefrandt JD, et al. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study. *J Nucl Med.* 2016;57:1685-1691
887. Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva-O'Callagan A, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. *J Nucl Med.* 2001;42:738-43
888. Wu JQ, Feng HJ, Ouyang W, Sun YG, Chen P, Wang J, et al. Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up. *Nucl Med Commun.* 2015;36:819-26. URL: <https://pubmed.ncbi.nlm.nih.gov/25932534/>
889. Jonklaas J. Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction. *Thyroid.* 2014;24:1806-14. URL: <https://pubmed.ncbi.nlm.nih.gov/25090584/>
890. Molinaro E, Leboeuf R, Shue B, Martorella AJ, Fleisher M, Larson S, et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. *Thyroid.* 2009;19:1035-41
891. Prinsen HT, Klein Hesselink EN, Brouwers AH, Plukker JT, Sluiter WJ, van der Horst-Schrivers AN, et al. Bone Marrow Function After (131)I Therapy in Patients With Differentiated Thyroid Carcinoma. *J Clin Endocrinol Metab.* 2015;100:3911-7
892. Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund K, et al. Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. *Ann ICRP.* 2015;44(2 Suppl):7-321. URL: <https://pubmed.ncbi.nlm.nih.gov/26069086/>
893. Andersson M, Eckerman K, Mattsson S. Lifetime attributable risk as an alternative to effective dose to describe the risk of cancer for patients in diagnostic and therapeutic nuclear medicine. *Phys Med Biol.* 2017;62(24):9177-9188. URL: <https://pubmed.ncbi.nlm.nih.gov/29064376/>
894. National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. 2006; URL: <https://nap.nationalacademies.org/catalog/11340/health-risks-from-exposure-to-low-levels-of-ionizing-radiation>
895. Eschner W, Schmidt M, Dietlein M, Schicha H. PROLARA: prognosis-based lifetime attributable risk approximation for cancer from diagnostic radiation exposure. *Eur J Nucl Med Mol Imaging.* 2010;37(1):131-5. URL: <https://pubmed.ncbi.nlm.nih.gov/19662409/>

896. Seo GH, Cho YY, Chung JH, Kim SW. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea. *Thyroid*. 2015;25:927-34
897. Lu CH, Lee KD, Chen PT, Chen CC, Kuan FC, Huang CE, et al. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. *Eur J Endocrinol*. 2013;169:577-85
898. Endo M, Liu JB, Dougan M, Lee JS. Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset. *J Thyroid Res*. 2018;2018:8765369. URL: <https://pubmed.ncbi.nlm.nih.gov>
899. Silva-Vieira M, Carrilho Vaz S, Esteves S, Ferreira TC, Limbert E, Salgado L, et al. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?. *Thyroid*. 2017;27:1068-1076
900. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2008;93:504-15. URL: <https://pubmed.ncbi.nlm.nih.gov/18029468/>
901. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schwartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. *Br J Cancer*. 2003;89:1638-44
902. Marti JL, Jain KS, Morris LG. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. *Thyroid*. 2015;25:681-7. URL: <https://pubmed.ncbi.nlm.nih.gov/25851829/>
903. Hirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer. *Thyroid*. 2016;26:1110-6. URL: <https://pubmed.ncbi.nlm.nih.gov/27302111/>
904. Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. *Clinical Endocrinology*. 2015;83:117-23. URL: <https://pubmed.ncbi.nlm.nih.gov/25115234/>
905. Kim S, Bang J, Boo D, Kim B, Choi I, Ko S, et al. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. *Eur J Nucl Med Mol Imaging*. 2022;49(10):3547-3556. URL: <https://pubmed.ncbi.nlm.nih.gov/35362796/>
906. Yu CY, Saeed O, Goldberg AS, Farooq S, Fazlizada R, Goldstein DP, et al. A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. *Thyroid*. 2018;28:1662-1673. URL: <https://pubmed.ncbi.nlm.nih.gov/30370820/>
907. Reinecke M, Ahlers G, Burchert A, Eilsberger F, Flux G, Marlowe R, et al. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence. *Eur J Nucl Med Mol Imaging*. 2022;49(9):3247-3256. URL: <https://pubmed.ncbi.nlm.nih.gov/35320386/>
908. Seo G, Kong K, Kim B, Kang S, Moon B, Yoon H, et al. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study. *J Clin Endocrinol Metab*. 2021;106(7):e2580-e2588. URL: <https://pubmed.ncbi.nlm.nih.gov/33755732/>
909. Teng CJ, Hu YW, Chen SC, Yeh CM, Chiang HL, Chen TJ, et al. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study. *J Natl Cancer Inst*. 2016;108

910. Hakala TT, Sand JA, Jukkola A, Huhtala HS, Metso S, Kellokumpu-Lehtinen PL. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. *Int J Clin Oncol*. 2016;21:231-239. URL: <https://pubmed.ncbi.nlm.nih.gov/26410770/>
911. Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. *Surgery*. 2012;151:844-50
912. Mei X, Yao X, Feng F, Cheng W, Wang H. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients. *BMC Cancer*. 2021;21:543. URL: <https://pubmed.ncbi.nlm.nih.gov/33980182/>
913. Ahn HY, Min HS, Yeo Y, Ma SH, Hwang Y, An JH, et al. Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer. *J Clin Endocrinol Metab*. 2015;100:3486-93. URL: <https://www.ncbi.nlm.nih.gov/pubmed/26147607>
914. Reiners C, Schneider R, Platonova T, Fridman M, Malzahn U, Mäder U, et al. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions Review of the Literature and Results of a Multi-Registry Survey. *Front Endocrinol (Lausanne)*. 2020;11:381
915. Piciu D, Pestean C, Barbus E, Larg MI, Piciu A. Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131. *Clujul Med*. 2016;89:384-9
916. Nappi C, Klain M, Cantoni V, Green R, Piscopo L, Volpe F, et al. Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging*. 2022;49(5):1630-1639. URL: <https://pubmed.ncbi.nlm.nih.gov/34820683/>
917. Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, et al. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. *Leukemia*. 2018;32:952-959. URL: <https://pubmed.ncbi.nlm.nih.gov/29104287/>
918. Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. *Journal of Clinical Oncology*. 2018;36:1831-1839. URL: <https://pubmed.ncbi.nlm.nih.gov/29252123/>
919. Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. *Ann Otol Rhinol Laryngol*. 2006;115:607-10. URL: <https://pubmed.ncbi.nlm.nih.gov/16944659/>
920. Hall P, Holm LE, Lundell G, Bjelkengren G, Larsson LG, Lindberg S, et al. Cancer risks in thyroid cancer patients. *Br J Cancer*. 1991;64:159-63. URL: <https://pubmed.ncbi.nlm.nih.gov/1854616/>
921. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. *Thyroid*. 2009;19:451-7
922. Rall JE, Alpers JB, Lewallen CG, Sonenberg M, Berman M, Rawson RW. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. *J Clin Endocrinol Metab*. 1957;17:1263-76
923. Dietlein M, Drzezga A. [Ablative Radioiodtherapie bei niedrigem und intermediärem Rezidivrisiko Höhere Überlebensrate beim Schilddrüsenkarzinom]. *Nuclear-Medizin*. 2016;55:71-6. URL: <https://pubmed.ncbi.nlm.nih.gov/27350003/>

924. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. *Am J Roentgenol Radium Ther Nucl Med.* 1962;87:171-82. URL: <https://pubmed.ncbi.nlm.nih.gov/13867399/>
925. Chen L, Shen Y, Luo Q, Yu Y, Lu H, Zhu R. Pulmonary fibrosis following radioiodine therapy of pulmonary metastases from differentiated thyroid carcinoma. *Thyroid.* 2010;20:337-40. URL: <https://pubmed.ncbi.nlm.nih.gov/20187786/>
926. Sgouros G, Song H, Ladenson PW, Wahl RL. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. *J Nucl Med.* 2006;47:1977-84
927. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with ¹³¹I. *J Nucl Med.* 2012;53:1633-51
928. Bledsoe TJ, Nath SK, Decker RH. Radiation Pneumonitis. *Clin Chest Med.* 2017;38:201-208. URL: <https://pubmed.ncbi.nlm.nih.gov/28477633/>
929. Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-Induced Lung Injury: Assessment and Management. *Chest.* 2019;156:150-162. URL: <https://pubmed.ncbi.nlm.nih.gov/30998908/>
930. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. *Nucl Med Commun.* 2014;35:808-17. URL: <https://pubmed.ncbi.nlm.nih.gov/24751702/>
931. Hebestreit H, Biko J, Drozd V, Demidchik Y, Burkhardt A, Trusen A, et al. Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl. *Eur J Nucl Med Mol Imaging.* 2011;38:1683-90. URL: <https://pubmed.ncbi.nlm.nih.gov/21626048/>
932. Kim K, Song J, Kim J, Bae J, Kim N, Yoo H, et al. Effects of radioactive iodine treatment on cardiovascular disease in thyroid cancer patients: a nationwide cohort study. *Ann Transl Med.* 2020;8(19):1235. URL: <https://pubmed.ncbi.nlm.nih.gov/33178767/>
933. Albano D, Bertagna F, Panarotto MB, Giubbini R. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer. *Pediatr Blood Cancer.* 2017;64: URL: <https://www.ncbi.nlm.nih.gov/pubmed/28436606>
934. Shalet SM, Tsatsoulis A, Whitehead E, Read G. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. *J Endocrinol.* 1989;120:161-5
935. Rivkees SA, Mazzaferri EL, Verburg FA, Reiners C, Luster M, Breuer CK, et al. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. *Endocr Rev.* 2011;32:798-826
936. Maier T, Schober O, Gerß J, Görlich D, Wenning C, Schaefer M, et al. Differentiated thyroid cancer patients more than 60 years old paradoxically show an increased life expectancy. *J Nucl Med.* 2015;56(2):190-5. URL: <https://pubmed.ncbi.nlm.nih.gov/25613533/>
937. Zaydfudim V, Feuer I, Griffin M, Phay J. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. *Surgery.* 2008;144(6):1070-7; discussion 1077-8. URL: <https://pubmed.ncbi.nlm.nih.gov/19041020/>
938. Randolph G, Duh Q, Heller K, LiVolsi V, Mandel S, Steward D, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. *Thyroid.* 2012;22(11):1144-52. URL: <https://pubmed.ncbi.nlm.nih.gov/23083442/>
939. Pacini F, Molinaro E, Castagna M, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the

- highest sensitivity in monitoring differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* 2003;88(8):3668-73. URL: <https://pubmed.ncbi.nlm.nih.gov/12915653/>
940. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. *J Clin Endocrinol Metab.* 2006;91(1):60-3. URL: <https://pubmed.ncbi.nlm.nih.gov/16219716/>
 941. Matrone A, Gambale C, Piaggi P, Viola D, Giani C, Agate L, et al. Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratisation and Decision to Perform 131I Ablation. *J Clin Endocrinol Metab.* 2017;102(3):893-902. URL: <https://pubmed.ncbi.nlm.nih.gov/27929713/>
 942. Ko M, Lee J, Shong Y, Gong G, Baek J. Normal and abnormal sonographic findings at the thyroidectomy sites in postoperative patients with thyroid malignancy. *AJR Am J Roentgenol.* 2010;194(6):1596-609. URL: <https://pubmed.ncbi.nlm.nih.gov/20489102/>
 943. Chua W, Langer J, Jones L. Surveillance Neck Sonography After Thyroidectomy for Papillary Thyroid Carcinoma: Pitfalls in the Diagnosis of Locally Recurrent and Metastatic Disease. *J Ultrasound Med.* 2017;36(7):1511-1530. URL: <https://pubmed.ncbi.nlm.nih.gov/28393379/>
 944. Kobaly K, Mandel S, Langer J. Clinical review: Thyroid cancer mimics on surveillance neck sonography. *J Clin Endocrinol Metab.* 2015;100(2):371-5. URL: <https://pubmed.ncbi.nlm.nih.gov/25375984/>
 945. Shin J, Han B, Ko E, Kang S. Sonographic findings in the surgical bed after thyroidectomy: comparison of recurrent tumors and nonrecurrent lesions. *J Ultrasound Med.* 2007;26(10):1359-66. URL: <https://pubmed.ncbi.nlm.nih.gov/17901139/>
 946. Melo M, da Rocha A, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. *J Clin Endocrinol Metab.* 2014;99(5):E754-65. URL: <https://pubmed.ncbi.nlm.nih.gov/24476079/>
 947. Tuttle R, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. *Thyroid.* 2010;20(12):1341-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21034228/>
 948. Castagna M, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. *Eur J Endocrinol.* 2011;165(3):441-6. URL: <https://pubmed.ncbi.nlm.nih.gov/21750043/>
 949. Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco R, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. *J Clin Endocrinol Metab.* 2011;96(6):1703-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21450986/>
 950. Kowalska A, Walczyk A, Pałyga I, Gąsior-Perczak D, Gadawska-Juszczak K, Szymonek M, et al. The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence. *PLoS One.* 2016;11(4):e0153242. URL: <https://pubmed.ncbi.nlm.nih.gov/27078258/>
 951. Hong C, Lee W, Jeong S, Lee S, Ahn B, Lee J. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation. *Nucl Med Commun.* 2014;35(11):1119-26. URL: <https://pubmed.ncbi.nlm.nih.gov/25144561/>
 952. Lee S, Lee W, Lee H, Moon J, Lee C, Kang S, et al. Practical Performance of the 2015 American Thyroid Association Guidelines for Predicting Tumor Recurrence in Patients with

- Papillary Thyroid Cancer in South Korea. *Thyroid*. 2017;27(2):174-181. URL: <https://pubmed.ncbi.nlm.nih.gov/27750028/>
953. Vaisman F, Momesso D, Bulzico D, Pessoa C, Dias F, Corbo R, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. *Clin Endocrinol (Oxf)*. 2012;77(1):132-8. URL: <https://pubmed.ncbi.nlm.nih.gov/22248037/>
 954. Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle R. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. *Thyroid*. 2013;23(11):1401-7. URL: <https://pubmed.ncbi.nlm.nih.gov/23517313/>
 955. Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. *Lancet Diabetes Endocrinol*. 2018;6(8):618-626. URL: <https://pubmed.ncbi.nlm.nih.gov/29807824/>
 956. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli J, et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. *Endocr Relat Cancer*. 2011;18(2):R29-40. URL: <https://pubmed.ncbi.nlm.nih.gov/21183629/>
 957. van Velsen E, Stegenga M, van Kemenade F, Kam B, van Ginhoven T, Visser W, et al. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients. *Thyroid*. 2019;29(8):1073-1079. URL: <https://pubmed.ncbi.nlm.nih.gov/31140385/>
 958. Grani G, Zatelli M, Alfò M, Montesano T, Torlontano M, Morelli S, et al. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. *Thyroid*. 2021;31(2):264-271. URL: <https://pubmed.ncbi.nlm.nih.gov/32475305/>
 959. Vaisman F, Tala H, Grewal R, Tuttle R. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. *Thyroid*. 2011;21(12):1317-22. URL: <https://pubmed.ncbi.nlm.nih.gov/22136267/>
 960. Shen F, Hsieh C, Huang I, Chang Y, Wang P. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation. *Thyroid*. 2017;27(4):531-536. URL: <https://pubmed.ncbi.nlm.nih.gov/28007013/>
 961. Trimboli P, Zilioli V, Imperiali M, Ceriani L, Giovanella L. High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas. *Eur J Endocrinol*. 2017;176(5):497-504. URL: <https://pubmed.ncbi.nlm.nih.gov/28137736/>
 962. Malandrino P, Tumino D, Russo M, Marescalco S, Fulco R, Frasca F. Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend. *J Endocrinol Invest*. 2019;42(10):1223-1230. URL: <https://pubmed.ncbi.nlm.nih.gov/30963467/>
 963. Lee Y, Cho J, Hong S, Yoon J. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm. *J Surg Oncol*. 2018;118(4):636-643. URL: <https://pubmed.ncbi.nlm.nih.gov/30114339/>
 964. Kim T, Ki C, Kim H, Kim K, Choe J, Kim J, et al. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations. *J Clin Endocrinol Metab*. 2017;102(5):1757-1764. URL: <https://pubmed.ncbi.nlm.nih.gov/28323925/>

965. Filetti S, Durante C, Hartl D, Leboulleux S, Locati L, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol*. 2019;30(12):1856-1883. URL: <https://pubmed.ncbi.nlm.nih.gov/31549998/>
966. Wiersinga W, Duntas L, Fadeyev V, Nygaard B, Vanderpump M. 2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. *Eur Thyroid J*. 2012;1(2):55-71. URL: <https://pubmed.ncbi.nlm.nih.gov/24782999/>
967. Rajput R, Chatterjee S, Rajput M. Can Levothyroxine Be Taken as Evening Dose? Comparative Evaluation of Morning versus Evening Dose of Levothyroxine in Treatment of Hypothyroidism. *J Thyroid Res*. 2011;2011:505239. URL: <https://pubmed.ncbi.nlm.nih.gov/21785690/>
968. Bolk N, Visser T, Nijman J, Jongste I, Tijssen J, Berghout A. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. *Arch Intern Med*. 2010;170(22):1996-2003. URL: <https://pubmed.ncbi.nlm.nih.gov/21149757/>
969. Ku E, Yoo W, Lee E, Ahn H, Woo S, Hong J, et al. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. *J Clin Endocrinol Metab*. 2021;106(12):3655-3667. URL: <https://pubmed.ncbi.nlm.nih.gov/34302730/>
970. Kwak D, Ha J, Won Y, Kwon Y, Park S. Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. *BMJ Open*. 2021;11(5):e043007. URL: <https://pubmed.ncbi.nlm.nih.gov/33986046/>
971. Bauer D, Ettinger B, Nevitt M, Stone K. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. *Ann Intern Med*. 2001;134(7):561-8. URL: <https://pubmed.ncbi.nlm.nih.gov/12803168/>
972. Hawkins Carranza F, Guadalix Iglesias S, Luisa De Mingo Domínguez M, Martín-Arriscado Arroba C, López Álvarez B, Allo Miguel G, et al. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy. *Cancer Med*. 2020;9(16):5746-5755. URL: <https://pubmed.ncbi.nlm.nih.gov/32583973/>
973. Flynn R, Bonellie S, Jung R, MacDonald T, Morris A, Leese G. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. *J Clin Endocrinol Metab*. 2010;95(1):186-93. URL: <https://pubmed.ncbi.nlm.nih.gov/19906785/>
974. Smit J, Eustatia-Rutten C, Corssmit E, Pereira A, Frölich M, Bleeker G, et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. *J Clin Endocrinol Metab*. 2005;90(11):6041-7. URL: <https://pubmed.ncbi.nlm.nih.gov/16131580/>
975. Mercurio G, Panzuto M, Bina A, Leo M, Cabula R, Petrini L, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. *J Clin Endocrinol Metab*. 2000;85(1):159-64. URL: <https://pubmed.ncbi.nlm.nih.gov/10634380/>
976. McGriff N, Csako G, Gourgiotis L, Lori C G, Pucino F, Sarlis N. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. *Ann Med*. 2002;34(7-8):554-64. URL: <https://pubmed.ncbi.nlm.nih.gov/12553495/>
977. Hovens G, Stokkel M, Kievit J, Corssmit E, Pereira A, Romijn J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2007;92(7):2610-5. URL: <https://pubmed.ncbi.nlm.nih.gov/17426094/>
978. Diessl S, Holzberger B, Mäder U, Grelle I, Smit J, Buck A, et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)*. 2012;76(4):586-92. URL: <https://pubmed.ncbi.nlm.nih.gov/22059804/>

979. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. *Surgery*. 1988;104(6):947-53. URL: <https://pubmed.ncbi.nlm.nih.gov/3194846/>
980. Sugitani I, Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. *J Clin Endocrinol Metab*. 2010;95(10):4576-83. URL: <https://pubmed.ncbi.nlm.nih.gov/20660039/>
981. Ritter A, Mizrahi A, Bachar G, Vainer I, Shimon I, Hirsch D, et al. Detecting Recurrence Following Lobectomy for Thyroid Cancer: Role of Thyroglobulin and Thyroglobulin Antibodies. *J Clin Endocrinol Metab*. 2020;105(6): URL: <https://pubmed.ncbi.nlm.nih.gov/32219303/>
982. van Dijk S, Coerts H, Loncar I, Verhoef C, Kruijff S, Engelsman A, et al. Deescalating Follow-up After Hemithyroidectomy for Patients With Low-risk Papillary Thyroid Microcarcinoma. *JAMA Otolaryngol Head Neck Surg*. 2023;149(1):42-48. URL: <https://pubmed.ncbi.nlm.nih.gov/36416850/>
983. Giovanella L, Ceriani L, Garo M. Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis. *Clin Chem Lab Med*. 2022;60(7):1091-1100. URL: <https://pubmed.ncbi.nlm.nih.gov/35475431/>
984. Görges R, Brandt-Mainz K, Freudenberg L, Frilling A, Grimm W, Bockisch A. [Continuously increasing sensitivity in thyroid cancer aftercare in the course of three generations of thyroglobulin IMAs]. *Nuklearmedizin*. 2003;42(4):157-66. URL: <https://pubmed.ncbi.nlm.nih.gov/12937694/>
985. Zöphel K, Wunderlich G, Smith B. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?. *Thyroid*. 2003;13(9):861-5. URL: <https://pubmed.ncbi.nlm.nih.gov/14588100/>
986. Sol B, Bravenboer B, Velkeniers B, Raeymaeckers S, Keyaerts M, Andreescu C. Undetectable thyroglobulin makes. *Thyroid Res*. 2021;14(1):23. URL: <https://pubmed.ncbi.nlm.nih.gov/34666793/>
987. Fernández-Velasco P, Díaz-Soto G, Pérez López P, Torres Torres B, de Luis D. Predictive value and dynamic risk stratification of high sensitive basal or stimulated thyroglobulin assay in a long-term thyroid carcinoma cohort. *Endocrine*. 2023;81(1):116-122. URL: <https://pubmed.ncbi.nlm.nih.gov/36820996/>
988. Pabst K, Seifert R, Hirmas N, Broecker-Preuss M, Weber M, Peter Fendler W, et al. Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer. *Endocr Connect*. 2023;12(2): URL: <https://pubmed.ncbi.nlm.nih.gov/36507775/>
989. Bögershausen L, Giovanella L, Stief T, Luster M, Verburg F. Long-term predictive value of highly sensitive thyroglobulin measurement. *Clin Endocrinol (Oxf)*. 2023;98(4):622-628. URL: <https://pubmed.ncbi.nlm.nih.gov/36263618/>
990. Rosario P, Mourão G, Calsolari M. Definition of the Response to Initial Therapy with Radioiodine in Patients with Differentiated Thyroid Carcinoma: Basal or Stimulated Thyroglobulin?. *Horm Metab Res*. 2019;51(10):634-638. URL: <https://pubmed.ncbi.nlm.nih.gov/31578049/>
991. Moreno I, Hirsch D, Duskin-Bitan H, Dicker-Cohen T, Shimon I, Robenshtok E. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?. *Thyroid*. 2020;30(6):863-870. URL: <https://pubmed.ncbi.nlm.nih.gov/31928205/>
992. Jeon M, Kim M, Park S, Oh H, Kim T, Kim W, et al. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better. *Thyroid*. 2018;28(2):187-192. URL: <https://pubmed.ncbi.nlm.nih.gov/29179642/>

993. Leenhardt L, Borson-Chazot F, Calzada M, Carnaille B, Charrié A, Cochand-Priollet B, et al. Good practice guide for cervical ultrasound scan and echo-guided techniques in treating differentiated thyroid cancer of vesicular origin. *Ann Endocrinol (Paris)*. 2011;72(3):173-97. URL: <https://pubmed.ncbi.nlm.nih.gov/21641577/>
994. Pacella C, Bizzarri G, Spiezia S, Bianchini A, Guglielmi R, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous laser thermal ablation. *Radiology*. 2004;232(1):272-80. URL: <https://pubmed.ncbi.nlm.nih.gov/15155898/>
995. Kamaya A, Gross M, Akatsu H, Jeffrey R. Recurrence in the thyroidectomy bed: sonographic findings. *AJR Am J Roentgenol*. 2011;196(1):66-70. URL: <https://pubmed.ncbi.nlm.nih.gov/21178048/>
996. Peiling Yang S, Bach A, Tuttle R, Fish S. Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation. *J Clin Endocrinol Metab*. 2015;100(4):1561-7. URL: <https://pubmed.ncbi.nlm.nih.gov/25632970/>
997. Yang S, Bach A, Tuttle R, Fish S. SERIAL NECK ULTRASOUND IS MORE LIKELY TO IDENTIFY FALSE-POSITIVE ABNORMALITIES THAN CLINICALLY SIGNIFICANT DISEASE IN LOW-RISK PAPILLARY THYROID CANCER PATIENTS. *Endocr Pract*. 2015;21(12):1372-9. URL: <https://pubmed.ncbi.nlm.nih.gov/26372300/>
998. Sek K, Tsang I, Lee X, Albaqmi O, Morosan Allo Y, Rosmarin M, et al. Frequent neck US in papillary thyroid cancer likely detects non-actionable findings. *Clin Endocrinol (Oxf)*. 2021;94(3):504-512. URL: <https://pubmed.ncbi.nlm.nih.gov/32886805/>
999. Grani G, Ramundo V, Falcone R, Lamartina L, Montesano T, Biffoni M, et al. Thyroid Cancer Patients With No Evidence of Disease: The Need for Repeat Neck Ultrasound. *J Clin Endocrinol Metab*. 2019;104(11):4981-4989. URL: <https://pubmed.ncbi.nlm.nih.gov/31206157/>
1000. Verburg F, Mäder U, Giovanella L, Luster M, Reiners C. Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and. *Thyroid*. 2018;28(6):722-728. URL: <https://pubmed.ncbi.nlm.nih.gov/29665748/>
1001. Ross D, Litofsky D, Ain K, Bigos T, Brierley J, Cooper D, et al. Recurrence after treatment of micropapillary thyroid cancer. *Thyroid*. 2009;19(10):1043-8. URL: <https://pubmed.ncbi.nlm.nih.gov/19772419/>
1002. Brassard M, Borget I, Edet-Sanson A, Giraudet A, Mundler O, Toubreau M, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. *J Clin Endocrinol Metab*. 2011;96(5):1352-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21389143/>
1003. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. *J Clin Endocrinol Metab*. 2013;98(2):636-42. URL: <https://pubmed.ncbi.nlm.nih.gov/23293334/>
1004. Hay I, Johnson T, Kaggal S, Reinalda M, Iniguez-Ariza N, Grant C, et al. Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015). *World J Surg*. 2018;42(2):329-342. URL: <https://pubmed.ncbi.nlm.nih.gov/29030676/>
1005. Hwangbo Y, Kim J, Park Y, Lee E, Lee Y, Park D, et al. Long-Term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study. *J Clin Endocrinol Metab*. 2017;102(2):625-633. URL: <https://pubmed.ncbi.nlm.nih.gov/27732329/>

1006. Dehbi H, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. *Lancet Diabetes Endocrinol.* 2019;7(1):44-51. URL: <https://pubmed.ncbi.nlm.nih.gov/30501974/>
1007. Elisei R, Molinaro E, Agate L, Bottici V, Masserini L, Ceccarelli C, et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. *J Clin Endocrinol Metab.* 2010;95(4):1516-27. URL: <https://pubmed.ncbi.nlm.nih.gov/20156922/>
1008. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?. *J Clin Endocrinol Metab.* 2012;97(8):2748-53. URL: <https://pubmed.ncbi.nlm.nih.gov/22679061/>
1009. Verburg F, Schmidt M, Kreissl M, Grünwald F, Lassmann M, Hänscheid H, et al. [Procedural guideline for Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma (version 5)]. *Nuklearmedizin.* 2019;58(3):228-241. URL: <https://pubmed.ncbi.nlm.nih.gov/31035298/>
1010. de Meer S, Vriens M, Zelissen P, Borel Rinkes I, de Keizer B. The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer. *J Nucl Med.* 2011;52(1):56-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21149483/>
1011. Spencer C. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). *J Clin Endocrinol Metab.* 2011;96(12):3615-27. URL: <https://pubmed.ncbi.nlm.nih.gov/21917876/>
1012. Verburg F, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. *Thyroid.* 2013;23(10):1211-25. URL: <https://pubmed.ncbi.nlm.nih.gov/23692026/>
1013. Côrtes M, Rosario P, Oliveira L, Calsolari M. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study. *Thyroid.* 2018;28(2):229-235. URL: <https://pubmed.ncbi.nlm.nih.gov/29325506/>
1014. Lee Z, Eslick G, Edirimanne S. Investigating Antithyroglobulin Antibody As a Prognostic Marker for Differentiated Thyroid Cancer: A Meta-Analysis and Systematic Review. *Thyroid.* 2020;30(11):1601-1612. URL: <https://pubmed.ncbi.nlm.nih.gov/32345152/>
1015. Zavala L, Barra M, Olmos R, Tuttle M, González H, Droppelmann N, et al. In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation. *Arch Endocrinol Metab.* 2019;63(3):293-299. URL: <https://pubmed.ncbi.nlm.nih.gov/31038590/>
1016. Hilditch T, Dempsey M, Bolster A, McMenemin R, Reed N. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. *Eur J Nucl Med Mol Imaging.* 2002;29(6):783-8. URL: <https://pubmed.ncbi.nlm.nih.gov/12029552/>
1017. Lassmann M, Luster M, Hänscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. *J Nucl Med.* 2004;45(4):619-25. URL: <https://pubmed.ncbi.nlm.nih.gov/15073258/>
1018. Wu D, Ylli D, Heimlich S, Burman K, Wartofsky L, Van Nostrand D. (124)I Positron Emission Tomography/Computed Tomography Versus Conventional Radioiodine Imaging in

- Differentiated Thyroid Cancer: A Review. *Thyroid*. 2019;29(11):1523-1535. URL: <https://pubmed.ncbi.nlm.nih.gov/31452449/>
1019. Giostra A, Richetta E, Pasquino M, Miranti A, Cutaia C, Brusasco G, et al. Red marrow and blood dosimetry in (131)I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results. *Phys Med Biol*. 2016;61(11):4316-26. URL: <https://pubmed.ncbi.nlm.nih.gov/27200493/>
 1020. Salvatori M, Rufini V, Reale F, Samanes Gajate A, Maussier M, Revelli L, et al. Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer. *World J Surg*. 2003;27(7):770-5. URL: <https://pubmed.ncbi.nlm.nih.gov/14509503/>
 1021. Vrachimis A, Riemann B, Mäder U, Reiners C, Verburg F. Endogenous TSH levels at the time of. *Eur J Nucl Med Mol Imaging*. 2016;43(2):224-231. URL: <https://pubmed.ncbi.nlm.nih.gov/26493309/>
 1022. Edmonds C, Hayes S, Kermode J, Thompson B. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. *Br J Radiol*. 1977;50(599):799-807. URL: <https://pubmed.ncbi.nlm.nih.gov/588901/>
 1023. Qichang W, Lin B, Gege Z, Youjia Z, Qingjie M, Renjie W, et al. Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobulin elevation and negative iodine scintigraphy: a meta-analysis. *Eur J Endocrinol*. 2019;181(2):93-102. URL: <https://pubmed.ncbi.nlm.nih.gov/31117054/>
 1024. Ma C, Xie J, Lou Y, Gao Y, Zuo S, Wang X. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. *Eur J Endocrinol*. 2010;163(2):177-83. URL: <https://pubmed.ncbi.nlm.nih.gov/20484385/>
 1025. Kim S, Lee S, Pak K, Shim S. Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab. *Endocr Relat Cancer*. 2018;25(6):643-652. URL: <https://pubmed.ncbi.nlm.nih.gov/29559552/>
 1026. Grabellus F, Nagarajah J, Bockisch A, Schmid K, Sheu S. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. *Clin Nucl Med*. 2012;37(2):121-7. URL: <https://pubmed.ncbi.nlm.nih.gov/22228332/>
 1027. Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi J, Talbot M, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. *Endocr Relat Cancer*. 2011;18(1):159-69. URL: <https://pubmed.ncbi.nlm.nih.gov/21118976/>
 1028. Robbins R, Wan Q, Grewal R, Reibke R, Gonen M, Strauss H, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. *J Clin Endocrinol Metab*. 2006;91(2):498-505. URL: <https://pubmed.ncbi.nlm.nih.gov/16303836/>
 1029. Phan H, Jager P, Paans A, Plukker J, Sturkenboom M, Sluiter W, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging*. 2008;35(5):958-65. URL: <https://pubmed.ncbi.nlm.nih.gov/18175115/>
 1030. Van Nostrand D, Moreau S, Bandaru V, Atkins F, Chennupati S, Mete M, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. *Thyroid*. 2010;20(8):879-83. URL: <https://pubmed.ncbi.nlm.nih.gov/20615132/>
 1031. Gulec S, Kuker R, Goryawala M, Fernandez C, Perez R, Khan-Ghany A, et al. (124)I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis. *Thyroid*. 2016;26(3):441-8. URL: <https://pubmed.ncbi.nlm.nih.gov/26857905/>

1032. Kist J, de Keizer B, van der Vlies M, Brouwers A, Huysmans D, van der Zant F, et al. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). J Nucl Med. 2016;57(5):701-7. URL: <https://pubmed.ncbi.nlm.nih.gov/26609180/>
1033. Pettinato C, Spezi E, Nanni C, Grassetto G, Monari F, Allegri V, et al. Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning. Clin Nucl Med. 2014;39(8):e367-74. URL: <https://pubmed.ncbi.nlm.nih.gov/24978332/>
1034. Jentzen W, Freudenberg L, Eising E, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49(6):1017-23. URL: <https://pubmed.ncbi.nlm.nih.gov/18483099/>
1035. Jentzen W, Weise R, Kupferschläger J, Freudenberg L, Brandau W, Bares R, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET/(CT) systems. Eur J Nucl Med Mol Imaging. 2008;35(3):611-23. URL: <https://pubmed.ncbi.nlm.nih.gov/17929014/>
1036. Eschmann S, Reischl G, Bilger K, Kupferschläger J, Thelen M, Dohmen B, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29(6):760-7. URL: <https://pubmed.ncbi.nlm.nih.gov/12029549/>
1037. Freudenberg L, Jentzen W, Görges R, Petrich T, Marlowe R, Knust J, et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin. 2007;46(4):121-8. URL: <https://pubmed.ncbi.nlm.nih.gov/17690789/>
1038. Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D. Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res. 2010;42(4):237-40. URL: <https://pubmed.ncbi.nlm.nih.gov/20094970/>
1039. Woelfl S, Bogner S, Huber H, Salaheddin-Nassr S, Hatzl M, Decristoforo C, et al. Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies. Nuklearmedizin. 2014;53(5):179-85. URL: <https://pubmed.ncbi.nlm.nih.gov/24967740/>
1040. Almeida L, Araújo M, Zantut-Wittmann D, Assumpção L, Souza T, Silva C, et al. Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study. Nucl Med Commun. 2018;39(5):441-450. URL: <https://pubmed.ncbi.nlm.nih.gov/29543624/>
1041. Kundu P, Lata S, Sharma P, Singh H, Malhotra A, Bal C. Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT. Eur J Nucl Med Mol Imaging. 2014;41(7):1354-62. URL: <https://pubmed.ncbi.nlm.nih.gov/24562651/>
1042. Jhaveri K, Fischer S, Hosseini-Nik H, Sreeharsha B, Menezes R, Gallinger S, et al. Prospective comparison of gadoxetic acid-enhanced liver MRI and contrast-enhanced CT with histopathological correlation for preoperative detection of colorectal liver metastases following chemotherapy and potential impact on surgical plan. HPB (Oxford). 2017;19(11):992-1000. URL: <https://pubmed.ncbi.nlm.nih.gov/28760631/>
1043. S1-Leitlinie 064-009. Atemwegserkrankung – Bildgebende Diagnostik. 2017; URL: <https://register.awmf.org/de/leitlinien/detail/064-009>
1044. Leitlinie der Bundesärztekammer zur Qualitätssicherung in der Computertomographie. 2022; URL: [10.3238/arztebl.2022.LL_Qualitätssicherung_Computertomographie](https://www.bundesaerztekammer.de/10.3238/arztebl.2022.LL_Qualitätssicherung_Computertomographie)
1045. McLoughlin L, O'Kelly F, O'Brien C, Sheikh M, Feeney J, Torreggiani W, et al. The improved accuracy of planar bone scintigraphy by adding single photon emission computed

- tomography (SPECT-CT) to detect skeletal metastases from prostate cancer. *Ir J Med Sci.* 2016;185(1):101-5. URL: <https://pubmed.ncbi.nlm.nih.gov/25394725/>
1046. Lee H, Lee W, Park S, Kim S. F-18 Sodium Fluoride Positron Emission Tomography/Computed Tomography for Detection of Thyroid Cancer Bone Metastasis Compared with Bone Scintigraphy. *Korean J Radiol.* 2016;17(2):281-8. URL: <https://pubmed.ncbi.nlm.nih.gov/26957915/>
1047. Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 15T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. *Acta Oncol.* 2016;55(1):59-67. URL: <https://pubmed.ncbi.nlm.nih.gov/25833330/>
1048. Teyateeti A, Tocharoenchai C, Muangsomboon K, Komoltri C, Pusuwan P. A Comparison of Accuracy of Planar and Evolution SPECT/CT Bone Imaging in Differentiating Benign from Metastatic Bone Lesions. *J Med Assoc Thai.* 2017;100(1):100-10. URL: <https://pubmed.ncbi.nlm.nih.gov/29911774/>
1049. Strobel K, Burger C, Seifert B, Husarik D, Soyka J, Hany T. Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. *AJR Am J Roentgenol.* 2007;188(5):W467-74. URL: <https://pubmed.ncbi.nlm.nih.gov/17449746/>
1050. Sedonja I, Budihna N. The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine. *Clin Nucl Med.* 1999;24(6):407-13. URL: <https://pubmed.ncbi.nlm.nih.gov/10361935/>
1051. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. *J Nucl Med.* 2006;47(2):287-97. URL: <https://pubmed.ncbi.nlm.nih.gov/16455635/>
1052. Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslanemir C, Buck A, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. *J Nucl Med.* 2001;42(12):1800-4. URL: <https://pubmed.ncbi.nlm.nih.gov/11752076/>
1053. Gurkan G, Sarikaya I, Sarikaya A. Semiquantitative assessment of osteoblastic, osteolytic, and mixed lytic-sclerotic bone lesions on fluorodeoxyglucose positron emission tomography/computed tomography and bone scintigraphy. *World J Nucl Med.* 2019;18(2):132-136. URL: <https://pubmed.ncbi.nlm.nih.gov/31040743/>
1054. Chua S, Gnanasegaran G, Cook G. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. *Semin Nucl Med.* 2009;39(6):416-30. URL: <https://pubmed.ncbi.nlm.nih.gov/19801221/>
1055. Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. *Radiology.* 2006;238(1):264-71. URL: <https://pubmed.ncbi.nlm.nih.gov/16304081/>
1056. Wertigkeit der SPECT/CT in der skelettszintigrafischen Diagnostik. *Der Nuklearmediziner.* 2016;8. URL: <https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0042-100693>
1057. Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Türler A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. *Eur J Nucl Med Mol Imaging.* 2014;41(1):59-67. URL: <https://pubmed.ncbi.nlm.nih.gov/23974666/>

1058. Löfgren J, Mortensen J, Rasmussen S, Madsen C, Loft A, Hansen A, et al. A Prospective Study Comparing. *J Nucl Med*. 2017;58(11):1778-1785. URL: <https://pubmed.ncbi.nlm.nih.gov/28798033/>
1059. Tenenbaum F, Schlumberger M, Bonnin F, Lumbroso J, Aubert B, Benali H, et al. Usefulness of technetium-99m hydroxymethylene diphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma. *Eur J Nucl Med*. 1993;20(12):1168-74. URL: <https://pubmed.ncbi.nlm.nih.gov/8299652/>
1060. Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. *J Clin Endocrinol Metab*. 1992;74(6):1401-4. URL: <https://pubmed.ncbi.nlm.nih.gov/1592886/>
1061. Frasoldati A, Toschi E, Zini M, Flora M, Caroggio A, Dotti C, et al. Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. *Thyroid*. 1999;9(2):105-11. URL: <https://pubmed.ncbi.nlm.nih.gov/10090308/>
1062. Torres M, Nóbrega Neto S, Rosas R, Martins A, Ramos A, da Cruz T. Thyroglobulin in the washout fluid of lymph-node biopsy: what is its role in the follow-up of differentiated thyroid carcinoma?. *Thyroid*. 2014;24(1):7-18. URL: <https://pubmed.ncbi.nlm.nih.gov/24044517/>
1063. Cunha N, Rodrigues F, Curado F, Ilhéu O, Cruz C, Naidenov P, et al. Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. *Eur J Endocrinol*. 2007;157(1):101-7. URL: <https://pubmed.ncbi.nlm.nih.gov/17609408/>
1064. Jeon S, Kim E, Park J, Son K, Baek J, Kim Y, et al. Diagnostic benefit of thyroglobulin measurement in fine-needle aspiration for diagnosing metastatic cervical lymph nodes from papillary thyroid cancer: correlations with US features. *Korean J Radiol*. 2009;10(2):106-11. URL: <https://pubmed.ncbi.nlm.nih.gov/19270855/>
1065. Sigstad E, Heilo A, Paus E, Holgersen K, Grøholt K, Jørgensen L, et al. The usefulness of detecting thyroglobulin in fine-needle aspirates from patients with neck lesions using a sensitive thyroglobulin assay. *Diagn Cytopathol*. 2007;35(12):761-7. URL: <https://pubmed.ncbi.nlm.nih.gov/18008339/>
1066. Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. *J Clin Endocrinol Metab*. 2014;99(6):1970-82. URL: <https://pubmed.ncbi.nlm.nih.gov/24617715/>
1067. S2k-Leitlinie Operative Therapie benigner Schilddrüsenerkrankungen. AWMF-Registernummer 088/007. 2021; URL: https://register.awmf.org/assets/guidelines/088-007l_S2k_operative_Therapie_benigner_Schilddruesenerkrankungen_2022-06_1_01.pdf
1068. Cusano N, Rubin M, McMahon D, Irani D, Anderson L, Levy E, et al. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. *J Clin Endocrinol Metab*. 2014;99(10):3694-9. URL: <https://pubmed.ncbi.nlm.nih.gov/24978675/>
1069. Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. *Osteoporos Int*. 2014;25(6):1717-26. URL: <https://pubmed.ncbi.nlm.nih.gov/24687385/>
1070. Mannstadt M, Clarke B, Vokes T, Brandi M, Ranganath L, Fraser W, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. *Lancet Diabetes Endocrinol*. 2013;1(4):275-83. URL: <https://pubmed.ncbi.nlm.nih.gov/24622413/>

1071. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. *J Bone Miner Res.* 2011;26(10):2358-70. URL: <https://pubmed.ncbi.nlm.nih.gov/21773992/>
1072. Orloff L, Wiseman S, Bernet V, Fahey T, Shaha A, Shindo M, et al. American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults. *Thyroid.* 2018;28(7):830-841. URL: <https://pubmed.ncbi.nlm.nih.gov/29848235/>
1073. Bollerslev J, Rejnmark L, Marcocci C, Shoback D, Sitges-Serra A, van Biesen W, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. *Eur J Endocrinol.* 2015;173(2):G1-20. URL: <https://pubmed.ncbi.nlm.nih.gov/26160136/>
1074. Khan A, Bilezikian J, Brandi M, Clarke B, Gittoes N, Pasieka J, et al. Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop. *J Bone Miner Res.* 2022;37(12):2568-2585. URL: <https://pubmed.ncbi.nlm.nih.gov/36054621/>
1075. Bilezikian J, Khan A, Potts J, Brandi M, Clarke B, Shoback D, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. *J Bone Miner Res.* 2011;26(10):2317-37. URL: <https://pubmed.ncbi.nlm.nih.gov/21812031/>
1076. Stack B, Bimston D, Bodenner D, Brett E, Dralle H, Orloff L, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: POSTOPERATIVE HYPOPARATHYROIDISM--DEFINITIONS AND MANAGEMENT. *Endocr Pract.* 2015;21(6):674-85. URL: <https://pubmed.ncbi.nlm.nih.gov/26135962/>
1077. Franch-Arcas G, González-Sánchez C, Aguilera-Molina Y, Rozo-Coronel O, Estévez-Alonso J, Muñoz-Herrera Á. Is there a case for selective, rather than routine, preoperative laryngoscopy in thyroid surgery?. *Gland Surg.* 2015;4(1):8-18. URL: <https://pubmed.ncbi.nlm.nih.gov/25713775/>
1078. Sittel C, Stennert E, Thumfart W, Dapunt U, Eckel H. Prognostic value of laryngeal electromyography in vocal fold paralysis. *Arch Otolaryngol Head Neck Surg.* 2001;127(2):155-60. URL: <https://pubmed.ncbi.nlm.nih.gov/11177032/>
1079. Farrag T, Samlan R, Lin F, Tufano R. The utility of evaluating true vocal fold motion before thyroid surgery. *Laryngoscope.* 2006;116(2):235-8. URL: <https://pubmed.ncbi.nlm.nih.gov/16467711/>
1080. Birben B, Özden S, Er S, Saylam B. Is Vocal Cord Assessment before Total Thyroidectomy Required for All Patients?. *Am Surg.* 2019;85(11):1265-1268. URL: <https://pubmed.ncbi.nlm.nih.gov/31775969/>
1081. Chandrasekhar S, Randolph G, Seidman M, Rosenfeld R, Angelos P, Barkmeier-Kraemer J, et al. Clinical practice guideline: improving voice outcomes after thyroid surgery. *Otolaryngol Head Neck Surg.* 2013;148(6 Suppl):S1-37. URL: <https://pubmed.ncbi.nlm.nih.gov/23733893/>
1082. Musholt T, Musholt P, Garm J, Napiontek U, Keilmann A. Changes of the speaking and singing voice after thyroid or parathyroid surgery. *Surgery.* 2006;140(6):978-88; discussion 988-9. URL: <https://pubmed.ncbi.nlm.nih.gov/17188147/>
1083. Kletzien H, Macdonald C, Orne J, Francis D, Levenson G, Wendt E, et al. Comparison Between Patient-Perceived Voice Changes and Quantitative Voice Measures in the First Postoperative Year After Thyroidectomy: A Secondary Analysis of a Randomized Clinical Trial.

- JAMA Otolaryngol Head Neck Surg. 2018;144(11):995-1003. URL: <https://pubmed.ncbi.nlm.nih.gov/29710208/>
1084. Hayward N, Grodski S, Yeung M, Johnson W, Serpell J. Recurrent laryngeal nerve injury in thyroid surgery: a review. ANZ J Surg. 2013;83(1-2):15-21. URL: <https://pubmed.ncbi.nlm.nih.gov/22989215/>
 1085. Schneider R, Machens A, Lorenz K, Dralle H. Intraoperative nerve monitoring in thyroid surgery-shifting current paradigms. Gland Surg. 2020;9(Suppl 2):S120-S128. URL: <https://pubmed.ncbi.nlm.nih.gov/32175252/>
 1086. Hong Y, Lim S, Hong K. Voice Outcome of Total Thyroidectomy in Comparison With Administration of Recombinant Human TSH. J Voice. 2021;35(2):317-322. URL: <https://pubmed.ncbi.nlm.nih.gov/31575434/>
 1087. Verdolini-Marston K, Burke M, Lessac A, Glaze L, Caldwell E. Preliminary study of two methods of treatment for laryngeal nodules. J Voice. 1995;9(1):74-85. URL: <https://pubmed.ncbi.nlm.nih.gov/7757153/>
 1088. Fu S, Theodoros D, Ward E. Intensive versus traditional voice therapy for vocal nodules: perceptual, physiological, acoustic and aerodynamic changes. J Voice. 2015;29(2):260.e31-44. URL: <https://pubmed.ncbi.nlm.nih.gov/25311594/>
 1089. da Cunha Pereira G, de Oliveira Lemos I, Dalbosco Gadenz C, Cassol M. Effects of Voice Therapy on Muscle Tension Dysphonia: A Systematic Literature Review. J Voice. 2018;32(5):546-552. URL: <https://pubmed.ncbi.nlm.nih.gov/28739332/>
 1090. Yu W, Wu C. Speech therapy after thyroidectomy. Gland Surg. 2017;6(5):501-509. URL: <https://pubmed.ncbi.nlm.nih.gov/29142841/>
 1091. Hess M, Fleischer S. Laryngeal framework surgery: current strategies. Curr Opin Otolaryngol Head Neck Surg. 2016;24(6):505-509. URL: <https://pubmed.ncbi.nlm.nih.gov/27585082/>
 1092. Kraus D, Orlikoff R, Rizk S, Rosenberg D. Arytenoid adduction as an adjunct to type I thyroplasty for unilateral vocal cord paralysis. Head Neck. 1999;21(1):52-9. URL: <https://pubmed.ncbi.nlm.nih.gov/9890351/>
 1093. Müller A, Förster G. [Reinnervation and neurostimulation of the larynx]. HNO. 2013;61(2):102-7. URL: <https://pubmed.ncbi.nlm.nih.gov/23241856/>
 1094. Tucker H. Long-term preservation of voice improvement following surgical medialization and reinnervation for unilateral vocal fold paralysis. J Voice. 1999;13(2):251-6. URL: <https://pubmed.ncbi.nlm.nih.gov/10442756/>
 1095. Mueller A, Hagen R, Pototschnig C, Foerster G, Grossmann W, Baumbusch K, et al. Laryngeal pacing for bilateral vocal fold paralysis: Voice and respiratory aspects. Laryngoscope. 2017;127(8):1838-1844. URL: <https://pubmed.ncbi.nlm.nih.gov/27943294/>
 1096. Lee D, Lee S, Lee M, Seok J, Park S, Jin Y, et al. Natural Course of Unilateral Vocal Fold Paralysis and Optimal Timing of Permanent Treatment. JAMA Otolaryngol Head Neck Surg. 2020;146(1):30-35. URL: <https://pubmed.ncbi.nlm.nih.gov/31750869/>
 1097. Tan L, Nan L, Thumboo J, Sundram F, Tan L. Health-related quality of life in thyroid cancer survivors. Laryngoscope. 2007;117(3):507-10. URL: <https://pubmed.ncbi.nlm.nih.gov/17334313/>
 1098. Hoftijzer H, Heemstra K, Corssmit E, van der Klaauw A, Romijn J, Smit J. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008;93(1):200-3. URL: <https://pubmed.ncbi.nlm.nih.gov/17956954/>
 1099. Gamper E, Wintner L, Rodrigues M, Buxbaum S, Nilica B, Singer S, et al. Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring

- programme. *Eur J Nucl Med Mol Imaging*. 2015;42(8):1179-88. URL: <https://pubmed.ncbi.nlm.nih.gov/25771905/>
1100. Eustatia-Rutten C, Corssmit E, Pereira A, Frölich M, Bax J, Romijn J, et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. *Clin Endocrinol (Oxf)*. 2006;64(3):284-91. URL: <https://pubmed.ncbi.nlm.nih.gov/16487438/>
1101. Schultz P, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. *Head Neck*. 2003;25(5):349-56. URL: <https://pubmed.ncbi.nlm.nih.gov/12692870/>
1102. Diamond-Rossi S, Jonklaas J, Jensen R, Kuo C, Stearns S, Esposito G, et al. Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer. *J Cancer Surviv*. 2020;14(6):847-857. URL: <https://pubmed.ncbi.nlm.nih.gov/32506220/>
1103. Husson O, Mols F, van de Poll-Franse L, de Vries J, Schep G, Thong M. Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry. *Support Care Cancer*. 2015;23(7):2165-74. URL: <https://pubmed.ncbi.nlm.nih.gov/25556703/>
1104. Husson O, Nieuwlaat W, Oranje W, Haak H, van de Poll-Franse L, Mols F. Fatigue among short- and long-term thyroid cancer survivors: results from the population-based PROFILES registry. *Thyroid*. 2013;23(10):1247-55. URL: <https://pubmed.ncbi.nlm.nih.gov/23578315/>
1105. Alhashemi A, Jones J, Goldstein D, Mina D, Thabane L, Sabiston C, et al. An Exploratory Study of Fatigue and Physical Activity in Canadian Thyroid Cancer Patients. *Thyroid*. 2017;27(9):1156-1163. URL: <https://pubmed.ncbi.nlm.nih.gov/28712348/>
1106. Vigário PS, Chachamovitz D, Cordeiro M, Teixeira PF, de Castro C, de Oliveira F, et al. Effects of physical activity on body composition and fatigue perception in patients on thyrotropin-suppressive therapy for differentiated thyroid carcinoma. *Thyroid*. 2011;21(7):695-700. URL: <https://pubmed.ncbi.nlm.nih.gov/21615309/>
1107. Ronga G, Totada M, D'Apollo R, De Cristofaro F, Filesi M, Acqualagna G, et al. Lymph node metastases from differentiated thyroid carcinoma: does radioiodine still play a role?. *Clin Ter*. 2012;163(5):377-81. URL: <https://pubmed.ncbi.nlm.nih.gov/23099964/>
1108. Trybek T, Kowalska A. Does the presence of regional lymph node metastases have any impact on the complete remission rate in patients with distant metastases of papillary thyroid carcinoma (PTC), treated by radioiodine therapy?. *Endokrynol Pol*. 2010;61(5):443-5. URL: <https://pubmed.ncbi.nlm.nih.gov/21049455/>
1109. Cao CJ, Dou CY, Lian J, Luan ZS, Zhou W, Xie W, et al. Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis. *Oncology Letters*. 2018;15:8141-8148. URL: <https://pubmed.ncbi.nlm.nih.gov/29740497/>
1110. İlhan H, Mustafa M, Bartenstein P, Kuwert T, Schmidt D. Rate of elimination of radioiodine-avid lymph node metastases of differentiated thyroid carcinoma by postsurgical radioiodine ablation A bicentric study. *Nuklearmedizin*. 2016;55:221-227. URL: <https://pubmed.ncbi.nlm.nih.gov/27588323/>
1111. Wu X, Gu H, Gao Y, Li B, Fan R. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma. *Nucl Med Commun*. 2018;39(1):22-27. URL: <https://pubmed.ncbi.nlm.nih.gov/29135721/>
1112. He Y, Pan MZ, Huang JM, Xie P, Zhang F, Wei LG. Iodine-131: An Effective Method for Treating Lymph Node Metastases of Differentiated Thyroid Cancer. *Med Sci Monit*. 2016;22:4924-4928. URL: <https://pubmed.ncbi.nlm.nih.gov/27974741/>

1113. Wojtczak B, Sutkowski K, Kaliszewski K, Barczyński M, Bolanowski M. Thyroid reoperation using intraoperative neuromonitoring. *Endocrine*. 2017;58(3):458-466. URL: <https://pubmed.ncbi.nlm.nih.gov/29052179/>
1114. Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. *J Clin Endocrinol Metab*. 2013;98:E829-36
1115. Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. *J Nucl Med*. 2011;52:683-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21498534/>
1116. Shokoohi A, Berthelet E, Gill S, Prisman E, Sexsmith G, Tran E, et al. Treatment for Recurrent Differentiated Thyroid Cancer: A Canadian Population Based Experience. *Cureus*. 2020;12:e7122
1117. Ywata de Carvalho A, Kohler HF, Gomes CC, Vartanian JG, Kowalski LP. Predictive factors for recurrence of papillary thyroid carcinoma: analysis of 4,085 patients. *Acta Otorhinolaryngol Ital*. 2021;41:236-242. URL: <https://pubmed.ncbi.nlm.nih.gov/34264917/>
1118. Cho SW, Choi HS, Yeom GJ, Lim JA, Moon JH, Park DJ, et al. Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors. *Thyroid*. 2014;24:277-86. URL: <https://pubmed.ncbi.nlm.nih.gov/23758653/>
1119. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. *Cancer*. 2007;110:1451-6
1120. Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR, Shah JP, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. *Thyroid*. 2012;22:884-9
1121. Lin JD, Hsueh C, Chao TC. Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis. *Medicine*. 2015;94:e1063. URL: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=26131826>, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504566/pdf/medi-94-e1063.pdf>
1122. Jung CK, Lee S, Bae JS, Lim DJ. Late-onset distant metastases confer poor prognosis in patients with well-differentiated thyroid cancer. *Gland Surg*. 2020;9:1857-1866
1123. Lin JD, Kuo SF, Huang BY, Lin SF, Chen ST. The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. *Nuclear Medicine Communications*. 2018;39:1091-1096. URL: <https://pubmed.ncbi.nlm.nih.gov/30180044/>
1124. Schlumberger M, Challeton C, De Vathaire F, Travaglini JP, Gardet P, Lombroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. *J Nucl Med*. 1996;37:598-605
1125. Durante C, Haddy N, Baudin E, Lebouilleux S, Hartl D, Travaglini JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab*. 2006;91:2892-9. URL: <https://pubmed.ncbi.nlm.nih.gov/16684830/>
1126. Ito Y, Masuoka H, Fukushima M, Inoue H, Kihara M, Tomoda C, et al. Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. *Endocr J*. 2010;57:523-31. URL: <https://pubmed.ncbi.nlm.nih.gov/20379035/>
1127. Li C, Wu Q, Sun S. Radioactive Iodine Therapy in Patients With Thyroid Carcinoma With Distant Metastases: A SEER-Based Study. *Cancer Control*. 2020;27:1073274820914661

1128. Kim H, Kim HI, Kim SW, Jung J, Jeon MJ, Kim WG, et al. Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea. *Endocrinol Metab* (Seoul). 2018;33:287-295
1129. Madani A, Jozaghi Y, Tabah R, How J, Mitmaker E. Rare metastases of well-differentiated thyroid cancers: a systematic review. *Ann Surg Oncol*. 2015;22(2):460-6. URL: <https://pubmed.ncbi.nlm.nih.gov/25192681/>
1130. Mihailovic J, Stefanovic L, Malesevic M, Erak M, Tesanovic D. Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. *Nucl Med Commun*. 2009;30(7):558-64. URL: <https://pubmed.ncbi.nlm.nih.gov/19436230/>
1131. Zhang X, Sun J, Qiu Z, Wang Y, Chen X, Zhao J, et al. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma. *Endocrine*. 2019;66(2):254-265. URL: <https://pubmed.ncbi.nlm.nih.gov/31317522/>
1132. Zunino A, Pitoia F, Faure E, Reyes A, Sala M, Sklate R, et al. Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases. *Endocrine*. 2019;65(3):630-636. URL: <https://pubmed.ncbi.nlm.nih.gov/31327159/>
1133. Sabra MM, Ghossein R, Tuttle RM. Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer. *Thyroid*. 2016;26:518-24
1134. Ohkuwa K, Sugino K, Nagahama M, Kitagawa W, Matsuzu K, Suzuki A, et al. Risk stratification in differentiated thyroid cancer with RAI-avid lung metastases. *Endocr Connect*. 2021;10:825-833
1135. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. *J Nucl Med*. 1993;34:1626-31. URL: <https://pubmed.ncbi.nlm.nih.gov/8410272/>
1136. Song HJ, Qiu ZL, Shen CT, Wei WJ, Luo QY. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. *European Journal of Endocrinology*. 2015;173:399-408. URL: <https://pubmed.ncbi.nlm.nih.gov/26104753/>
1137. Zhang X, Liu DS, Luan ZS, Zhang F, Liu XH, Zhou W, et al. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature. *Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies & of the National Cancer Institute of Mexico*. 2018;20:928-935. URL: <https://pubmed.ncbi.nlm.nih.gov/29119458/>
1138. Wang C, Zhang R, Wang R, Meng Z, Zhang G, Dong F, et al. Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma. *Front Endocrinol (Lausanne)*. 2021;12:667544. URL: <https://pubmed.ncbi.nlm.nih.gov/34040584/>
1139. Yang J, Zheng R, Liang M, Jia Y, Lin L, Geng J, et al. Association of the Cumulative Dose of Radioactive Iodine Therapy With Overall Survival in Patients With Differentiated Thyroid Cancer and Pulmonary Metastases. *Front Oncol*. 2019;9:558. URL: <https://pubmed.ncbi.nlm.nih.gov/31316914/>
1140. Kim M, Kim W, Park S, Kwon H, Jeon M, Lee J, et al. Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung. *Thyroid*. 2017;27(1):49-58. URL: <https://pubmed.ncbi.nlm.nih.gov/27750021/>
1141. Lin JD, Chao TC, Hsueh C. Follicular thyroid carcinomas with lung metastases: a 23-year retrospective study. *Endocr J*. 2004;51:219-25

1142. Sabra MM, Sherman EJ, Tuttle RM. Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma. *Cancer*. 2017;123:2955-2964
1143. Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Jeong SY, et al. Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer. *Nucl Med Mol Imaging*. 2014;48:55-62
1144. Long B, Yang M, Yang Z, Yi H, Li L. Assessment of radioiodine therapy efficacy for treatment of differentiated thyroid cancer patients with pulmonary metastasis undetected by chest computed tomography. *Oncol Lett*. 2016;11:965-968
1145. Zhang X, Song H, Qiu Z, Shen C, Chen X, Sun Z, et al. Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with. *Endocrine*. 2018;62(1):149-158. URL: <https://pubmed.ncbi.nlm.nih.gov/30022382/>
1146. Slook O, Levy S, Slutzky-Shraga I, Tsvetov G, Robenshtok E, Shimon I, et al. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES. *Endocr Pract*. 2019;25(5):427-437. URL: <https://pubmed.ncbi.nlm.nih.gov/30657361/>
1147. Qi L, Zhang W, Ren X, Xu R, Liu C, Tu C, et al. Incidence and Predictors of Synchronous Bone Metastasis in Newly Diagnosed Differentiated Thyroid Cancer: A Real-World Population-Based Study. *Front Surg*. 2022;9:778303
1148. Iñiguez-Ariza NM, Bible KC, Clarke BL. Bone metastases in thyroid cancer. *J Bone Oncol*. 2020;21:100282. URL: <https://pubmed.ncbi.nlm.nih.gov/32154098/>
1149. Varadarajan V, Pace E, Patel V, Sawhney R, Amdur R, Dziegielewski P. Follicular thyroid carcinoma metastasis to the facial skeleton: a systematic review. *BMC Cancer*. 2017;17(1):225. URL: <https://pubmed.ncbi.nlm.nih.gov/28351395/>
1150. Halnan KE, Roberts PH. Paraplegia caused by spinal metastasis from thyroid cancer. *Br Med J*. 1967;3:534-6. URL: <https://pubmed.ncbi.nlm.nih.gov/6038321/>
1151. Ramadan S, Ugas M, Berwick R, Notay M, Cho H, Jerjes W, et al. Spinal metastasis in thyroid cancer. *Head Neck Oncol*. 2012;4:39. URL: <https://pubmed.ncbi.nlm.nih.gov/22730910/>
1152. Califano I, Deutsch S, Löwenstein A, Cabezón C, Pitoia F. Outcomes of patients with bone metastases from differentiated thyroid cancer. *Arch Endocrinol Metab*. 2018;62(1):14-20. URL: <https://pubmed.ncbi.nlm.nih.gov/29694635/>
1153. Petrich T, Widjaja A, Musholt TJ, Hofmann M, Brunkhorst T, Ehrenheim C, et al. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. *Eur J Nucl Med*. 2001;28:203-8
1154. Robenshtok E, Farooki A, Grewal RK, Tuttle RM. Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. *Endocrine*. 2014;47:266-72
1155. Osborne JR, Kondraciuk JD, Rice SL, Zhou X, Knezevic A, Spratt DE, et al. Thyroid Cancer Brain Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort. *Clin Nucl Med*. 2019;44:544-549
1156. Mazziotti G, Formenti A, Panarotto M, Arvat E, Chiti A, Cuocolo A, et al. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. *Endocrine*. 2018;59(1):90-101. URL: <https://pubmed.ncbi.nlm.nih.gov/29110129/>

1157. Kato S, Demura S, Shinmura K, Yokogawa N, Shimizu T, Tsuchiya H. Current Management of Bone Metastases from Differentiated Thyroid Cancer. *Cancers (Basel)*. 2021;13
1158. Shen J, Wang S, Zhao X, Shao X, Jiang X, Dai Y, et al. Skull metastasis from follicular thyroid carcinoma: report of three cases and review of literature. *Int J Clin Exp Pathol*. 2015;8:15285-93. URL: <https://pubmed.ncbi.nlm.nih.gov/26823882/>
1159. Shimmura H, Mori E, Sekine R, Tei M, Otori N. Metastasis of Papillary Thyroid Carcinoma to the Maxillary Sinus: Case Report and Review of the Literature. *Case Rep Otolaryngol*. 2020;2020:4056901
1160. Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, et al. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. *J Nucl Med*. 2017;58(5):717-722. URL: <https://pubmed.ncbi.nlm.nih.gov/27738010/>
1161. Hong Y, Lin J, Yu M, Hsu C, Lin Y. Outcomes and prognostic factors in thyroid cancer patients with cranial metastases: A retrospective cohort study of 4,683 patients. *Int J Surg*. 2018;55:182-187. URL: <https://pubmed.ncbi.nlm.nih.gov/29883619/>
1162. Wu T, Jiao Z, Li Y, Peng J, Yao F, Chen W, et al. Brain Metastases From Differentiated Thyroid Carcinoma: A Retrospective Study of 22 Patients. *Front Endocrinol (Lausanne)*. 2021;12:730025. URL: <https://pubmed.ncbi.nlm.nih.gov/34603207/>
1163. Simões-Pereira J, Macedo D, Bugalho MJ. Clinical outcomes of a cohort of patients with central nervous system metastases from thyroid cancer. *Endocr Connect*. 2016;5:82-88
1164. Slutzky-Shraga I, Gorshtein A, Popovitzer A, Robenshtok E, Tsvetov G, Akirov A, et al. Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases. *Oncol Lett*. 2018;15:672-676
1165. Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, et al. Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. *J Endocr Soc*. 2019;3:359-371. URL: <https://pubmed.ncbi.nlm.nih.gov/30706042/>
1166. Guelho D, Ribeiro C, Melo M, Carrilho F. Long-term survival in a patient with brain metastases of papillary thyroid carcinoma. *BMJ Case Rep*. 2016;2016: URL: <https://pubmed.ncbi.nlm.nih.gov/26961557/>
1167. Vrachimis A, Schmid K, Jürgens H, Schober O, Weckesser M, Riemann B. Cerebral metastases from thyroid carcinoma: complete remission following radioiodine treatment. *Dtsch Arztebl Int*. 2013;110(50):861-6. URL: <https://pubmed.ncbi.nlm.nih.gov/24399028/>
1168. Spitzweg C, Bible K, Hofbauer L, Morris J. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. *Lancet Diabetes Endocrinol*. 2014;2(10):830-42. URL: <https://pubmed.ncbi.nlm.nih.gov/24898835/>
1169. Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, et al. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. *Eur Thyroid J*. 2019;8(5):227-245. URL: <https://pubmed.ncbi.nlm.nih.gov/31768334/>
1170. Filetti S, Durante C, Hartl D, Leboulleux S, Locati L, Newbold K, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. *Ann Oncol*. 2022;33(7):674-684. URL: <https://pubmed.ncbi.nlm.nih.gov/35491008/>
1171. Schutz F, Je Y, Richards C, Choueiri T. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. *J Clin Oncol*. 2012;30(8):871-7. URL: <https://pubmed.ncbi.nlm.nih.gov/22312105/>
1172. Brose M, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised,

- double-blind, phase 3 trial. *Lancet*. 2014;384(9940):319-28. URL: <https://pubmed.ncbi.nlm.nih.gov/24768112/>
1173. Schlumberger M, Tahara M, Wirth L, Robinson B, Brose M, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. *N Engl J Med*. 2015;372(7):621-30. URL: <https://pubmed.ncbi.nlm.nih.gov/25671254/>
1174. Brose M, Robinson B, Sherman S, Krajewska J, Lin C, Vaisman F, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2021;22(8):1126-1138. URL: <https://pubmed.ncbi.nlm.nih.gov/34237250/>
1175. Brose M, Robinson B, Sherman S, Jarzab B, Lin C, Vaisman F, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. *Cancer*. 2022;128(24):4203-4212. URL: <https://pubmed.ncbi.nlm.nih.gov/36259380/>
1176. Brose M, Worden F, Newbold K, Guo M, Hurria A. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. *J Clin Oncol*. 2017;35(23):2692-2699. URL: <https://pubmed.ncbi.nlm.nih.gov/28613956/>
1177. Hanna G, Busaidy N, Chau N, Wirth L, Barletta J, Calles A, et al. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. *Clin Cancer Res*. 2018;24(7):1546-1553. URL: <https://pubmed.ncbi.nlm.nih.gov/29301825/>
1178. Bible K, Suman V, Molina J, Smallridge R, Maples W, Menefee M, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. *Lancet Oncol*. 2010;11(10):962-72. URL: <https://pubmed.ncbi.nlm.nih.gov/20851682/>
1179. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. *Lancet Oncol*. 2012;13(9):897-905. URL: <https://pubmed.ncbi.nlm.nih.gov/22898678/>
1180. Impact of TSH levels on response to vandetanib in patients with locally advanced or metastatic differentiated thyroid cancer (DTC) who are refractory or unsuitable for radioiodine (RAI) therapy: a phase III study (VERIFY). 2016
1181. Carr L, Mankoff D, Goulart B, Eaton K, Capell P, Kell E, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. *Clin Cancer Res*. 2010;16(21):5260-8. URL: <https://pubmed.ncbi.nlm.nih.gov/20847059/>
1182. Cohen E, Needles B, Cullen K, Wong S, III J, Ivy S, et al. Phase 2 study of sunitinib in refractory thyroid cancer. 2008/05/20;26:6025
1183. Cohen E, Rosen L, Vokes E, Kies M, Forastiere A, Worden F, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. *J Clin Oncol*. 2008;26(29):4708-13. URL: <https://pubmed.ncbi.nlm.nih.gov/18541897/>
1184. Locati L, Licitra L, Agate L, Ou S, Boucher A, Jarzab B, et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. *Cancer*. 2014;120(17):2694-703. URL: <https://pubmed.ncbi.nlm.nih.gov/24844950/>
1185. Rao S, Cabanillas M. Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond. *J Endocr Soc*. 2018;2(10):1109-1130. URL: <https://pubmed.ncbi.nlm.nih.gov/30250937/>

1186. Wirth L, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of Selpercatinib in. *N Engl J Med*. 2020;383(9):825-835. URL: <https://pubmed.ncbi.nlm.nih.gov/32846061/>
1187. Subbiah V, Hu M, Wirth L, Schuler M, Mansfield A, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. *Lancet Diabetes Endocrinol*. 2021;9(8):491-501. URL: <https://pubmed.ncbi.nlm.nih.gov/34118198/>
1188. Sherman EJ, Wirth LJ, Shah MH, Cabanillas ME, Robinson B, Laskin JJ, et al. Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update. *Journal of Clinical Oncology*. 2021;39:6073. URL: https://doi.org/10.1200/JCO.2021.39.15_suppl.6073
1189. Waguespack S, Drilon A, Lin J, Brose M, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. *Eur J Endocrinol*. 2022;186(6):631-643. URL: <https://pubmed.ncbi.nlm.nih.gov/35333737/>
1190. Bazhenova L, Liu S, Lin J, Lu S, Drilon AE, Chawla S, et al. 533P Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours. 2021/09/01;32:S598
1191. Demeure M, Aziz M, Rosenberg R, Gurley S, Bussey K, Carpten J. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. *World J Surg*. 2014;38(6):1296-305. URL: <https://pubmed.ncbi.nlm.nih.gov/24633422/>
1192. Lee H, Krishnan V, Wirth L, Nucera C, Venturina M, Sadow P, et al. Case Report of. *Thyroid*. 2022;32(12):1580-1585. URL: <https://pubmed.ncbi.nlm.nih.gov/36150036/>
1193. Zhu L, Ma S, Xia B. Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report. *Front Oncol*. 2022;12:1009076. URL: <https://pubmed.ncbi.nlm.nih.gov/36439495/>
1194. Busaidy N, Konda B, Wei L, Wirth L, Devine C, Daniels G, et al. Dabrafenib Versus Dabrafenib + Trametinib in. *Thyroid*. 2022;32(10):1184-1192. URL: <https://pubmed.ncbi.nlm.nih.gov/35658604/>
1195. Falchook G, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack S, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. *Thyroid*. 2015;25(1):71-7. URL: <https://pubmed.ncbi.nlm.nih.gov/25285888/>
1196. Brose M, Cabanillas M, Cohen E, Wirth L, Riehl T, Yue H, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. *Lancet Oncol*. 2016;17(9):1272-82. URL: <https://pubmed.ncbi.nlm.nih.gov/27460442/>
1197. Lee Y, Lee H, Im S, Song Y, Oh D, Kang H, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. *J Clin Invest*. 2021;131(18). URL: <https://pubmed.ncbi.nlm.nih.gov/34237031/>
1198. Werner R, Sayehli C, Hänscheid H, Higuchi T, Serfling S, Fassnacht M, et al. Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma. *Eur J Nucl Med Mol Imaging*. 2023;50(6):1833-1834. URL: <https://pubmed.ncbi.nlm.nih.gov/36522435/>
1199. Groussin L, Theodon H, Bessiene L, Bricaire L, Bonnet-Serrano F, Cochand-Priollet B, et al. Redifferentiating Effect of Larotrectinib in. *Thyroid*. 2022;32(5):594-598. URL: <https://pubmed.ncbi.nlm.nih.gov/35171708/>
1200. Groussin L, Bessiene L, Arrondeau J, Garinet S, Cochand-Priollet B, Lupo A, et al. *Thyroid*. 2021;31(10):1603-1604. URL: <https://pubmed.ncbi.nlm.nih.gov/34405703/>

1201. Rothenberg S, McFadden D, Palmer E, Daniels G, Wirth L. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. *Clin Cancer Res*. 2015;21(5):1028-35. URL: <https://pubmed.ncbi.nlm.nih.gov/25549723/>
1202. Dunn L, Sherman E, Baxi S, Tchekmedyian V, Grewal R, Larson S, et al. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. *J Clin Endocrinol Metab*. 2019;104(5):1417-1428. URL: <https://pubmed.ncbi.nlm.nih.gov/30256977/>
1203. Leboulleux S, Cao CD, Zerdoud S, Attard M, Bournaud C, Benisvy D, et al. MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956). 2021;5:A876. URL: <https://doi.org/10.1210/jendso/bvab048.1789>
1204. Pembrolizumab for advanced papillary and follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. 2016;33(Suppl 15)
1205. Lenvatinib and pembrolizumab as safe and effective combination treatment in 8 patients with metastasized anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer. 2018;29(Suppl_8):viii645
1206. Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. *Thyroid*. 2021;31(7):1076-1085. URL: <https://pubmed.ncbi.nlm.nih.gov/33509020/>
1207. Haugen B, French J, Worden F, Konda B, Sherman E, Dadu R, et al. Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial. 2020/05/20;38:6512
1208. Haugen B, French J, Worden F, Konda B, Sherman E, Dadu R, et al. 1917P Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial. 2020/09/01;31:S1086
1209. Choksi P, Papaleontiou M, Guo C, Worden F, Banerjee M, Haymart M. Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study. *J Clin Endocrinol Metab*. 2017;102(4):1254-1260. URL: <https://pubmed.ncbi.nlm.nih.gov/28324052/>
1210. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. *Br J Cancer*. 2001;84(12):1586-90. URL: <https://pubmed.ncbi.nlm.nih.gov/11401309/>
1211. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. *Breast Cancer Res Treat*. 2011;127(2):429-38. URL: <https://pubmed.ncbi.nlm.nih.gov/21394500/>
1212. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. *Br J Cancer*. 2005;92(10):1869-76. URL: <https://pubmed.ncbi.nlm.nih.gov/15870721/>
1213. Orita Y, Sugitani I, Toda K, Manabe J, Fujimoto Y. Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. *Thyroid*. 2011;21(1):31-5. URL: <https://pubmed.ncbi.nlm.nih.gov/21058881/>

1214. Meijer J, Bakker L, Valk G, de Herder W, de Wilt J, Netea-Maier R, et al. Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. *Eur J Endocrinol*. 2013;168(5):779-86. URL: <https://pubmed.ncbi.nlm.nih.gov/23462866/>
1215. Kebebew E, Greenspan F, Clark O, Woeber K, Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. *J Am Coll Surg*. 2005;200(6):890-6. URL: <https://pubmed.ncbi.nlm.nih.gov/15922202/>
1216. Roman S, Lin R, Sosa J. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. *Cancer*. 2006;107(9):2134-42. URL: <https://pubmed.ncbi.nlm.nih.gov/17019736/>
1217. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. *World J Surg*. 2002;26(1):22-8. URL: <https://pubmed.ncbi.nlm.nih.gov/11898029/>
1218. Raue F, Frank-Raue K. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma. *Recent Results Cancer Res*. 2015;204:61-90. URL: <https://pubmed.ncbi.nlm.nih.gov/26494384/>
1219. Randle R, Balentine C, Levenson G, Havlena J, Sippel R, Schneider D, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. *Surgery*. 2017;161(1):137-146. URL: <https://pubmed.ncbi.nlm.nih.gov/27842913/>
1220. Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry German MTC/MEN Study Group Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2. *Langenbecks Arch Surg*. 1998;383(5):334-6. URL: <https://pubmed.ncbi.nlm.nih.gov/9860226/>
1221. Opsahl E, Akslen L, Schlichting E, Aas T, Brauckhoff K, Hagen A, et al. Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study. *Eur Thyroid J*. 2019;8(1):31-40. URL: <https://pubmed.ncbi.nlm.nih.gov/30800639/>
1222. Frank-Raue K, Machens A, Leidig-Bruckner G, Rondot S, Haag C, Schulze E, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. *Thyroid*. 2013;23(3):294-300. URL: <https://pubmed.ncbi.nlm.nih.gov/22946486/>
1223. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. *J Clin Endocrinol Metab*. 2004;89(1):163-8. URL: <https://pubmed.ncbi.nlm.nih.gov/14715844/>
1224. Machens A, Dralle H. Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. *Eur J Endocrinol*. 2016;175(3):219-28. URL: <https://pubmed.ncbi.nlm.nih.gov/27334331/>
1225. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. *J Clin Endocrinol Metab*. 2010;95(6):2655-63. URL: <https://pubmed.ncbi.nlm.nih.gov/20339026/>
1226. Chambon G, Alovisetti C, Idoux-Louche C, Reynaud C, Rodier M, Guedj A, et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients. *J Clin Endocrinol Metab*. 2011;96(1):75-81. URL: <https://pubmed.ncbi.nlm.nih.gov/20881258/>
1227. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. *J Clin Endocrinol Metab*. 2007;92(2):450-5. URL: <https://pubmed.ncbi.nlm.nih.gov/17119000/>

1228. Herrmann B, Schmid K, Goerges R, Kemen M, Mann K. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease. *Eur J Endocrinol*. 2010;162(6):1141-5. URL: <https://pubmed.ncbi.nlm.nih.gov/20332126/>
1229. Eckelt F, Vogel M, Geserick M, Kirsten T, Bae Y, Baber R, et al. Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases. *Clin Chem Lab Med*. 2019;57(8):1242-1250. URL: <https://pubmed.ncbi.nlm.nih.gov/30794525/>
1230. Castagna M, Fugazzola L, Maino F, Covelli D, Memmo S, Sestini F, et al. Reference range of serum calcitonin in pediatric population. *J Clin Endocrinol Metab*. 2015;100(5):1780-4. URL: <https://pubmed.ncbi.nlm.nih.gov/25955324/>
1231. Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuss M, Görges R, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. *Clin Chem*. 2011;57(3):467-74. URL: <https://pubmed.ncbi.nlm.nih.gov/21159900/>
1232. Kahaly G, Algeciras-Schimnich A, Davis T, Diana T, Feldkamp J, Karger S, et al. United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin. *Clin Chem*. 2017;63(9):1489-1496. URL: <https://pubmed.ncbi.nlm.nih.gov/28687633/>
1233. Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G, Ferrero S, et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. *J Clin Endocrinol Metab*. 2014;99(5):1656-64. URL: <https://pubmed.ncbi.nlm.nih.gov/24552221/>
1234. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. *Nat Clin Pract Endocrinol Metab*. 2009;5(1):35-44. URL: <https://pubmed.ncbi.nlm.nih.gov/19079272/>
1235. Preissner C, Dodge L, O'Kane D, Singh R, Grebe S. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. *Clin Chem*. 2005;51(1):208-10. URL: <https://pubmed.ncbi.nlm.nih.gov/15613712/>
1236. Schneider R, Waldmann J, Swaid Z, Ramaswamy A, Fendrich V, Bartsch D, et al. Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity. *Pancreas*. 2011;40(2):213-21. URL: <https://pubmed.ncbi.nlm.nih.gov/21178652/>
1237. Ahmed S, Ball D. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. *J Clin Endocrinol Metab*. 2011;96(5):1237-45. URL: <https://pubmed.ncbi.nlm.nih.gov/21346073/>
1238. Valle L, Kloos R. The prevalence of occult medullary thyroid carcinoma at autopsy. *J Clin Endocrinol Metab*. 2011;96(1):E109-13. URL: <https://pubmed.ncbi.nlm.nih.gov/20943788/>
1239. Karges W, Dralle H, Raue F, Mann K, Reiners C, Grussendorf M, et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. *Exp Clin Endocrinol Diabetes*. 2004;112(1):52-8. URL: <https://pubmed.ncbi.nlm.nih.gov/14758572/>
1240. Elisei R, Romei C. Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. *Thyroid Res*. 2013;6 Suppl 1(Suppl 1):S2. URL: <https://pubmed.ncbi.nlm.nih.gov/23514432/>
1241. Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit J. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. *Eur Thyroid J*. 2012;1(1):5-14. URL: <https://pubmed.ncbi.nlm.nih.gov/24782992/>

1242. Pacini F, Castagna M, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7:vii110-9. URL: <https://pubmed.ncbi.nlm.nih.gov/22997443/>
1243. Haugen B. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?. *Cancer*. 2017;123(3):372-381. URL: <https://pubmed.ncbi.nlm.nih.gov/27741354/>
1244. Verbeek H, de Groot J, Sluiter W, Muller Kobold A, van den Heuvel E, Plukker J, et al. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. *Cochrane Database Syst Rev*. 2020;3(3):CD010159. URL: <https://pubmed.ncbi.nlm.nih.gov/32176812/>
1245. Niederle M, Scheuba C, Riss P, Selberherr A, Koperek O, Niederle B. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?. *Thyroid*. 2020;30(7):974-984. URL: <https://pubmed.ncbi.nlm.nih.gov/32056502/>
1246. Lorenz K, Elwerr M, Machens A, Abuazab M, Holzhausen H, Dralle H. Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin. *Langenbecks Arch Surg*. 2013;398(3):403-9. URL: <https://pubmed.ncbi.nlm.nih.gov/23408061/>
1247. Russo M, Scollo C, Padova G, Vigneri R, Pellegriti G. Cardiac arrest after intravenous calcium administration for calcitonin stimulation test. *Thyroid*. 2014;24(3):606-7. URL: <https://pubmed.ncbi.nlm.nih.gov/24015826/>
1248. Rosario P, Calsolari M. Usefulness of Serum Calcitonin in Patients Without a Suspicious History of Medullary Thyroid Carcinoma and with Thyroid Nodules Without an Indication for Fine-Needle Aspiration or with Benign Cytology. *Horm Metab Res*. 2016;48(6):372-276. URL: <https://pubmed.ncbi.nlm.nih.gov/27203410/>
1249. Allelein S, Ehlers M, Morneau C, Schwartz K, Goretzki P, Seppel T, et al. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. *Horm Metab Res*. 2018;50(1):23-28. URL: <https://pubmed.ncbi.nlm.nih.gov/29169190/>
1250. Colombo C, Verga U, Mian C, Ferrero S, Perrino M, Vicentini L, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. *J Clin Endocrinol Metab*. 2012;97(3):905-13. URL: <https://pubmed.ncbi.nlm.nih.gov/22170709/>
1251. Barbosa S, Rodien P, Leboulleux S, Niccoli-Sire P, Kraimps J, Caron P, et al. Ectopic adrenocorticotrophic hormone-syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature. *Thyroid*. 2005;15(6):618-23. URL: <https://pubmed.ncbi.nlm.nih.gov/16029131/>
1252. Choi N, Moon W, Lee J, Baek J, Kim D, Park S. Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results. *Acta Radiol*. 2011;52(3):312-6. URL: <https://pubmed.ncbi.nlm.nih.gov/21498368/>
1253. Trimboli P, Nasrollah N, Amendola S, Rossi F, Ramacciato G, Romanelli F, et al. Should we use ultrasound features associated with papillary thyroid cancer in diagnosing medullary thyroid cancer?. *Endocr J*. 2012;59(6):503-8. URL: <https://pubmed.ncbi.nlm.nih.gov/22447142/>
1254. Woliński K, Rewaj-Łosyk M, Ruchała M. Sonographic features of medullary thyroid carcinomas--a systematic review and meta-analysis. *Endokrynol Pol*. 2014;65(4):314-8. URL: <https://pubmed.ncbi.nlm.nih.gov/25185855/>
1255. Kim S, Kim B, Jung S, Lee J, Yang P, Kang B, et al. Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. *Korean J Radiol*. 2009;10(2):101-5. URL: <https://pubmed.ncbi.nlm.nih.gov/19270854/>

1256. Lee S, Shin J, Han B, Ko E. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. *AJR Am J Roentgenol*. 2010;194(4):1090-4. URL: <https://pubmed.ncbi.nlm.nih.gov/20308516/>
1257. Liu M, Liu Z, Hou Y, Men Y, Zhang Y, Gao L, et al. Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. *Oncotarget*. 2017;8(16):27520-27528. URL: <https://pubmed.ncbi.nlm.nih.gov/28460476/>
1258. Cho K, Gweon H, Park A, Yoo M, Kim J, Youk J, et al. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?. *Asian Pac J Cancer Prev*. 2016;17(7):3357-62. URL: <https://pubmed.ncbi.nlm.nih.gov/27509975/>
1259. Oh H, Kwon H, Song E, Jeon M, Song D, Kim T, et al. Preoperative Clinical and Sonographic Predictors for Lateral Cervical Lymph Node Metastases in Sporadic Medullary Thyroid Carcinoma. *Thyroid*. 2018;28(3):362-368. URL: <https://pubmed.ncbi.nlm.nih.gov/29350102/>
1260. Trimboli P, Giovanella L, Valabrega S, Andrioli M, Baldelli R, Cremonini N, et al. Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. *J Exp Clin Cancer Res*. 2014;33(1):87. URL: <https://pubmed.ncbi.nlm.nih.gov/25344474/>
1261. Valderrabano P, Klippenstein D, Tourtelot J, Ma Z, Thompson Z, Lilienfeld H, et al. New American Thyroid Association Sonographic Patterns for Thyroid Nodules Perform Well in Medullary Thyroid Carcinoma: Institutional Experience, Systematic Review, and Meta-Analysis. *Thyroid*. 2016;26(8):1093-100. URL: <https://pubmed.ncbi.nlm.nih.gov/27267210/>
1262. Yun G, Kim Y, Choi S, Kim J. Medullary thyroid carcinoma: Application of Thyroid Imaging Reporting and Data System (TI-RADS) Classification. *Endocrine*. 2018;61(2):285-292. URL: <https://pubmed.ncbi.nlm.nih.gov/29680915/>
1263. Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg F, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. *Eur J Nucl Med Mol Imaging*. 2020;47(1):61-77. URL: <https://pubmed.ncbi.nlm.nih.gov/31482429/>
1264. Brammen L, Niederle M, Riss P, Scheuba C, Selberherr A, Karanikas G, et al. Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?. *Ann Surg Oncol*. 2018;25(13):3919-3927. URL: <https://pubmed.ncbi.nlm.nih.gov/30306375/>
1265. Rosai J. Handling of thyroid follicular patterned lesions. *Endocr Pathol*. 2005;16(4):279-83. URL: <https://pubmed.ncbi.nlm.nih.gov/16627915/>
1266. Pandit A, Phulpagar M. Worrisome histologic alterations following fine needle aspiration of the thyroid. *Acta Cytol*. 2001;45(2):173-9. URL: <https://pubmed.ncbi.nlm.nih.gov/11284302/>
1267. Bolat F, Kayaselcuk F, Nursal T, Reyhan M, Bal N, Yildirim S, et al. Histopathological changes in thyroid tissue after fine needle aspiration biopsy. *Pathol Res Pract*. 2007;203(9):641-5. URL: <https://pubmed.ncbi.nlm.nih.gov/17582696/>
1268. Kaserer K, Scheuba C, Neuhold N, Weinhäusel A, Haas O, Vierhapper H, et al. Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. *Am J Surg Pathol*. 2001;25(10):1245-51. URL: <https://pubmed.ncbi.nlm.nih.gov/11688458/>
1269. Aubert S, Berdelou A, Gnemmi V, Behal H, Caiazzo R, D'herbomez M, et al. Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement. *Virchows Arch*. 2018;472(3):461-468. URL: <https://pubmed.ncbi.nlm.nih.gov/29388012/>

1270. Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, et al. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). *Clin Endocrinol (Oxf)*. 2011;74(2):241-7. URL: <https://pubmed.ncbi.nlm.nih.gov/21054478/>
1271. Machens A, Dralle H. Biological relevance of medullary thyroid microcarcinoma. *J Clin Endocrinol Metab*. 2012;97(5):1547-53. URL: <https://pubmed.ncbi.nlm.nih.gov/22399508/>
1272. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. *World J Surg*. 2007;31(10):1960-5. URL: <https://pubmed.ncbi.nlm.nih.gov/17665245/>
1273. Chandeze M, Noullet S, Faron M, Trésallet C, Godiris-Petit G, Tissier F, et al. Can We Predict the Lateral Compartment Lymph Node Involvement in RET-Negative Patients with Medullary Thyroid Carcinoma?. *Ann Surg Oncol*. 2016;23(11):3653-3659. URL: <https://pubmed.ncbi.nlm.nih.gov/27271930/>
1274. Dralle H. Lymph node dissection and medullary thyroid carcinoma. *Br J Surg*. 2002;89(9):1073-5. URL: <https://pubmed.ncbi.nlm.nih.gov/12190669/>
1275. Moley J, Fialkowski E. Evidence-based approach to the management of sporadic medullary thyroid carcinoma. *World J Surg*. 2007;31(5):946-56. URL: <https://pubmed.ncbi.nlm.nih.gov/17426901/>
1276. Selberherr A, Riss P, Scheuba C, Niederle B. Prophylactic "First-Step" Central Neck Dissection (Level 6) Does Not Increase Morbidity After (Total) Thyroidectomy. *Ann Surg Oncol*. 2016;23(12):4016-4022. URL: <https://pubmed.ncbi.nlm.nih.gov/27393573/>
1277. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. *World J Surg*. 2002;26(8):1023-8. URL: <https://pubmed.ncbi.nlm.nih.gov/12016484/>
1278. Raffel A, Cupisti K, Krausch M, Wolf A, Schulte K, Röher H. Incidentally found medullary thyroid cancer: treatment rationale for small tumors. *World J Surg*. 2004;28(4):397-401. URL: <https://pubmed.ncbi.nlm.nih.gov/14994142/>
1279. Hartung-Knemeyer V, Müller S, Nagarajah J, Lahner H, Broecker-Preuss M, Bockisch A, et al. [Influence of the calcitonin assay on the definition of biochemical cure in patients with medullary thyroid carcinoma]. *Nuklearmedizin*. 2012;51(4):125-32. URL: <https://pubmed.ncbi.nlm.nih.gov/22526413/>
1280. Rowland K, Jin L, Moley J. Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. *Ann Surg Oncol*. 2015;22(1):96-102. URL: <https://pubmed.ncbi.nlm.nih.gov/25234024/>
1281. Machens A, Dralle H. Benefit-risk balance of reoperation for persistent medullary thyroid cancer. *Ann Surg*. 2013;257(4):751-7. URL: <https://pubmed.ncbi.nlm.nih.gov/23023200/>
1282. Machens A, Lorenz K, Dralle H. Prediction of biochemical cure in patients with medullary thyroid cancer. *Br J Surg*. 2020;107(6):695-704. URL: <https://pubmed.ncbi.nlm.nih.gov/32108330/>
1283. Scheuba C, Kaserer K, Bieglmayer C, Asari R, Riss P, Drosten R, et al. Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience. *Surgery*. 2007;142(6):1003-10; discussion 1010.e1-3. URL: <https://pubmed.ncbi.nlm.nih.gov/18063088/>
1284. Kim J, Pyo J, Cho W. Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta-analysis. *World J Surg*. 2017;41(10):2551-2558. URL: <https://pubmed.ncbi.nlm.nih.gov/28451761/>

1285. Lindsey S, Ganly I, Palmer F, Tuttle R. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. *Thyroid*. 2015;25(2):242-9. URL: <https://pubmed.ncbi.nlm.nih.gov/25338223/>
1286. Tuttle R, Ganly I. Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. *Oral Oncol*. 2013;49(7):695-701. URL: <https://pubmed.ncbi.nlm.nih.gov/23601563/>
1287. Kwon H, Kim W, Jeon M, Song D, Lee Y, Sung T, et al. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. *Endocrine*. 2016;53(1):174-81. URL: <https://pubmed.ncbi.nlm.nih.gov/26754662/>
1288. Choi J, Lee S, Kim M, Kim T, Ban E, Lee C, et al. Dynamic risk stratification in medullary thyroid carcinoma: Single institution experiences. *Medicine (Baltimore)*. 2018;97(3):e9686. URL: <https://pubmed.ncbi.nlm.nih.gov/29505021/>
1289. Leidig-Bruckner G, Bruckner T, Raue F, Frank-Raue K. Long-Term Follow-Up and Treatment of Postoperative Permanent Hypoparathyroidism in Patients with Medullary Thyroid Carcinoma: Differences in Complete and Partial Disease. *Horm Metab Res*. 2016;48(12):806-813. URL: <https://pubmed.ncbi.nlm.nih.gov/27813050/>
1290. Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. *Cancer*. 2000;88(8):1909-15. URL: <https://pubmed.ncbi.nlm.nih.gov/10760769/>
1291. Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. *World J Surg*. 2008;32(5):754-65. URL: <https://pubmed.ncbi.nlm.nih.gov/18188643/>
1292. Barbet J, Campion L, Kraeber-Bodéré F, Chatal J. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. *J Clin Endocrinol Metab*. 2005;90(11):6077-84. URL: <https://pubmed.ncbi.nlm.nih.gov/16091497/>
1293. Randle R, Bates M, Schneider D, Sippel R, Pitt S. Survival in patients with medullary thyroid cancer after less than the recommended initial operation. *J Surg Oncol*. 2018;117(6):1211-1216. URL: <https://pubmed.ncbi.nlm.nih.gov/29266278/>
1294. Machens A, Lorenz K, Dralle H. Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer. *Br J Surg*. 2019;106(4):412-418. URL: <https://pubmed.ncbi.nlm.nih.gov/30725475/>
1295. Kloos R, Eng C, Evans D, Francis G, Gagel R, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. *Thyroid*. 2009;19(6):565-612. URL: <https://pubmed.ncbi.nlm.nih.gov/19469690/>
1296. Laure Giraudet A, Al Ghulzan A, Aupérin A, Leboulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. *Eur J Endocrinol*. 2008;158(2):239-46. URL: <https://pubmed.ncbi.nlm.nih.gov/18230832/>
1297. Romei C, Ciampi R, Casella F, Tacito A, Torregrossa L, Ugolini C, et al. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. *Oncotarget*. 2018;9(11):9875-9884. URL: <https://pubmed.ncbi.nlm.nih.gov/29515777/>
1298. Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R, et al. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. *Thyroid*. 2012;22(5):476-81. URL: <https://pubmed.ncbi.nlm.nih.gov/22404432/>
1299. Schilling T, Bürck J, Sinn H, Clemens A, Otto H, Höppner W, et al. Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. *Int J Cancer*. 2001;95(1):62-6. URL: <https://pubmed.ncbi.nlm.nih.gov/11241313/>

1300. Kushchayev S, Kushchayeva Y, Tella S, Glushko T, Pacak K, Teytelboym O. Medullary Thyroid Carcinoma: An Update on Imaging. *J Thyroid Res.* 2019;2019:1893047. URL: <https://pubmed.ncbi.nlm.nih.gov/31360432/>
1301. Raue F, Frank-Raue K. Long-Term Follow-up in Medullary Thyroid Carcinoma. *Recent Results Cancer Res.* 2015;204:207-25. URL: <https://pubmed.ncbi.nlm.nih.gov/26494391/>
1302. Giraudet A, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. *J Clin Endocrinol Metab.* 2007;92(11):4185-90. URL: <https://pubmed.ncbi.nlm.nih.gov/17726071/>
1303. Terroir M, Caramella C, Borget I, Bidault S, Dromain C, El Farsaoui K, et al. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients. *Thyroid.* 2019;29(10):1457-1464. URL: <https://pubmed.ncbi.nlm.nih.gov/31530235/>
1304. Caobelli F, Chiaravalloti A, Evangelista L, Saladini G, Schillaci O, Vadrucchi M, et al. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. *Ann Nucl Med.* 2018;32(1):7-15. URL: <https://pubmed.ncbi.nlm.nih.gov/28986764/>
1305. Romero-Lluch A, Cuenca-Cuenca J, Guerrero-Vázquez R, Martínez-Ortega A, Tirado-Hospital J, Borrego-Dorado I, et al. Diagnostic utility of PET/CT with. *Eur J Nucl Med Mol Imaging.* 2017;44(12):2004-2013. URL: <https://pubmed.ncbi.nlm.nih.gov/28646462/>
1306. Golubić A, Pasini Nemir E, Žuvić M, Mutvar A, Kusačić Kuna S, Despot M, et al. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values. *Nucl Med Commun.* 2017;38(7):636-641. URL: <https://pubmed.ncbi.nlm.nih.gov/28562377/>
1307. Archier A, Heimbürger C, Guérin C, Morange I, Palazzo F, Henry J, et al. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. *Eur J Nucl Med Mol Imaging.* 2016;43(6):1027-33. URL: <https://pubmed.ncbi.nlm.nih.gov/26497699/>
1308. Sesti A, Mayerhoefer M, Weber M, Anner P, Wadsak W, Dudczak R, et al. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. *Anticancer Res.* 2014;34(11):6647-54. URL: <https://pubmed.ncbi.nlm.nih.gov/25368270/>
1309. Verbeek H, Plukker J, Koopmans K, de Groot J, Hofstra R, Muller Kobold A, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. *J Nucl Med.* 2012;53(12):1863-71. URL: <https://pubmed.ncbi.nlm.nih.gov/23081996/>
1310. Luster M, Karges W, Zeich K, Pauls S, Verburg F, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. *Thyroid.* 2010;20(5):527-33. URL: <https://pubmed.ncbi.nlm.nih.gov/20450432/>
1311. Kauhanen S, Schalin-Jäntti C, Seppänen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. *J Nucl Med.* 2011;52(12):1855-63. URL: <https://pubmed.ncbi.nlm.nih.gov/22052128/>
1312. Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. *Acad Radiol.* 2012;19(10):1290-9. URL: <https://pubmed.ncbi.nlm.nih.gov/22819076/>
1313. Treglia G, Castaldi P, Villani M, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. *Eur J Nucl Med Mol Imaging.* 2012;39(4):569-80. URL: <https://pubmed.ncbi.nlm.nih.gov/22223169/>

1314. Conry B, Papathanasiou N, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. *Eur J Nucl Med Mol Imaging*. 2010;37(1):49-57. URL: <https://pubmed.ncbi.nlm.nih.gov/19662413/>
1315. Pühr-Westerheide D, Cyran C, Sargsyan-Bergmann J, Todica A, Gildehaus F, Kunz W, et al. The added diagnostic value of complementary gadoxetic acid-enhanced MRI to. *Cancer Imaging*. 2019;19(1):73. URL: <https://pubmed.ncbi.nlm.nih.gov/31727170/>
1316. Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. *Eur J Nucl Med Mol Imaging*. 2007;34(10):1604-9. URL: <https://pubmed.ncbi.nlm.nih.gov/17435996/>
1317. Naswa N, Sharma P, Suman Kc S, Lata S, Kumar R, Malhotra A, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. *Nucl Med Commun*. 2012;33(7):766-74. URL: <https://pubmed.ncbi.nlm.nih.gov/22531829/>
1318. Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot J, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. *Nucl Med Commun*. 2012;33(7):775-9. URL: <https://pubmed.ncbi.nlm.nih.gov/22546877/>
1319. Rowell N. The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: A systematic review. *Radiother Oncol*. 2019;136:113-120. URL: <https://pubmed.ncbi.nlm.nih.gov/31015112/>
1320. Kukulska A, Krajewska J, Kolosza Z, Paliczka-Cieslik E, Kropinska A, Pawlaczek A, et al. The role of postoperative adjuvant radiotherapy in the local control in medullary thyroid carcinoma. *Endocr Connect*. 2019;9(1):1-8. URL: <https://pubmed.ncbi.nlm.nih.gov/31778360/>
1321. Xu J, Murphy W, Milton D, Jimenez C, Rao S, Habra M, et al. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. *J Clin Endocrinol Metab*. 2016;101(12):4871-4877. URL: <https://pubmed.ncbi.nlm.nih.gov/27662441/>
1322. Vogel T, Wendler J, Frank-Raue K, Kreissl M, Spitzweg C, Fassnacht M, et al. Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. *J Clin Endocrinol Metab*. 2020;105(6): URL: <https://pubmed.ncbi.nlm.nih.gov/32072159/>
1323. Polascik T. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. *Drug Des Devel Ther*. 2009;3:27-40. URL: <https://pubmed.ncbi.nlm.nih.gov/19920919/>
1324. Tappenden P, Carroll C, Hamilton J, Kaltenthaler E, Wong R, Wadsley J, et al. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. *Health Technol Assess*. 2019;23(8):1-144. URL: <https://pubmed.ncbi.nlm.nih.gov/30821231/>
1325. Wells S, Robinson B, Gagel R, Dralle H, Fagin J, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *J Clin Oncol*. 2012;30(2):134-41. URL: <https://pubmed.ncbi.nlm.nih.gov/22025146/>
1326. Elisei R, Schlumberger M, Müller S, Schöffski P, Brose M, Shah M, et al. Cabozantinib in progressive medullary thyroid cancer. *J Clin Oncol*. 2013;31(29):3639-46. URL: <https://pubmed.ncbi.nlm.nih.gov/24002501/>
1327. Wells S, Gosnell J, Gagel R, Moley J, Pfister D, Sosa J, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. *J Clin Oncol*. 2010;28(5):767-72. URL: <https://pubmed.ncbi.nlm.nih.gov/20065189/>

1328. Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. *Ann Oncol*. 2017;28(11):2813-2819. URL: <https://pubmed.ncbi.nlm.nih.gov/29045520/>
1329. Bible K, Suman V, Molina J, Smallridge R, Maples W, Menefee M, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. *J Clin Endocrinol Metab*. 2014;99(5):1687-93. URL: <https://pubmed.ncbi.nlm.nih.gov/24606083/>
1330. Lam E, Ringel M, Kloos R, Prior T, Knopp M, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. *J Clin Oncol*. 2010;28(14):2323-30. URL: <https://pubmed.ncbi.nlm.nih.gov/20368568/>
1331. Schlumberger M, Jarzab B, Cabanillas M, Robinson B, Pacini F, Ball D, et al. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. *Clin Cancer Res*. 2016;22(1):44-53. URL: <https://pubmed.ncbi.nlm.nih.gov/26311725/>
1332. Capdevila J, Trigo J, Aller J, Manzano J, Adrián S, Llopis C, et al. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). *Eur J Endocrinol*. 2017;177(4):309-317. URL: <https://pubmed.ncbi.nlm.nih.gov/28687563/>
1333. Efstathiadou Z, Tsentidis C, Bargiota A, Daraki V, Kotsa K, Ntali G, et al. Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis. *Eur Thyroid J*. 2021;10(2):125-139. URL: <https://pubmed.ncbi.nlm.nih.gov/33981617/>
1334. Subbiah V, Hu M, Wirth L, Schuler M, Mansfield A, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. *Lancet Diabetes Endocrinol*. 2021;9(8):491-501. URL: <https://pubmed.ncbi.nlm.nih.gov/34118198/>
1335. Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. *Fam Cancer*. 2010;9(3):449-57. URL: <https://pubmed.ncbi.nlm.nih.gov/20087666/>
1336. Frank-Raue K, Rybicki L, Erlic Z, Schweizer H, Winter A, Milos I, et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. *Hum Mutat*. 2011;32(1):51-8. URL: <https://pubmed.ncbi.nlm.nih.gov/20979234/>
1337. Raue F, Dralle H, Machens A, Bruckner T, Frank-Raue K. Long-Term Survivorship in Multiple Endocrine Neoplasia Type 2B Diagnosed Before and in the New Millennium. *J Clin Endocrinol Metab*. 2018;103(1):235-243. URL: <https://pubmed.ncbi.nlm.nih.gov/29077903/>
1338. Castinetti F, Moley J, Mulligan L, Waguespack S. A comprehensive review on MEN2B. *Endocr Relat Cancer*. 2018;25(2):T29-T39. URL: <https://pubmed.ncbi.nlm.nih.gov/28698189/>
1339. Schmid K. Histopathology of C Cells and Medullary Thyroid Carcinoma. *Recent Results Cancer Res*. 2015;204:41-60. URL: <https://pubmed.ncbi.nlm.nih.gov/26494383/>
1340. Machens A, Lorenz K, Dralle H. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. *Ann Surg*. 2009;250(2):305-10. URL: <https://pubmed.ncbi.nlm.nih.gov/19638924/>
1341. Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau J, et al. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Français d'Etude des Tumeurs Endocrines. *J Clin Endocrinol Metab*. 2011;96(3):E509-18. URL: <https://pubmed.ncbi.nlm.nih.gov/21190982/>

1342. Machens A, Elwerr M, Lorenz K, Weber F, Dralle H. Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations. *Br J Surg*. 2018;105(2):e150-e157. URL: <https://pubmed.ncbi.nlm.nih.gov/29341155/>
1343. Mucha L, Leidig-Bruckner G, Frank-Raue K, Bruckner T, Kroiss M, Raue F. Pheochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. *Clin Endocrinol (Oxf)*. 2017;87(4):320-326. URL: <https://pubmed.ncbi.nlm.nih.gov/28605116/>
1344. Därr R, Pamporaki C, Peitzsch M, Miehle K, Prejbisz A, Peczkowska M, et al. Biochemical diagnosis of pheochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. *Clin Endocrinol (Oxf)*. 2014;80(4):478-86. URL: <https://pubmed.ncbi.nlm.nih.gov/24102244/>
1345. Castinetti F, Qi X, Walz M, Maia A, Sansó G, Peczkowska M, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in pheochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. *Lancet Oncol*. 2014;15(6):648-55. URL: <https://pubmed.ncbi.nlm.nih.gov/24745698/>
1346. Asari R, Scheuba C, Kaczirek K, Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. *Arch Surg*. 2006;141(12):1199-205; discussion 1205. URL: <https://pubmed.ncbi.nlm.nih.gov/17178962/>
1347. Machens A, Lorenz K, Dralle H. Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. *J Clin Endocrinol Metab*. 2013;98(2):E336-45. URL: <https://pubmed.ncbi.nlm.nih.gov/23284010/>
1348. Raue F, Kraimps J, Dralle H, Cougard P, Proye C, Frilling A, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. *J Intern Med*. 1995;238(4):369-73. URL: <https://pubmed.ncbi.nlm.nih.gov/7595174/>
1349. Scholten A, Schreinemakers J, Pieterman C, Valk G, Vriens M, Borel Rinkes I. Evolution of surgical treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. *Endocr Pract*. 2011;17(1):7-15. URL: <https://pubmed.ncbi.nlm.nih.gov/20570815/>
1350. Moley J, Skinner M, Gillanders W, Lairmore T, Rowland K, Traugott A, et al. Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2. *Ann Surg*. 2015;262(4):641-6. URL: <https://pubmed.ncbi.nlm.nih.gov/26366543/>
1351. Chintakuntlawar A, Foote R, Kasperbauer J, Bible K. Diagnosis and Management of Anaplastic Thyroid Cancer. *Endocrinol Metab Clin North Am*. 2019;48(1):269-284. URL: <https://pubmed.ncbi.nlm.nih.gov/30717908/>
1352. Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5(6):649-55. URL: <https://pubmed.ncbi.nlm.nih.gov/7165009/>
1353. Haymart M, Banerjee M, Yin H, Worden F, Griggs J. Marginal treatment benefit in anaplastic thyroid cancer. *Cancer*. 2013;119(17):3133-9. URL: <https://pubmed.ncbi.nlm.nih.gov/23839797/>
1354. Deeken-Draisey A, Yang G, Gao J, Alexiev B. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study. *Hum Pathol*. 2018;82:140-148. URL: <https://pubmed.ncbi.nlm.nih.gov/30075157/>
1355. Loevner L, Kaplan S, Cunnane M, Moonis G. Cross-sectional imaging of the thyroid gland. *Neuroimaging Clin N Am*. 2008;18(3):445-61, vii. URL: <https://pubmed.ncbi.nlm.nih.gov/18656027/>

1356. Salama J, Golden D, Yom S, Garg M, Lawson J, McDonald M, et al. ACR Appropriateness Criteria® thyroid carcinoma. *Oral Oncol.* 2014;50(6):577-86. URL: <https://pubmed.ncbi.nlm.nih.gov/24824115/>
1357. Rios A, Torregrosa B, Rodríguez J, Rodríguez D, Cepero A, Abellán M, et al. Ultrasonographic risk factors of malignancy in thyroid nodules. *Langenbecks Arch Surg.* 2016;401(6):839-49. URL: <https://pubmed.ncbi.nlm.nih.gov/27263038/>
1358. Smallridge R, Ain K, Asa S, Bible K, Brierley J, Burman K, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. *Thyroid.* 2012;22(11):1104-39. URL: <https://pubmed.ncbi.nlm.nih.gov/23130564/>
1359. Goffredo P, Thomas S, Adam M, Sosa J, Roman S. Impact of Timeliness of Resection and Thyroidectomy Margin Status on Survival for Patients with Anaplastic Thyroid Cancer: An Analysis of 335 Cases. *Ann Surg Oncol.* 2015;22(13):4166-74. URL: <https://pubmed.ncbi.nlm.nih.gov/26271394/>
1360. Haddad R, Nasr C, Bischoff L, Busaidy N, Byrd D, Callender G, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. *J Natl Compr Canc Netw.* 2018;16(12):1429-1440. URL: <https://pubmed.ncbi.nlm.nih.gov/30545990/>
1361. Nguyen B, Ram P. PET/CT staging and posttherapeutic monitoring of anaplastic thyroid carcinoma. *Clin Nucl Med.* 2007;32(2):145-9. URL: <https://pubmed.ncbi.nlm.nih.gov/17242574/>
1362. Bogsrud T, Karantanis D, Nathan M, Mullan B, Wiseman G, Kasperbauer J, et al. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. *Thyroid.* 2008;18(7):713-9. URL: <https://pubmed.ncbi.nlm.nih.gov/18630999/>
1363. Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. *Eur J Nucl Med Mol Imaging.* 2010;37(12):2277-85. URL: <https://pubmed.ncbi.nlm.nih.gov/20694463/>
1364. Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. *Thyroid.* 2011;21(11):1183-9. URL: <https://pubmed.ncbi.nlm.nih.gov/21936674/>
1365. Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. *World J Surg.* 2012;36(6):1247-54. URL: <https://pubmed.ncbi.nlm.nih.gov/22311136/>
1366. Samih N, Hovsepian S, Notel F, Prorok M, Zattara-Cannoni H, Mathieu S, et al. The impact of N- and O-glycosylation on the functions of Glut-1 transporter in human thyroid anaplastic cells. *Biochim Biophys Acta.* 2003;1621(1):92-101. URL: <https://pubmed.ncbi.nlm.nih.gov/12667615/>
1367. Chiu A, Delpassand E, Sherman S. Prognosis and treatment of brain metastases in thyroid carcinoma. *J Clin Endocrinol Metab.* 1997;82(11):3637-42. URL: <https://pubmed.ncbi.nlm.nih.gov/9360519/>
1368. Salvati M, Frati A, Rocchi G, Masciangelo R, Antonaci A, Gagliardi F, et al. Single brain metastasis from thyroid cancer: report of twelve cases and review of the literature. *J Neurooncol.* 2001;51(1):33-40. URL: <https://pubmed.ncbi.nlm.nih.gov/11349878/>
1369. Antoch G, Vogt F, Freudenberg L, Nazaradeh F, Goehde S, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. *JAMA.* 2003;290(24):3199-206. URL: <https://pubmed.ncbi.nlm.nih.gov/14693872/>

1370. Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. *Minerva Endocrinol.* 2008;33(4):341-57. URL: <https://pubmed.ncbi.nlm.nih.gov/18923370/>
1371. Ribechini A, Bottici V, Chella A, Elisei R, Vitti P, Pinchera A, et al. Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer. *J Endocrinol Invest.* 2006;29(2):131-5. URL: <https://pubmed.ncbi.nlm.nih.gov/16610238/>
1372. Yuasa R, Hata Y, Otsuka H, Makino T, Koezuka S, Sato F, et al. Placement of self-expandable metallic stents for tracheal stenosis secondary to thyroid cancer. *Mol Clin Oncol.* 2014;2(6):1003-1008. URL: <https://pubmed.ncbi.nlm.nih.gov/25279189/>
1373. Pozdeyev N, Gay L, Sokol E, Hartmaier R, Deaver K, Davis S, et al. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. *Clin Cancer Res.* 2018;24(13):3059-3068. URL: <https://pubmed.ncbi.nlm.nih.gov/29615459/>
1374. Godbert Y, Henriques de Figueiredo B, Bonichon F, Chibon F, Hostein I, Pérot G, et al. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma. *J Clin Oncol.* 2015;33(20):e84-7. URL: <https://pubmed.ncbi.nlm.nih.gov/24687827/>
1375. Liu S, Macke L, Colton B, Imran S, Christiansen J, Chow-Maneval E, et al. Response to Entrectinib in Differentiated Thyroid Cancer With a. *JCO Precis Oncol.* 2017;1: URL: <https://pubmed.ncbi.nlm.nih.gov/32913977/>
1376. Wagle N, Grabiner B, Van Allen E, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. *N Engl J Med.* 2014;371(15):1426-33. URL: <https://pubmed.ncbi.nlm.nih.gov/25295501/>
1377. Sugitani I, Hasegawa Y, Sugasawa M, Tori M, Higashiyama T, Miyazaki M, et al. Super-radical surgery for anaplastic thyroid carcinoma: a large cohort study using the Anaplastic Thyroid Carcinoma Research Consortium of Japan database. *Head Neck.* 2014;36(3):328-33. URL: <https://pubmed.ncbi.nlm.nih.gov/23729360/>
1378. Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. *Nat Rev Endocrinol.* 2017;13(11):644-660. URL: <https://pubmed.ncbi.nlm.nih.gov/28707679/>
1379. Mitchell G, Huddart R, Harmer C. Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. *Radiother Oncol.* 1999;50(1):33-8. URL: <https://pubmed.ncbi.nlm.nih.gov/10225555/>
1380. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. *Br J Cancer.* 2002;86(12):1848-53. URL: <https://pubmed.ncbi.nlm.nih.gov/12085174/>
1381. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. *Cancer.* 2006;107(8):1786-92. URL: <https://pubmed.ncbi.nlm.nih.gov/16967442/>
1382. Kebebew E, Greenspan F, Clark O, Woeber K, McMillan A. Anaplastic thyroid carcinoma Treatment outcome and prognostic factors. *Cancer.* 2005;103(7):1330-5. URL: <https://pubmed.ncbi.nlm.nih.gov/15739211/>
1383. Levendag P, De Porre P, van Putten W. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. *Int J Radiat Oncol Biol Phys.* 1993;26(1):125-8. URL: <https://pubmed.ncbi.nlm.nih.gov/8482618/>
1384. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. *Eur J Surg Oncol.* 2001;27(3):260-4. URL: <https://pubmed.ncbi.nlm.nih.gov/11373102/>

1385. Haigh P, Ituarte P, Wu H, Treseler P, Posner M, Quivey J, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. *Cancer*. 2001;91(12):2335-42. URL: <https://pubmed.ncbi.nlm.nih.gov/11413523/>
1386. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli J, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. *Int J Radiat Oncol Biol Phys*. 2004;60(4):1137-43. URL: <https://pubmed.ncbi.nlm.nih.gov/15519785/>
1387. Fan D, Ma J, Bell A, Groen A, Olsen K, Lok B, et al. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. *Cancer*. 2020;126(2):444-452. URL: <https://pubmed.ncbi.nlm.nih.gov/31593317/>
1388. Xia Q, Wang W, Xu J, Chen X, Zhong Z, Sun C. Evidence from an updated meta-analysis of the prognostic impacts of postoperative radiotherapy and chemotherapy in patients with anaplastic thyroid carcinoma. *Onco Targets Ther*. 2018;11:2251-2257. URL: <https://pubmed.ncbi.nlm.nih.gov/29719407/>
1389. Pezzi T, Mohamed A, Sheu T, Blanchard P, Sandulache V, Lai S, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. *Cancer*. 2017;123(9):1653-1661. URL: <https://pubmed.ncbi.nlm.nih.gov/28026871/>
1390. Wendler J, Kroiss M, Gast K, Kreissl M, Allelein S, Lichtenauer U, et al. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. *Eur J Endocrinol*. 2016;175(6):521-529. URL: <https://pubmed.ncbi.nlm.nih.gov/27926471/>
1391. Prasongsook N, Kumar A, Chintakuntlawar A, Foote R, Kasperbauer J, Molina J, et al. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. *J Clin Endocrinol Metab*. 2017;102(12):4506-4514. URL: <https://pubmed.ncbi.nlm.nih.gov/29029287/>
1392. Derbel O, Limem S, Ségura-Ferlay C, Lifante J, Carrie C, Peix J, et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). *BMC Cancer*. 2011;11:469. URL: <https://pubmed.ncbi.nlm.nih.gov/22044775/>
1393. Seto A, Sugitani I, Toda K, Kawabata K, Takahashi S, Saotome T. Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases. *Surg Today*. 2015;45(2):221-6. URL: <https://pubmed.ncbi.nlm.nih.gov/25734195/>
1394. Zhao X, Wang J, Dadu R, Busaidy N, Xu L, Learned K, et al. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF. *Thyroid*. 2023;33(4):484-491. URL: <https://pubmed.ncbi.nlm.nih.gov/36762947/>
1395. Lorimer C, Cheng L, Chandler R, Garcez K, Gill V, Graham K, et al. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres. *Clin Oncol (R Coll Radiol)*. 2023;35(1):e60-e66. URL: <https://pubmed.ncbi.nlm.nih.gov/36379836/>
1396. Higashiyama T, Ito Y, Hirokawa M, Fukushima M, Uruno T, Miya A, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. *Thyroid*. 2010;20(1):7-14. URL: <https://pubmed.ncbi.nlm.nih.gov/20025538/>
1397. Wang J, Zafereo M, Dadu R, Ferrarotto R, Busaidy N, Lu C, et al. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in. *Thyroid*. 2019;29(8):1036-1043. URL: <https://pubmed.ncbi.nlm.nih.gov/31319771/>
1398. Brown R, Ducic Y. Aggressive surgical resection of anaplastic thyroid carcinoma may provide long-term survival in selected patients. *Otolaryngol Head Neck Surg*. 2013;148(4):564-71. URL: <https://pubmed.ncbi.nlm.nih.gov/23396588/>

1399. Sosa J, Elisei R, Jarzab B, Balkissoon J, Lu S, Bal C, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. *Thyroid*. 2014;24(2):232-40. URL: <https://pubmed.ncbi.nlm.nih.gov/23721245/>
1400. Nachalon Y, Stern-Shavit S, Bachar G, Shvero J, Limon D, Popovtzer A. Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma. *JAMA Otolaryngol Head Neck Surg*. 2015;141(12):1128-32. URL: <https://pubmed.ncbi.nlm.nih.gov/26512447/>
1401. Cabanillas M, Zafereo M, Gunn G, Ferrarotto R. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. *J Oncol Pract*. 2016;12(6):511-8. URL: <https://pubmed.ncbi.nlm.nih.gov/27288464/>
1402. Subbiah V, Kreitman R, Wainberg Z, Cho J, Schellens J, Soria J, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. *J Clin Oncol*. 2018;36(1):7-13. URL: <https://pubmed.ncbi.nlm.nih.gov/29072975/>
1403. Dias-Santagata D, Lennerz J, Sadow P, Frazier R, Govinda Raju S, Henry D, et al. Response to RET-Specific Therapy in. *Thyroid*. 2020;30(9):1384-1389. URL: <https://pubmed.ncbi.nlm.nih.gov/32292131/>
1404. Drilon A, Laetsch T, Kummar S, DuBois S, Lassen U, Demetri G, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med*. 2018;378(8):731-739. URL: <https://pubmed.ncbi.nlm.nih.gov/29466156/>
1405. Cabanillas M, Drilon A, Farago A, Brose M, McDermott R, Sohal D, et al. 1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer. *Annals of Oncology*. 2020;31:S1086. URL: <https://doi.org/10.1016/j.annonc.2020.08.1404>
1406. Cabanillas M, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. *Endocr Rev*. 2019;40(6):1573-1604. URL: <https://pubmed.ncbi.nlm.nih.gov/31322645/>
1407. Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. Lenvatinib for Anaplastic Thyroid Cancer. *Front Oncol*. 2017;7:25. URL: <https://pubmed.ncbi.nlm.nih.gov/28299283/>
1408. Wirth L, Brose M, Sherman E, Licitra L, Schlumberger M, Sherman S, et al. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. *J Clin Oncol*. 2021;39(21):2359-2366. URL: <https://pubmed.ncbi.nlm.nih.gov/33961488/>
1409. Iyer P, Dadu R, Ferrarotto R, Busaidy N, Habra M, Zafereo M, et al. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. *Thyroid*. 2018;28(1):79-87. URL: <https://pubmed.ncbi.nlm.nih.gov/29161986/>
1410. Iyer P, Dadu R, Gule-Monroe M, Busaidy N, Ferrarotto R, Habra M, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. *J Immunother Cancer*. 2018;6(1):68. URL: <https://pubmed.ncbi.nlm.nih.gov/29996921/>
1411. Besic N, Gazic B. Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. *Thyroid*. 2013;23(6):709-13. URL: <https://pubmed.ncbi.nlm.nih.gov/23148580/>
1412. Baek S, Lee M, Hah J, Ahn S, Son Y, Rho Y, et al. Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012. *Head Neck*. 2017;39(1):133-139. URL: <https://pubmed.ncbi.nlm.nih.gov/27534388/>
1413. Hugen N, Sloot Y, Netea-Maier R, van de Water C, Smit J, Nagtegaal I, et al. Divergent Metastatic Patterns Between Subtypes of Thyroid Carcinoma Results From the Nationwide

- Dutch Pathology Registry. *J Clin Endocrinol Metab.* 2020;105(3):e299-306. URL: <https://pubmed.ncbi.nlm.nih.gov/31641763/>
1414. Rades D, Janssen S, Käsmann L, Bolm L, Schild S. Outcomes After Irradiation of Epidural Spinal Cord Compression Due to Metastatic Thyroid Cancer. *Anticancer Res.* 2016;36(4):2035-9. URL: <https://pubmed.ncbi.nlm.nih.gov/27069199/>
 1415. Tickoo S, Pittas A, Adler M, Fazzari M, Larson S, Robbins R, et al. Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. *Arch Pathol Lab Med.* 2000;124(10):1440-7. URL: <https://pubmed.ncbi.nlm.nih.gov/11035572/>
 1416. Kim J, Leeper R. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. *Cancer.* 1987;60(10):2372-5. URL: <https://pubmed.ncbi.nlm.nih.gov/3664425/>
 1417. Venkatesh Y, Ordonez N, Schultz P, Hickey R, Goepfert H, Samaan N. Anaplastic carcinoma of the thyroid A clinicopathologic study of 121 cases. *Cancer.* 1990;66(2):321-30. URL: <https://pubmed.ncbi.nlm.nih.gov/1695118/>
 1418. Demeter J, De Jong S, Lawrence A, Paloyan E. Anaplastic thyroid carcinoma: risk factors and outcome. *Surgery.* 1991;110(6):956-61; discussion 961-3. URL: <https://pubmed.ncbi.nlm.nih.gov/1745983/>
 1419. Schlumberger M, Parmentier C, Delisle M, Couette J, Droz J, Sarrazin D. Combination therapy for anaplastic giant cell thyroid carcinoma. *Cancer.* 1991;67(3):564-6. URL: <https://pubmed.ncbi.nlm.nih.gov/1985750/>
 1420. Wong C, Van Dyk J, Simpson W. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. *Radiother Oncol.* 1991;20(1):3-9. URL: <https://pubmed.ncbi.nlm.nih.gov/1902319/>
 1421. Hadar T, Mor C, Shvero J, Levy R, Segal K. Anaplastic carcinoma of the thyroid. *Eur J Surg Oncol.* 1993;19(6):511-6. URL: <https://pubmed.ncbi.nlm.nih.gov/8270035/>
 1422. Tan R, Finley R, Driscoll D, Bakamjian V, Hicks W, Shedd D. Anaplastic carcinoma of the thyroid: a 24-year experience. *Head Neck.* 1995;17(1):41-7; discussion 47-8. URL: <https://pubmed.ncbi.nlm.nih.gov/7883548/>
 1423. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. *J Clin Endocrinol Metab.* 1999;84(11):4043-9. URL: <https://pubmed.ncbi.nlm.nih.gov/10566647/>
 1424. Busnardo B, Daniele O, Pelizzo M, Mazzarotto R, Nacamulli D, Devido D, et al. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. *J Endocrinol Invest.* 2000;23(11):755-61. URL: <https://pubmed.ncbi.nlm.nih.gov/11194710/>
 1425. Rodriguez J, Piñero A, Ortiz S, Moreno A, Sola J, Soria T, et al. Clinical and histological differences in anaplastic thyroid carcinoma. *Eur J Surg.* 2000;166(1):34-8. URL: <https://pubmed.ncbi.nlm.nih.gov/10688214/>
 1426. McIver B, Hay I, Giuffrida D, Dvorak C, Grant C, Thompson G, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. *Surgery.* 2001;130(6):1028-34. URL: <https://pubmed.ncbi.nlm.nih.gov/11742333/>
 1427. Swaak-Kragten A, de Wilt J, Schmitz P, Bontenbal M, Levendag P. Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. *Radiother Oncol.* 2009;92(1):100-4. URL: <https://pubmed.ncbi.nlm.nih.gov/19328572/>
 1428. Levy A, Leboulleux S, Lepoutre-Lussey C, Baudin E, Ghuzlan A, Hartl D, et al. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. *Oral Oncol.* 2015;51(4):370-5. URL: <https://pubmed.ncbi.nlm.nih.gov/25595614/>

1429. Lee E, Kim S, Kim B, Kim M, Lim D, Kim M, et al. Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study. *Thyroid*. 2019;29(12):1811-1819. URL: <https://pubmed.ncbi.nlm.nih.gov/31482759/>
1430. Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Nakayama H, Toda S, et al. Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study. *Oncol Lett*. 2018;16(6):7271-7277. URL: <https://pubmed.ncbi.nlm.nih.gov/30546466/>
1431. Wahl R, Jacene H, Kasamon Y, Lodge M. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. *J Nucl Med*. 2009;50 Suppl 1(Suppl 1):122S-50S. URL: <https://pubmed.ncbi.nlm.nih.gov/19403881/>
1432. Spitzweg C, Harrington K, Pinke L, Vile R, Morris J. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. *J Clin Endocrinol Metab*. 2001;86(7):3327-35. URL: <https://pubmed.ncbi.nlm.nih.gov/11443208/>
1433. Graff-Baker A, Roman S, Thomas D, Udelsman R, Sosa J. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. *Surgery*. 2009;146(6):1105-15. URL: <https://pubmed.ncbi.nlm.nih.gov/19958938/>
1434. Ohye H, Fukata S, Hirokawa M. [Malignant lymphoma of the thyroid]. *Nihon Rinsho*. 2007;65(11):2092-8. URL: <https://pubmed.ncbi.nlm.nih.gov/18018576/>
1435. Pedersen R, Pedersen N. Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study. *Histopathology*. 1996;28(1):25-32. URL: <https://pubmed.ncbi.nlm.nih.gov/8838117/>
1436. Skacel M, Ross C, Hsi E. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma. *Histopathology*. 2000;37(1):10-8. URL: <https://pubmed.ncbi.nlm.nih.gov/10931213/>
1437. Compagno J, Oertel J. Malignant lymphoma and other lymphoproliferative disorders of the thyroid gland A clinicopathologic study of 245 cases. *Am J Clin Pathol*. 1980;74(1):1-11. URL: <https://pubmed.ncbi.nlm.nih.gov/7395811/>
1438. Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K, et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. *Thyroid*. 1993;3(2):93-9. URL: <https://pubmed.ncbi.nlm.nih.gov/8369658/>
1439. Walsh S, Lowery A, Evoy D, McDermott E, Prichard R. Thyroid lymphoma: recent advances in diagnosis and optimal management strategies. *Oncologist*. 2013;18(9):994-1003. URL: <https://pubmed.ncbi.nlm.nih.gov/23881987/>
1440. Luo J, Huang F, Zhou P, Chen J, Sun Y, Xu F, et al. Is ultrasound combined with computed tomography useful for distinguishing between primary thyroid lymphoma and Hashimoto's thyroiditis?. *Endokrynol Pol*. 2019;70(6):463-468. URL: <https://pubmed.ncbi.nlm.nih.gov/31529457/>
1441. Aiken A. Imaging of thyroid cancer. *Semin Ultrasound CT MR*. 2012;33(2):138-49. URL: <https://pubmed.ncbi.nlm.nih.gov/22410362/>
1442. Sakorafas G, Kokkoris P, Farley D. Primary thyroid lymphoma (correction of lymphoma): diagnostic and therapeutic dilemmas. *Surg Oncol*. 2010;19(4):e124-9. URL: <https://pubmed.ncbi.nlm.nih.gov/20620043/>
1443. Onal C, Li Y, Miller R, Poortmans P, Constantinou N, Weber D, et al. Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study. *Ann Oncol*. 2011;22(1):156-164. URL: <https://pubmed.ncbi.nlm.nih.gov/20587509/>
1444. Watanabe N, Noh J, Narimatsu H, Takeuchi K, Yamaguchi T, Kameyama K, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study

- involving 24553 patients with Hashimoto's disease. *Br J Haematol*. 2011;153(2):236-43. URL: <https://pubmed.ncbi.nlm.nih.gov/21371004/>
1445. Wang X, Huang Y, Zheng Z, Cao W, Chen B, Wang X. Metastases to the thyroid gland: A retrospective analysis of 21 patients. *J Cancer Res Ther*. 2018;14(7):1515-1518. URL: <https://pubmed.ncbi.nlm.nih.gov/30589032/>
1446. Straccia P, Mosseri C, Brunelli C, Rossi E, Lombardi C, Pontecorvi A, et al. Diagnosis and Treatment of Metastases to the Thyroid Gland: a Meta-Analysis. *Endocr Pathol*. 2017;28(2):112-120. URL: <https://pubmed.ncbi.nlm.nih.gov/28332062/>
1447. Chung A, Tran T, Brumund K, Weisman R, Bouvet M. Metastases to the thyroid: a review of the literature from the last decade. *Thyroid*. 2012;22(3):258-68. URL: <https://pubmed.ncbi.nlm.nih.gov/22313412/>
1448. Mistelou A, Papadatos S, Kousi C, Lampri E, Mitsis M, Vougiouklakis T, et al. Thyroid Gland as a Target of Secondary Malignancies - an Autopsy Study and Review Data. *Folia Med (Plovdiv)*. 2019;61(2):277-288. URL: <https://pubmed.ncbi.nlm.nih.gov/31301659/>
1449. Heffess C, Wenig B, Thompson L. Metastatic renal cell carcinoma to the thyroid gland: a clinicopathologic study of 36 cases. *Cancer*. 2002;95(9):1869-78. URL: <https://pubmed.ncbi.nlm.nih.gov/12404280/>
1450. Hegerova L, Griebeler M, Reynolds J, Henry M, Gharib H. Metastasis to the thyroid gland: report of a large series from the Mayo Clinic. *Am J Clin Oncol*. 2015;38(4):338-42. URL: <https://pubmed.ncbi.nlm.nih.gov/23799287/>
1451. Cordes M, Kuwert T. Metastases of non-thyroidal tumors to the thyroid gland: a regional survey in middle franconia. *Exp Clin Endocrinol Diabetes*. 2014;122(5):273-6. URL: <https://pubmed.ncbi.nlm.nih.gov/24839221/>
1452. Queipo F, Panizo A, Yagüe A, Ruiz-Azua Y, Rodriguez I, Gutiérrez-Pecharroman A, et al. Metastatic clear cell renal cell carcinoma to the thyroid gland: A clinico-pathological and immunohistochemical study of 8 cases and review of the literature. *Rev Esp Patol*. 2019;52(2):81-86. URL: <https://pubmed.ncbi.nlm.nih.gov/30902382/>
1453. Nixon I, Coca-Pelaz A, Kaleva A, Triantafyllou A, Angelos P, Owen R, et al. Metastasis to the Thyroid Gland: A Critical Review. *Ann Surg Oncol*. 2017;24(6):1533-1539. URL: <https://pubmed.ncbi.nlm.nih.gov/27873099/>
1454. Surov A, Machens A, Holzhausen H, Spielmann R, Dralle H. Radiological features of metastases to the thyroid. *Acta Radiol*. 2016;57(4):444-50. URL: <https://pubmed.ncbi.nlm.nih.gov/25907117/>
1455. Ishikawa M, Hirano S, Tsuji T, Ito J. Management of metastasis to the thyroid gland. *Auris Nasus Larynx*. 2011;38(3):426-30. URL: <https://pubmed.ncbi.nlm.nih.gov/21239125/>
1456. Zhou L, Chen L, Xu D, Shao Q, Guo Z, Ge M. Breast cancer metastasis to thyroid: a retrospective analysis. *Afr Health Sci*. 2017;17(4):1035-1043. URL: <https://pubmed.ncbi.nlm.nih.gov/29937874/>
1457. Nixon I, Whitcher M, Glick J, Palmer F, Shaha A, Shah J, et al. Surgical management of metastases to the thyroid gland. *Ann Surg Oncol*. 2011;18(3):800-4. URL: <https://pubmed.ncbi.nlm.nih.gov/21046263/>
1458. Papi G, Fadda G, Corsello S, Corrado S, Rossi E, Radighieri E, et al. Metastases to the thyroid gland: prevalence, clinicopathological aspects and prognosis: a 10-year experience. *Clin Endocrinol (Oxf)*. 2007;66(4):565-71. URL: <https://pubmed.ncbi.nlm.nih.gov/17371476/>
1459. Gesetzliche Krankenversicherung. Stand: Zuletzt geändert durch Art. 1b G v. 20.12.2022. 2022;279

1460. Gesetzliche Rentenversicherung. Stand: Zuletzt geändert durch Art. 13 G v. 2.3.2023. 2023;56
1461. Rehabilitation und Teilhabe von Menschen mit Behinderungen. Stand: Zuletzt geändert durch Art. 4 G v. 20.12.2022. 2022;2560
1462. Rehabilitation und sozialmedizinische Leistungsbeurteilung beim Schilddrüsenkarzinom. 5:Doc08. 2016; URL: <https://dx.doi.org/10.3205/ors000030>
1463. S3-Leitlinie Müdigkeit. AWMF-Register Nr. 053-002. 2022
1464. Goswami S, Mongelli M, Peipert B, Helenowski I, Yount S, Sturgeon C. Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data. *Surgery*. 2018;164(5):986-992. URL: <https://pubmed.ncbi.nlm.nih.gov/30149935/>
1465. Altuntaş S, Hocaoglu Ç. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer. *Horm Metab Res*. 2021;53(10):683-691. URL: <https://pubmed.ncbi.nlm.nih.gov/34607367/>
1466. Gülsoy Kirnap N, Turhan İyidir Ö, Bozkuş Y, Işildak Ş, Anil C, Firat S, et al. The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma. *Turk J Med Sci*. 2020;50(4):870-876. URL: <https://pubmed.ncbi.nlm.nih.gov/32490648/>
1467. Sawka A, Ghai S, Tomlinson G, Rotstein L, Gilbert R, Gullane P, et al. A protocol for a Canadian prospective observational study of decision-making on active surveillance or surgery for low-risk papillary thyroid cancer. *BMJ Open*. 2018;8(4):e020298. URL: <https://pubmed.ncbi.nlm.nih.gov/29654030/>
1468. Sawka A, Straus S, Gafni A, Meiyappan S, David D, Rodin G, et al. Thyroid cancer patients' involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study. *Support Care Cancer*. 2012;20(3):641-5. URL: <https://pubmed.ncbi.nlm.nih.gov/22072050/>
1469. Sutton W, Genberg B, Prescott J, Segev D, Zeiger M, Bandeen-Roche K, et al. Understanding surgical decision-making in older adults with differentiated thyroid cancer: A discrete choice experiment. *Surgery*. 2021;169(1):14-21. URL: <https://pubmed.ncbi.nlm.nih.gov/32475718/>
1470. Urken M, Milas M, Randolph G, Tufano R, Bergman D, Bernet V, et al. Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative. *Head Neck*. 2015;37(4):605-14. URL: <https://pubmed.ncbi.nlm.nih.gov/24436291/>
1471. Banach R, Bartès B, Farnell K, Rimmel H, Shey J, Singer S, et al. Results of the Thyroid Cancer Alliance international patient/survivor survey: Psychosocial/informational support needs, treatment side effects and international differences in care. *Hormones (Athens)*. 2013;12(3):428-38. URL: <https://pubmed.ncbi.nlm.nih.gov/24121384/>
1472. Büttner M, Rimmel H, Bartès B, Singer S, Luster M. Management of thyroid cancer: results from a German and French patient survey. *Hormones (Athens)*. 2021;20(2):323-332. URL: <https://pubmed.ncbi.nlm.nih.gov/33184762/>
1473. Husson O, Mols F, Oranje W, Haak H, Nieuwlaar W, Netea-Maier R, et al. Unmet information needs and impact of cancer in (long-term) thyroid cancer survivors: results of the PROFILES registry. *Psychooncology*. 2014;23(8):946-52. URL: <https://pubmed.ncbi.nlm.nih.gov/24619907/>

1474. Pitt S, Saucke M, Roman B, Alexander S, Voils C. The Influence of Emotions on Treatment Decisions About Low-Risk Thyroid Cancer: A Qualitative Study. *Thyroid*. 2021;31(12):1800-1807. URL: <https://pubmed.ncbi.nlm.nih.gov/34641715/>
1475. Pitt S, Saucke M, Wendt E, Schneider D, Orne J, Macdonald C, et al. Patients' Reaction to Diagnosis with Thyroid Cancer or an Indeterminate Thyroid Nodule. *Thyroid*. 2021;31(4):580-588. URL: <https://pubmed.ncbi.nlm.nih.gov/33012267/>
1476. Smith S, Eatough V, Smith J, Mihai R, Weaver A, Sadler G. 'I know I'm not invincible': An interpretative phenomenological analysis of thyroid cancer in young people. *Br J Health Psychol*. 2018;23(2):352-370. URL: <https://pubmed.ncbi.nlm.nih.gov/29356226/>
1477. Husson O, Haak H, Oranje W, Mols F, Reemst P, van de Poll-Franse L. Health-related quality of life among thyroid cancer survivors: a systematic review. *Clin Endocrinol (Oxf)*. 2011;75(4):544-54. URL: <https://pubmed.ncbi.nlm.nih.gov/21615448/>
1478. Hyun Y, Alhashemi A, Fazelzad R, Goldberg A, Goldstein D, Sawka A. A Systematic Review of Unmet Information and Psychosocial Support Needs of Adults Diagnosed with Thyroid Cancer. *Thyroid*. 2016;26(9):1239-50. URL: <https://pubmed.ncbi.nlm.nih.gov/27350421/>
1479. Adeyemi O, Gill T, Paul R, Huber L. Evaluating the association of self-reported psychological distress and self-rated health on survival times among women with breast cancer in the US. *PLoS One*. 2021;16(12):e0260481. URL: <https://pubmed.ncbi.nlm.nih.gov/34852013/>
1480. Chen J, Hua Y, Su L, Wang C, Zhang H, Ye J, et al. The effect of psychological condition before radiotherapy on prognosis in 390 patients initially treated for nasopharyngeal carcinoma. *Support Care Cancer*. 2021;29(10):5967-5972. URL: <https://pubmed.ncbi.nlm.nih.gov/33765206/>
1481. Kim G, Kim S, Song S, Kim H, Kang B, Noh S, et al. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. *BMC Cancer*. 2017;17(1):283. URL: <https://pubmed.ncbi.nlm.nih.gov/28427439/>
1482. Loth F, Meraner V, Holzner B, Singer S, Virgolini I, Gamper E. Following patient pathways to psycho-oncological treatment: Identification of treatment needs by clinical staff and electronic screening. *Psychooncology*. 2018;27(4):1312-1319. URL: <https://pubmed.ncbi.nlm.nih.gov/29462499/>
1483. Singer S, Lincke T, Gamper E, Bhaskaran K, Schreiber S, Hinz A, et al. Quality of life in patients with thyroid cancer compared with the general population. *Thyroid*. 2012;22(2):117-24. URL: <https://pubmed.ncbi.nlm.nih.gov/22191388/>
1484. Goldfarb M, Casillas J. Thyroid Cancer-Specific Quality of Life and Health-Related Quality of Life in Young Adult Thyroid Cancer Survivors. *Thyroid*. 2016;26(7):923-32. URL: <https://pubmed.ncbi.nlm.nih.gov/27161396/>
1485. Hedman C, Djärv T, Strang P, Lundgren C. Determinants of long-term quality of life in patients with differentiated thyroid carcinoma - a population-based cohort study in Sweden. *Acta Oncol*. 2016;55(3):365-9. URL: <https://pubmed.ncbi.nlm.nih.gov/26541091/>
1486. Singer S, Husson O, Tomaszewska I, Locati L, Kiyota N, Scheidemann-Wesp U, et al. Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study. *Thyroid*. 2016;26(11):1605-1613. URL: <https://pubmed.ncbi.nlm.nih.gov/27605136/>
1487. Singer S, Jordan S, Locati L, Pinto M, Tomaszewska I, Araújo C, et al. The EORTC module for quality of life in patients with thyroid cancer: phase III. *Endocr Relat Cancer*. 2017;24(4):197-207. URL: <https://pubmed.ncbi.nlm.nih.gov/28223365/>

1488. Applewhite M, James B, Kaplan S, Angelos P, Kaplan E, Grogan R, et al. Quality of Life in Thyroid Cancer is Similar to That of Other Cancers with Worse Survival. *World J Surg*. 2016;40(3):551-61. URL: <https://pubmed.ncbi.nlm.nih.gov/26546191/>
1489. Dionisi-Vici M, Fantoni M, Botto R, Nervo A, Felicetti F, Rossetto R, et al. Distress, anxiety, depression and unmet needs in thyroid cancer survivors: a longitudinal study. *Endocrine*. 2021;74(3):603-610. URL: <https://pubmed.ncbi.nlm.nih.gov/34143334/>
1490. Choi H, Park B, Ji Y, Tae K, Song C. Depressive Disorder in Thyroid Cancer Patients after Thyroidectomy: A Longitudinal Follow-up Study Using a National Cohort. *Otolaryngol Head Neck Surg*. 2019;160(2):239-245. URL: <https://pubmed.ncbi.nlm.nih.gov/30274554/>
1491. Hedman C, Strang P, Djärv T, Widberg I, Lundgren C. Anxiety and Fear of Recurrence Despite a Good Prognosis: An Interview Study with Differentiated Thyroid Cancer Patients. *Thyroid*. 2017;27(11):1417-1423. URL: <https://pubmed.ncbi.nlm.nih.gov/28874092/>
1492. Noto B, Asmus I, Schäfers M, Görlich D, Riemann B. Predictors of Anxiety and Depression in Differentiated Thyroid Cancer Survivors: Results of a Cross-Sectional Study. *Thyroid*. 2022;32(9):1077-1085. URL: <https://pubmed.ncbi.nlm.nih.gov/35734910/>
1493. Henry M, Frenkiel S, Chartier G, MacDonald C, Payne R, Black M, et al. Thyroid cancer patients receiving an interdisciplinary team-based care approach (ITCA-ThyCa) appear to display better outcomes: Program evaluation results indicating a need for further integrated care and support. *Psychooncology*. 2018;27(3):937-945. URL: <https://pubmed.ncbi.nlm.nih.gov/29178318/>
1494. Javaloyes N, Crespo A, Redal M, Brugarolas A, Botella L, Escudero-Ortiz V, et al. Psycho-Oncological Intervention Through Counseling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine (COUNTHY, NCT05054634): A Non-randomized Controlled Study. *Front Psychol*. 2022;13:767093. URL: <https://pubmed.ncbi.nlm.nih.gov/35282223/>
1495. Pei J, Meng J, Xue Y, Zhang L. Disease Experience of Patients With Differentiated Thyroid Cancer at Different Phases Based on Timing It Right Framework: A Qualitative Longitudinal Study. *Cancer Nurs*. 2023;: URL: <https://pubmed.ncbi.nlm.nih.gov/36907952/>
1496. Wang S, Huang H, Wang L, Wang X. A Psychological Nursing Intervention for Patients With Thyroid Cancer on Psychological Distress and Quality of Life: A Randomized Clinical Trial. *J Nerv Ment Dis*. 2020;208(7):533-539. URL: <https://pubmed.ncbi.nlm.nih.gov/32187128/>
1497. Husson O, Poort H, Sansom-Daly U, Netea-Maier R, Links T, Mols F. Psychological Distress and Illness Perceptions in Thyroid Cancer Survivors: Does Age Matter?. *J Adolesc Young Adult Oncol*. 2020;9(3):375-383. URL: <https://pubmed.ncbi.nlm.nih.gov/31990604/>